<SEC-DOCUMENT>0001193125-19-113378.txt : 20190422
<SEC-HEADER>0001193125-19-113378.hdr.sgml : 20190422
<ACCEPTANCE-DATETIME>20190422160957
ACCESSION NUMBER:		0001193125-19-113378
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		11
CONFORMED PERIOD OF REPORT:	20190517
FILED AS OF DATE:		20190422
DATE AS OF CHANGE:		20190422
EFFECTIVENESS DATE:		20190422

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Calyxt, Inc.
		CENTRAL INDEX KEY:			0001705843
		STANDARD INDUSTRIAL CLASSIFICATION:	AGRICULTURE CHEMICALS [2870]
		IRS NUMBER:				271967997
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38161
		FILM NUMBER:		19759541

	BUSINESS ADDRESS:	
		STREET 1:		2800 MOUNT RIDGE ROAD
		CITY:			ROSEVILLE
		STATE:			MN
		ZIP:			55113
		BUSINESS PHONE:		(651) 683-2807

	MAIL ADDRESS:	
		STREET 1:		2800 MOUNT RIDGE ROAD
		CITY:			ROSEVILLE
		STATE:			MN
		ZIP:			55113
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>d718407ddef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML><HEAD>
<TITLE>DEF 14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the
Registrant&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Filed by a Party other than the
Registrant&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="96%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Preliminary Proxy Statement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Confidential, for Use of the Commission Only (as permitted by Rule <FONT STYLE="white-space:nowrap">14a-6(e)(2))</FONT></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Definitive Proxy Statement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Definitive Additional Materials</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Soliciting Material Pursuant to <FONT STYLE="white-space:nowrap">&#167;240.14a-12</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>CALYXT, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified in its Charter) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check the appropriate box): </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">No fee required.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Fee computed on table below per Exchange Act Rules <FONT STYLE="white-space:nowrap">14a-6(i)(4)</FONT> and <FONT STYLE="white-space:nowrap">0-11.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title of each class of securities to which transaction applies:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aggregate number of securities to which transaction applies:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule <FONT STYLE="white-space:nowrap">0-11</FONT>
(set forth the amount on which the filing fee is calculated and state how it was determined):</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(4)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proposed maximum aggregate value of transaction:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(5)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total fee paid:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Fee paid previously with preliminary materials.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Check box if any part of the fee is offset as provided by Exchange Act Rule <FONT STYLE="white-space:nowrap">0-11(a)(2)</FONT> and identify the filing for which the offsetting fee was paid previously. Identify the
previous filing by registration statement number, or the Form or Schedule and the date of its filing.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amount Previously Paid:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form, Schedule or Registration Statement No.:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filing Party:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(4)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date Filed:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g718407g62g95.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CALYXT, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notice of 2019 Annual Meeting of Stockholders </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>to be held on May&nbsp;17, 2019 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear
Stockholder: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You are cordially invited to attend the 2019 Annual Meeting of Stockholders of Calyxt, Inc., to be held at 90 South Seventh
Street, Suite 4950, Minneapolis, MN 55402, on Friday, May&nbsp;17, 2019 at 10:00 a.m. Central Time for the following purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To elect seven directors to our Board of Directors, all of whom are currently serving on our Board of
Directors, each to serve until the next annual meeting of stockholders and until his or her successor has been elected and qualified, or until his or her earlier death, resignation or removal; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To ratify the appointment by the Audit Committee of Ernst&nbsp;&amp; Young LLP as our independent registered
public accounting firm for the year ending December&nbsp;31, 2019; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To act on such other business and matters or proposals as may properly come before the Annual Meeting.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These items of business are more fully described in the Proxy Statement accompanying this Notice. All of Calyxt&#146;s
stockholders are invited to attend the Annual Meeting in person. The record date for the Annual Meeting is April&nbsp;3, 2019. Only stockholders of record at the close of business on that date are entitled to notice of and to vote at the Annual
Meeting or any adjournment thereof. Your vote as a stockholder of Calyxt is very important. Each share of stock that you own represents one vote. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="27%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By Order of the Board of Directors,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">James A.
Blome</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">James A. Blome</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roseville, Minnesota</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">April&nbsp;22, 2019</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Whether or not you expect to attend the meeting in person, please submit voting instructions for your shares promptly by
marking, dating and signing your proxy card and returning it in the accompanying postage-paid envelope or by voting over the internet at <U>www.investorvote.com/CLXT</U> or by telephone at <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-652-8683</FONT></FONT></FONT> (toll free). Even if you have voted by proxy, you may still vote in person if you attend the Annual Meeting. Please note, however, that if your shares
are held of record by a broker, bank or other nominee and you wish to vote at the Annual Meeting, you must obtain a proxy issued in your name from that record holder. </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CALYXT, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROXY STATEMENT FOR 2019 ANNUAL MEETING OF STOCKHOLDERS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx718407_1">Information about Proxy Materials and Voting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx718407_2">Information about the Annual Meeting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx718407_3">Proposal No.&nbsp;1 &#150; Election of Directors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx718407_4">Directors, Executive Officers and Corporate Governance</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx718407_5">Stockholder Communications</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx718407_6">Proposal No.&nbsp;
2 &#150; Ratification of Appointment of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx718407_7">Transaction of Other Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx718407_8">Executive Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx718407_9">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder
 Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx718407_10">Section&nbsp;16(a) Beneficial Ownership Reporting Compliance</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx718407_11">Certain Relationships and Related Transactions, and Director
Independence</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx718407_12">Report of the Audit Committee</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx718407_13">Other Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx718407_1"></A>INFORMATION ABOUT PROXY MATERIALS AND VOTING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Calyxt, Inc. Board of Directors is providing you with these proxy materials because the Board is soliciting your proxy to vote at the Annual Meeting,
including at any adjournments or postponements of the Annual Meeting. The Board requests that you vote on the proposals described in this Proxy Statement. You are invited to attend the Annual Meeting, but you do not need to attend the Annual Meeting
in order to vote your shares. Instead, you may simply vote your shares by proxy by completing, signing and returning the enclosed proxy card. The Proxy Statement includes information that Calyxt is required to provide to you pursuant to rules
adopted by the Securities and Exchange Commission (the &#147;SEC&#148;) and that is designed to assist you in voting your shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Proxy Statement is
first being mailed on April&nbsp;22, 2019 (the &#147;Mailing Date&#148;) to stockholders of record entitled to vote at the Annual Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this Proxy
Statement, the terms &#147;Calyxt,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;us,&#148; and &#147;our&#148; refer to Calyxt, Inc. and the term &#147;Cellectis&#148; refers to Cellectis S.A., our majority stockholder. The mailing address of
the principal executive offices is Calyxt, Inc., 2800 Mount Ridge Road, Roseville, MN 55113. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proxy materials are available online at:
<U>http://www.calyxt.com/general-meetings/</U> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx718407_2"></A>INFORMATION ABOUT THE ANNUAL MEETING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Annual Meeting will be held on May&nbsp;17, 2019 at 10:00 a.m. Central Time at 90 South Seventh Street, Suite 4950, Minneapolis, MN 55402. Information on
how to vote in person at the Annual Meeting is discussed below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Record Date </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Only stockholders of record at the close of business on April&nbsp;3, 2019 will be entitled to vote at the Annual Meeting. On this record date, there were
32,697,089 shares of common stock outstanding and entitled to vote. Holders of each share of common stock are entitled to one vote for each share held as of the record date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stockholder of Record: Shares Registered in Your Name </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If
on April&nbsp;3, 2019 your shares were registered directly in your name with our transfer agent, ComputerShare Trust Company, N.A., then you are a stockholder of record. As a stockholder of record, you may vote in person at the Annual Meeting or
vote by proxy. Whether or not you plan to attend the Annual Meeting, we urge you to fill out and return the enclosed proxy card or vote by proxy over the internet or by telephone as instructed below to ensure your vote is counted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Beneficial Owner: Shares Registered in the Name of a Broker, Bank or Other Agent </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If on April&nbsp;3, 2019 your shares were held in an account at a brokerage firm, bank, dealer or other similar organization (as opposed to in your name), then
you are the beneficial owner of shares held in &#147;street name&#148; and the Notice is being forwarded to you by that organization. The organization holding your account is considered to be the stockholder of record for purposes of voting at the
Annual Meeting. As a beneficial owner, you have the right to direct your broker or other agent regarding how to vote the shares in your account. As a beneficial owner, you are also invited to attend the Annual Meeting. However, as you are not the
stockholder of record, you may not vote your shares in person at the meeting unless you request and obtain a valid proxy from your broker or other agent in whose name the shares are held. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recommendations of the Board of Directors on Each of the Proposals </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are two matters scheduled for a vote: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Proposal
No.&nbsp;1 &#150; Election of Directors. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board recommends that you vote FOR the election of each of the seven nominees named in this Proxy
Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Proposal No.&nbsp;2 &#150; Ratification of Appointment of Independent Registered Public Accounting Firm. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board recommends that you vote FOR the ratification of the appointment of Ernst&nbsp;&amp; Young LLP as our independent registered public accounting firm
for the year ending December&nbsp;31, 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board knows of no other matters that will be presented for consideration at the Annual Meeting. If any
other matters are properly brought before the Annual Meeting, it is the intention of the persons named in the accompanying proxy to vote on those matters in accordance with their best judgment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Instructions; Voting of Proxies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may either
vote &#147;For&#148; each of the nominees to the Board or you may &#147;Withhold&#148; your vote for any nominee you specify. With respect to the ratification of the appointment of Ernst&nbsp;&amp; Young LLP as our independent registered public
accounting firm, you may vote &#147;For&#148; or &#147;Against&#148; or you may abstain from voting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The procedures for voting are: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stockholder of Record: Shares Registered in Your Name </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If
you are a stockholder of record, you may (1)&nbsp;vote in person at the Annual Meeting, (2)&nbsp;vote by proxy by using the proxy card enclosed with the mailed proxy materials, (3)&nbsp;vote over the internet or (4)&nbsp;vote by telephone. Whether
or not you plan to attend the Annual Meeting, we urge you to vote by proxy card, internet or telephone to ensure your vote is counted. You may still attend the Annual Meeting and vote in person even if you have already voted. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You can vote by promptly completing and returning your signed proxy card in the envelope provided. You should
mail your signed proxy card sufficiently in advance for it to be received by May&nbsp;16, 2019. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">To vote in person, come to the Annual Meeting and we will give you a ballot when you arrive.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">To vote online prior to the Annual Meeting, visit <B><U>www.investorvote.com/CLXT</U></B> and follow the steps
outlined on the secure website. Your vote must be received by 1:00 a.m., Central Time on May&nbsp;17, 2019 to be counted. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">To vote by telephone within the United States and Canada, call <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-652-VOTE</FONT></FONT></FONT> (8683) (toll free) on a touch tone telephone and follow the instructions provided by the recorded message. Your vote must be received by 1:00 a.m.,
Central Time on May&nbsp;17, 2019 to be counted. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We provide Internet proxy voting to allow you to vote your shares online with
procedures designed to ensure the authenticity and correctness of your proxy vote instructions. Please be aware that you must bear any costs associated with your Internet access, such as usage charges from Internet access providers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Beneficial Owner: Shares Registered in the Name of a Broker, Bank or Other Agent </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are a beneficial owner of shares registered in the name of your broker, bank or other agent, you should have received a notice containing voting
instructions from that organization rather than from us. Please follow the voting instructions in that notice to ensure that your vote is counted. Alternatively, you may vote over the Internet as instructed by your broker, bank or other agent. To
vote in person at the Annual Meeting, you must obtain a valid proxy from your broker, bank or other agent and follow the instructions included with those proxy materials. You may contact the broker, bank or other agent in whose name your shares are
registered in order to request a proxy form. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Number of Votes per Share of Common Stock </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On each matter to be voted upon, you have one vote for each share of common stock you own as of April&nbsp;3, 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Consequences of Not Voting </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Stockholder of Record: Shares Registered in Your Name </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are a stockholder of record and do not vote by completing your proxy card, through the internet, by telephone or in person at the Annual Meeting, your
shares will not be voted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Beneficial Owner: Shares Registered in the Name of a Broker, Bank or Other Agent </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A broker <FONT STYLE="white-space:nowrap">non-vote</FONT> occurs when shares registered in the name of a broker are not voted with respect to a particular
proposal because the broker does not have discretionary authority to vote on the matter and has not received voting instructions from its client who beneficially owns those shares. If your broker holds your shares in its name and you do not instruct
your broker how to vote, your broker will only have discretion to vote your shares on &#147;routine&#148; matters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where a proposal is not &#147;routine,&#148; a broker who has received no instructions from its clients does
not have discretion to vote its clients&#146; uninstructed shares on that proposal. Proposal No.&nbsp;1 (the election of directors) is considered a <FONT STYLE="white-space:nowrap">non-routine</FONT> matter under applicable rules, and your broker or
other nominee will not have discretion to vote on Proposal No.&nbsp;1 absent direction from you. Accordingly, there may be broker <FONT STYLE="white-space:nowrap">non-votes</FONT> on Proposal No.&nbsp;1 (the election of directors). Proposal
No.&nbsp;2 (the ratification of the appointment of Ernst&nbsp;&amp; Young LLP as our independent registered public accounting firm for the year ending December&nbsp;31, 2019) is considered a routine matter under applicable rules, and your broker or
other nominee may generally vote in its discretion. Accordingly, no broker <FONT STYLE="white-space:nowrap">non-votes</FONT> are expected to exist in connection with Proposal No.&nbsp;2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Amended and Restated Bylaws (&#147;Bylaws&#148;) provide that a majority of the shares entitled to vote, present in person or represented by proxy, will
constitute a quorum for the transaction of business at the Annual Meeting. In addition, under the General Corporation Law of the State of Delaware, shares that are voted &#147;abstain&#148; or &#147;withheld&#148; and broker <FONT
STYLE="white-space:nowrap">non-votes</FONT> are counted as present for purposes of determining whether a quorum is present at the Annual Meeting. As a result, broker <FONT STYLE="white-space:nowrap">non-votes</FONT> and abstentions by stockholders
from voting (including brokers holding their clients&#146; shares of record who cause abstentions to be recorded) will be counted towards determining whether or not a quorum is present. However, because broker
<FONT STYLE="white-space:nowrap">non-votes</FONT> and abstentions are not voted affirmatively or negatively, they will have no effect on the approval of Proposal No.&nbsp;1. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Returning Blank Proxy Card </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you return a signed and
dated proxy card or otherwise vote without marking voting selections, your shares will be voted, &#147;For&#148; the election of each of the nominees for director, and &#147;For&#148; the ratification of the selection of Ernst&nbsp;&amp; Young LLP
as our independent registered public accounting firm. If any other matter is properly presented at the Annual Meeting, your proxyholder (one of the individuals named on your proxy card) will vote your shares using his or her best judgment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Expenses of Soliciting Proxies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will pay for the
entire cost of soliciting proxies. In addition to these proxy materials, our directors and employees may also solicit proxies in person, by telephone, or by other means of communication. Directors and employees will not be paid any additional
compensation for soliciting proxies. We will also reimburse brokerage firms, banks and other agents for the cost of forwarding proxy materials to beneficial owners. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Receiving More than One Proxy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you receive more than
one Notice, your shares may be registered in more than one name or in different accounts. Please follow the voting instructions on each Notice that you receive to ensure that all of your shares are voted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Revocation of Proxies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stockholder of Record: Shares
Registered in Your Name </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You can revoke your proxy at any time before the final vote at the Annual Meeting. If you are the record holder of your
shares, you may revoke your proxy in any one of the following ways: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You may submit another properly completed proxy card with a later date. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You may grant a subsequent proxy through the internet or by telephone. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You may send a timely written notice that you are revoking your proxy to Calyxt&#146;s General Counsel at 2800
Mount Ridge Road, Roseville, MN 55113. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You may attend the Annual Meeting and vote in person. Simply attending the Annual Meeting will not, by itself,
revoke your proxy. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your most current proxy card is the one that is counted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Beneficial Owner: Shares Registered in the Name of a Broker, Bank or Other Agent </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If your shares are held by your broker, bank or other agent, as a nominee or agent, you should follow the instructions provided by such broker, bank or other
agent. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Procedure for Submitting Stockholders Proposals </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For nominations of individuals for election to our Board of Directors, or other business to be properly brought by a stockholder before next year&#146;s annual
meeting, the stockholder must give timely notice thereof in writing to the Secretary of Calyxt, and any such proposed business (other than the nominations of persons for election to the Board) must constitute a proper matter for stockholder action.
To be timely for our 2020 annual meeting, a stockholder&#146;s notice must be delivered to or mailed and received by the Secretary of Calyxt at our principal executive offices no later than February&nbsp;17, 2020 nor earlier than January&nbsp;18,
2020; provided, however, that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in the event that the date of the annual meeting is advanced more than 30 days prior to the first anniversary of Calyxt&#146;s 2019 Annual Meeting or delayed more than 30 days after such
anniversary date then to be timely such notice must be received by Calyxt no earlier than 120 days prior to such annual meeting and no later than the later of 70 days prior to the date of the meeting or the 10th day following the day on which public
announcement of the date of the meeting was first made by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your notice to the Secretary of Calyxt must set forth information specified in our Bylaws.
For more information, and for more detailed requirements, please refer to our Bylaws, filed as Exhibit 3.2 to our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> filed with the SEC on March&nbsp;12, 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Counting Votes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Votes will be counted by the inspector of
election appointed for the Annual Meeting. For Proposal No.&nbsp;1, the inspector of election will separately count &#147;For&#148; and &#147;Withheld&#148; votes and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> for each nominee. For
Proposal No.&nbsp;2, the inspector of election will separately count &#147;For&#148; and &#147;Against&#148; votes and abstentions. For Proposal No.&nbsp;1, broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will have no effect and will not be
counted toward the vote total for any director nominee. Proposal No.&nbsp;2 is considered routine under applicable rules and, as a result, a broker or other nominee may generally vote on Proposal No.&nbsp;2 and no broker <FONT
STYLE="white-space:nowrap">non-votes</FONT> are expected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Required Votes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to our Bylaws: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">nominees for election to our Board of Directors will be elected by a plurality of the votes of the shares present
in person or represented by proxy at the Annual Meeting and entitled to vote on the election of directors.&nbsp;This means that the seven nominees receiving the highest number of affirmative &#147;For&#148; votes will be elected.&nbsp;Only votes
&#147;For&#148; will affect the outcome. Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will have no effect on the outcome of the vote. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the appointment of Ernst&nbsp;&amp; Young LLP as our independent public accounting firm for the fiscal year
ending December&nbsp;31, 2019 will be ratified by a majority of the votes of the shares present in person or represented by proxy at the Annual Meeting and entitled to vote on this matter. If you &#147;Abstain&#148; from voting, it will have the
same effect as an &#147;Against&#148; vote. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quorum </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A quorum of stockholders is necessary to hold a valid meeting. The presence, in person or by proxy, of the holders of a majority of the outstanding common
shares of Calyxt entitled to vote at the Annual Meeting shall constitute a quorum for the transaction of business. On the record date, there were 32,697,089 shares outstanding and entitled to vote. Thus, the holders of 16,348,545 shares must be
present in person or represented by proxy at the Annual Meeting to have a quorum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your shares will be counted towards the quorum only if you submit a
valid proxy (or one is submitted on your behalf by your broker, bank or other nominee) or if you vote in person at the meeting. Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will be counted towards the quorum requirement.
If, however, a quorum is not present at the Annual Meeting, either the Chair of the Annual Meeting or a majority of the holders of common stock present in person or represented by proxy will adjourn the Annual Meeting, without notice other than
announcement at the Annual Meeting, until a quorum is present. At such adjourned meeting at which a quorum is present any business may be transacted which would have been transacted at the original Annual Meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Voting at the Annual Meeting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Preliminary
voting results will be announced at the Annual Meeting. In addition, final voting results will be published in a current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> that we expect to file within four business days after the Annual
Meeting. If final voting results are not available to us in time to file a <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> within four business days after the Annual Meeting, we intend to file a
<FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> to publish preliminary results and, within four business days after the final results are known to us, file an additional <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> to publish the
final results. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an &#147;Emerging Growth Company&#148; </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; under applicable federal securities laws and therefore permitted to take advantage of certain reduced public
company reporting requirements. As an emerging growth company, we provide in this Proxy Statement the scaled disclosure permitted under the Jumpstart Our Business Startups Act of 2012 (the &#147;JOBS Act&#148;), including the compensation
disclosures required of a &#147;smaller reporting company,&#148; as that term is defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> promulgated under the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;). In
addition, as an emerging growth company, we are not required to conduct votes seeking approval, on an advisory basis, of the compensation of our named executive officers or the frequency with which such votes must be conducted. We will remain an
&#147;emerging growth company&#148; until the earliest of (i)&nbsp;the last day of the fiscal year in which we have total annual gross revenues of $1.07&nbsp;billion or more; (ii)&nbsp;December&nbsp;31, 2022; (iii) the date on which we have issued
more than $1&nbsp;billion in nonconvertible debt during the previous three years; or (iv)&nbsp;the date on which we are deemed to be a large accelerated filer under the rules of the SEC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx718407_3"></A>PROPOSAL NO. 1 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ELECTION OF DIRECTORS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to our
Amended and Restated Certificate of Incorporation (&#147;Certificate of Incorporation&#148;), our Board of Directors shall consist of not less than five nor more than 11 directors, with the exact number of directors to be determined from time to
time solely by resolution adopted by a majority of the Board of Directors. Immediately prior to the Annual Meeting, our Board consists of nine members. As previously announced, Mr.&nbsp;Laurent Arthaud and Mr.&nbsp;Alain Godard have elected not to
stand for reelection at the Annual Meeting. Accordingly, in connection with the Annual Meeting, our Board has adopted a resolution fixing the number of directors at seven members. Until the first date on which Cellectis and its affiliates no longer
beneficially own more than 50% of the outstanding shares of our Common Stock, all of the directors will be elected to our Board annually at the annual meeting of stockholders. From and after such date, our Board will transition to a staggered board
divided into three classes, with directors serving three-year terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Directors will be elected by a plurality of the votes of the shares of our common
stock present in person or represented by proxy at the Annual Meeting and entitled to vote on the election of directors. This means that the seven nominees receiving the highest number of affirmative &#147;For&#148; votes will be elected. If
elected, each of these individuals will serve until the next annual meeting of stockholders and until his or her successor has been elected and qualified, or until his or her earlier death, resignation or removal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There will be no cumulative voting in the election of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise provided by law and subject to the terms of our Stockholders Agreement dated July&nbsp;25, 2017 with Cellectis (as amended, the
&#147;Stockholders Agreement&#148;), any vacancy on the Board, including a vacancy created by an increase in the authorized number of directors, may be filled solely by a majority of the directors then in office or by the sole remaining director.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nominees for Election for a <FONT STYLE="white-space:nowrap">One-Year</FONT> Term Expiring at the 2020 Annual Meeting of Stockholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The individuals listed below, all of whom are currently serving on our Board of Directors, are nominated for election this year.&nbsp;In addition to the names
of the nominees and their ages provided in the table below, additional biographical information for each nominee follows the table. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the
Stockholders Agreement, Cellectis has a right to designate as nominees to the Board the greater of three members of the Board or a majority of the directors on the Board, and to designate the chair of the Board and one member to each committee of
the Board. Cellectis has designated Dr.&nbsp;Choulika as its nominee to the Board and as its designee to be the chair of the Board and as a member of each of the Compensation Committee and the Nominating and Corporate Governance Committee. Cellectis
has reserved its rights under the Stockholders Agreement to make additional designations from time to time. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="border-bottom:1.00pt solid #000000" ALIGN="center"><B>Age</B> <P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Position</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Andr&eacute; Choulika, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">54</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chair and Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Philippe Dumont</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">67</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Jonathan B. Fassberg<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">53</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Anna Ewa Kozicz-Stankiewicz</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">44</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Kimberly K. Nelson<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">52</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Christopher J. Neugent<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">58</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Yves J. Ribeill<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">59</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Fassberg joined the Board of Directors on August&nbsp;22, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ms.&nbsp;Nelson joined the Board of Directors on January&nbsp;17, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Neugent joined the Board of Directors on September&nbsp;11, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Ribeill joined the Board of Directors on July&nbsp;3, 2018. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a brief biography of each nominee for director and a discussion of the specific experience, qualifications, attributes or skills of each
nominee that led the Nominating and Corporate Governance Committee to recommend that person as a nominee for director, as of the date of this Proxy Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Andr&eacute; Choulika</I></B>, Ph.D., has served as Chair of our Board since August 2010. Dr.&nbsp;Choulika is one of the founders of
Cellectis (NASDAQ: CLLS), and has served as its Chief Executive Officer since its inception in 1999. He has served as the Chairman of the Board of Cellectis since 2011. Since December 2014, Dr.&nbsp;Choulika has served as Chief Executive Officer of
Cellectis, Inc. From 1997 to 1999, Dr.&nbsp;Choulika worked as a post-doctoral fellow in the Division of Molecular Medicine at Boston Children&#146;s Hospital, where he was one of the inventors of nuclease-based genome editing technologies and a
pioneer in the analysis and use of meganucleases to modify complex genomes. After receiving his Ph.D. in molecular virology from the University of Paris VI (Pierre et Marie Curie), he </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
completed a research fellowship in the Harvard Medical School Department of Genetics. His management training is from HEC (Challenge +). Based on Dr.&nbsp;Choulika&#146;s deep knowledge of Calyxt
and his scientific experience, we believe Dr.&nbsp;Choulika has the appropriate set of skills to serve as a member of our Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Philippe Dumont</I></B> has served as a member of our Board since July 2017. Mr.&nbsp;Dumont retired in December 2012 from Bayer
CropScience, where he was employed since May 2002. At Bayer he held the position of Head of Technology Management, Seeds, and was responsible for supervising globally the Regulatory Affairs and Regulatory Science functions, Stewardship, Public and
Governmental Affairs and Communication impacting GMOs and seeds. Until 2006 Mr.&nbsp;Dumont also supervised the Legal and Intellectual Property functions in the seed business. Mr.&nbsp;Dumont also held the same responsibilities at Aventis Crop
Science from December 1998 until April 2002. From 1987 to 1998, Mr.&nbsp;Dumont was General Counsel of <FONT STYLE="white-space:nowrap">Rh&ocirc;ne-Poulenc</FONT> Agrochimie. Prior to moving to France in 1987, Philippe held positions as an associate
at Cravath Swaine&nbsp;&amp; Moore (1975-1981), international legal counsel at Gulf Oil Corporation (1981-1983) and as solo practitioner in Washington D.C. from 1983-1986. Philippe is retired from the New York and District of Columbia Bars and is a
graduate of the Georgetown University Law Center (JD 1975) and Columbia University (BA, magna cum laude 1972). Since June 2013 he has been serving as a director of Association Fran&ccedil;aise des Biotechnologies V&eacute;g&eacute;tales, responsible
for international relations, where he tries to promote public and governmental understanding of new breeding techniques and related regulatory issues. Based on his leadership and regulatory experience in the plant biotechnology industry both in the
United States and Europe, we believe Mr.&nbsp;Dumont has the appropriate set of skills to serve as a member of our Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Jonathan
B. Fassberg</I></B> has served as a member of our Board since August 2018. Mr.&nbsp;Fassberg founded The Trout Group in 1996 and has been the <FONT STYLE="white-space:nowrap">Co-Chief</FONT> Executive Officer of Solebury Trout LLC since the Trout
Group&#146;s acquisition by Solebury Communications in 2017. Mr.&nbsp;Fassberg holds a Bachelor of Science degree in biology and chemistry from The University of North Carolina &#150; Chapel Hill and a Master of Business Administration degree in
finance from New York University&#146;s Stern School of Business. Based on his deep financial expertise and experience, we believe Mr.&nbsp;Fassberg has the appropriate set of skills to serve as a member of our Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Anna Ewa Kozicz-Stankiewicz</I></B> has served as a member of our Board since July 2017. Ms.&nbsp;Kozicz received a Bachelor of Arts in
Math and Economics from Columbia College and her MBA from Columbia Business School. She started her career in investment banking in 1996 at Credit Suisse First Boston in its Financial Institutions Group before moving to Goldman Sachs in 2000 where
she held multiple positions, including Managing Director, and spent most of her time in the Principal Strategies Group with a focus on investing in the global agricultural sector. She moved to Caxton Associates in 2009 to work as an equity Portfolio
Manager before moving to BlackRock in 2012 where she held management roles as Head of US Strategy and Corporate Development as well as investing roles as Portfolio Manager of a private assets portfolio for ABR Reinsurance Ltd., a Bermuda based
reinsurance company which Ms.&nbsp;Kozicz helped to set up on behalf of BlackRock. During her time at Goldman Sachs, she served as a director on the board of a New York-based federal credit union (PSFCU). In 2017, she left BlackRock and partnered
with Cowen Investment Management to create a new investment fund focused on sustainability in agriculture, energy and transportation services. We believe Ms.&nbsp;Kozicz&#146;s extensive investment experience in the agriculture industry qualifies
her to serve as a member on our Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Kimberly K. Nelson </I></B>has served as a member of our Board since January 2019.
Ms.&nbsp;Nelson has served as the Executive Vice President and Chief Financial Officer of SPS Commerce (NASDAQ: SPSC), a provider of cloud-based supply chain management solutions, since November 2007. Ms.&nbsp;Nelson has also served on the Board of
Qumu Corporation (NASDAQ: QUMU), a video content management company, from March 2012 until her anticipated retirement from the Qumu Board in May 2019. She holds a Bachelor of Arts degree in finance from Babson College, Wellesley, Massachusetts, and
completed the Executive MBA program at the University of Saint Thomas. Ms.&nbsp;Nelson has provided financial direction at a number of companies over her <FONT STYLE="white-space:nowrap">30-year</FONT> career including Amazon.com, Nestl&eacute; USA
Inc. and The Pillsbury Company. Based on her strong finance and investor relations experience and her broad experience with premier food and consumer companies, we believe Ms.&nbsp;Nelson has the appropriate set of skills to serve as a member of our
Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Christopher J. Neugent </I></B>has served as a member of our Board since September 2018. Mr.&nbsp;Neugent has served as the
Executive Vice President of Strategy of Post Holdings, Inc. (NYSE: POST), which is a $6.0&nbsp;billion holding company with six operating divisions, since July 2018. Prior to this, he served as President and CEO of Post Consumer Brands from its
creation in November 2015 until July 2018. Previously, Mr.&nbsp;Neugent held leadership roles at MOM Brands Company beginning in 2001. He served as the President and Chief Executive Officer of MOM Brands Company beginning in 2008, and also assumed
the responsibilities of Chairman of the Board in 2011. Mr.&nbsp;Neugent held these roles until Post acquired MOM Brands Company in 2015. Mr.&nbsp;Neugent has served on the Board of Welch Foods, Inc. since February 2016. He holds a Bachelor of Arts
degree in economics from Princeton University and completed the Advanced Management Program at the Wharton School of Business. We believe Mr.&nbsp;Neugent&#146;s extensive experience in the consumer food products space qualifies him to serve on our
Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Yves J. Ribeill</I></B><I>, </I>Ph.D., has served as a member of our Board since July 2018. Dr.&nbsp;Ribeill served as
Calyxt&#146;s interim Chief Executive Officer from August 2018 until October 2018. Since August 2017, he has served as the Chief Executive Officer of COREzonada, Inc., which is a private biotechnology company working on microbiome <FONT
STYLE="white-space:nowrap">re-engineering.</FONT> Dr.&nbsp;Ribeill was also a founder of Scynexis, Inc (NASDAQ: SCYX), served as its President from November 1999 until July 2015 and served as its Chief Executive
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Officer from November 1999 until April 2015. Before his work with Scynexis, Dr.&nbsp;Ribeill served in various positions during the 25 years of his international career with Rhone-Poulenc,
Aventis including Discovery Chemistry Group leader for Anti-Viral Research and later in the Central Nervous System Group in France. He served as Group Leader in the Cardiovascular Group in England. Upon his return to France, Dr.&nbsp;Ribeill served
as Director of Chemistry for the Anti-Infective Group. He was involved in all phases of the drug discovery and development effort that resulted in the FDA approval of multiple drugs. He served as a Director of Scynexis, Inc. from November 1999 to
March 2016 and has been a director of various other biotechnology companies in Europe and the United States. He is the author of more than 26 publications and 15 patents. He was a member of the Scientific Advisory Committee of the World Health
Organization and of the Medicine Malaria Venture in Geneva. Dr.&nbsp;Ribeill has a Ph.D. in Chemistry from the University of Montpellier (France). Based on his deep understanding of research and development and his experience with numerous
biotechnology companies, we believe Dr.&nbsp;Ribeill has the appropriate skills to serve as a member of our Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE
BOARD OF DIRECTORS RECOMMENDS A VOTE &#147;<U>FOR</U>&#148; EACH NAMED NOMINEE. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx718407_4"></A>DIRECTORS, EXECUTIVE
OFFICERS AND CORPORATE GOVERNANCE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of Directors and Leadership Structure </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Corporate Governance Guidelines, Certificate of Incorporation and Bylaws provide the Board flexibility in determining its leadership structure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors may establish the authorized number of directors from time to time by resolution. Immediately prior to the Annual Meeting, our Board
consists of nine members, six of whom are independent under the listing standards of the NASDAQ Global Market (the &#147;NASDAQ&#148;). As previously announced, Mr.&nbsp;Laurent Arthaud and Mr.&nbsp;Alain Godard have elected not to stand for
reelection at the Annual Meeting. Accordingly, in connection with the Annual Meeting, our Board has adopted a resolution fixing the number of directors at seven members. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board currently separates the role of Chair of the Board and Chief Executive Officer, with Dr.&nbsp;Choulika serving as Chair and Mr.&nbsp;Blome serving
as Chief Executive Officer. The Board believes it is important to retain its flexibility to allocate the responsibilities of the offices of the Chair of the Board and Chief Executive Officer in any way that is in our best interests at a given point
in time. The Board may make a determination as to the appropriateness of its current policies in connection with the recruitment and succession of the Chair of the Board and/or the Chief Executive Officer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Independence </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The NASDAQ listing standards
generally require that a majority of the members of a listed company&#146;s Board be independent. In addition, the listing rules generally require that, subject to specified exceptions, each member of a listed company&#146;s audit, compensation, and
nominating committees be independent. Audit committee members must also satisfy the independence criteria set forth in Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act. Under Rule
<FONT STYLE="white-space:nowrap">10A-3,</FONT> a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee: accept, directly
or indirectly, any consulting, advisory or other compensatory fee from the listed company or any of its subsidiaries; or be an affiliated person of the listed company or any of its subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although the NASDAQ listing standards allow a &#147;controlled company,&#148; such as us, to elect not to comply with certain corporate governance
requirements, such &#147;controlled company&#148; exemptions do not modify the independence requirements for the audit committee. The controlled company exemptions are discussed further below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board has undertaken a review of the independence of our directors and has considered whether any director has a material relationship with us that could
compromise his or her ability to exercise independent judgment in carrying out his or her responsibilities. Based on this evaluation, the Board determined that each of Mr.&nbsp;Dumont, Mr.&nbsp;Fassberg, Ms.&nbsp;Kozicz, Ms.&nbsp;Nelson,
Mr.&nbsp;Neugent and Dr.&nbsp;Ribeill are independent. Because of his status as both a director and the Chief Executive Officer of Cellectis, the Board determined that Dr.&nbsp;Choulika is not independent under the independence provisions of the
NASDAQ listing standards and Rule <FONT STYLE="white-space:nowrap">10A-3.</FONT> Because of their status as directors of Cellectis, Mr.&nbsp;Arthaud and Mr.&nbsp;Godard, who are retiring from our Board, were not independent under the independence
provisions of the NASDAQ listing standards and Rule <FONT STYLE="white-space:nowrap">10A-3.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In making such independence determinations, our Board
considered the relationships that each of the directors has with us and all other facts and circumstances our Board deemed relevant in determining their independence, including the beneficial ownership of our capital stock held by each director.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no family relationships among any of our directors or executive officers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Controlled Company Exemption </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cellectis controls a majority of the voting power of our outstanding common stock. As a result, we are a &#147;controlled company&#148; within the meaning of
the NASDAQ listing standards. Under the NASDAQ listing standards, a company of which more than 50% of the voting power is held by an individual, group or another company is a &#147;controlled company&#148; and may elect not to comply with certain
corporate governance requirements, including the requirements that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a majority of the Board consist of independent directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">director nominees be selected, or recommended to the Board, either by (i)&nbsp;independent directors constituting
a majority of the Board&#146;s independent directors or (ii)&nbsp;a nominations committee composed entirely of independent directors, with a written charter or board resolution, as applicable, addressing the nominations process; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have a compensation committee that is composed entirely of independent directors with a written charter
addressing the committee&#146;s purpose and responsibilities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board has established an Audit Committee, Nominating and Corporate
Governance Committee and Compensation Committee, each of which has a written charter that addresses its purpose and responsibilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With the exception
of Dr.&nbsp;Choulika, each of the other nominees for election to the Board at the 2019 Annual Meeting is an independent director under the independence provisions of the NASDAQ listing standards. Accordingly, our Board is currently comprised of a
majority of independent directors. However, pursuant to the Stockholders Agreement, Cellectis has a right to designate as nominees to the Board the greater of three members of the Board or a majority of the directors on the Board. To date, Cellectis
has designated only Dr.&nbsp;Choulika as its nominee to the Board and has otherwise reserved its rights under the Stockholders Agreement to make additional designations from time to time. In the event that Cellectis exercised its designation rights
and designated nominees that were not independent, we would rely on the controlled company exemption to the requirement that a majority of our Board consist of independent directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because Cellectis has designated Dr.&nbsp;Choulika as a member of each of the Compensation Committee and the Nominating and Corporate Governance Committee
pursuant to the Stockholders Agreement, we rely on the controlled company exemption with respect to the independence requirements for those committees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Role of the Board in Risk Oversight </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board is
actively involved in the oversight of our risk management process. The Board does not have a standing risk management committee, but administers this oversight function directly through the Board as a whole, as well as through its standing
committees that address risks inherent in their respective areas of oversight. In particular, our Audit Committee has the responsibility to consider and discuss our major financial risk exposures and the steps our management has taken to monitor and
control these exposures. Our Compensation Committee assesses and monitors whether any of our compensation policies and programs has the potential to encourage excessive risk-taking. Our Board is responsible for monitoring and assessing strategic
risk exposure and other risks not covered by our committees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The full Board, or the appropriate committee, receives reports on risks facing Calyxt from
our Chief Executive Officer or other members of management to enable it to understand our risk identification, risk management and risk mitigation strategies. We believe that our Board&#146;s leadership structure is consistent with and supports the
effective administration of the Board&#146;s risk oversight function. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective as of April 15, 2019, Calyxt adopted a formal risk management policy and
established a risk management committee (the &#147;CRC&#148;), which comprises executive and other senior staff. The risk management policy provides a framework for the definition, measurement and reporting of price risks relating to all hedging
activity and empowers the CRC to proactively manage and reduce the impact of volatile raw material prices, interest rates, and currency values on operating costs and margins. The CRC, under the supervision of the Board, will be responsible for
Calyxt&#146;s risk management policy and general risk management oversight. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Attendance at Meetings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the fiscal year ended December&nbsp;31, 2018, the Board acted by written consent on two occasions and held twelve meetings. Members of the Board are
expected to regularly attend all meetings of the Board and committees on which they serve. With respect to each of our incumbent director&#146;s period of service, such director attended more than 75&nbsp;percent of the meetings of the Board and of
the committees on which the director served that were held during the last fiscal year and during such director&#146;s period of service. The <FONT STYLE="white-space:nowrap">non-management</FONT> directors meet in conjunction with regular meetings
of the Board outside of the presence of management in executive session and the independent members of our Board also meet in executive sessions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Members of the Board are invited to attend each annual meeting of our stockholders. Only Dr.&nbsp;Choulika
attended our 2018 annual meeting of stockholders, which was held on May&nbsp;24, 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Committees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board has established three standing committees: an Audit Committee, Nominating and Corporate Governance Committee and Compensation Committee, each of
which is described below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Audit Committee </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Current Members</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Members During 2018</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Philippe Dumont (Chair)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Philippe Dumont (Chair)</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jonathan B. Fassberg<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andr&eacute; Choulika<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anna Eva Kozicz-Stankiewicz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jonathan B. Fassberg<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kimberly K. Nelson<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anna Eva Kozicz-Stankiewicz</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Yves J. Ribeill<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Fassberg was appointed to the Audit Committee on August&nbsp;22, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ms.&nbsp;Nelson was appointed to the Audit Committee on March&nbsp;4, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consistent with the permitted <FONT STYLE="white-space:nowrap">phase-in</FONT> period for complying with audit
committee independence requirements following an initial public offering, Dr. Choulika served on the Audit Committee until July&nbsp;3, 2018 when he was succeeded by Dr. Ribeill. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Ribeill served on the Audit Committee from July&nbsp;3, 2018 until his appointment as interim Chief
Executive Officer of Calyxt on August&nbsp;22, 2018 when he was succeeded by Mr.&nbsp;Fassberg. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee is composed of
Mr.&nbsp;Dumont (Chair), Mr.&nbsp;Fassberg, Ms.&nbsp;Kozicz and Ms.&nbsp;Nelson. Our Board of Directors has determined that Mr.&nbsp;Dumont, Mr.&nbsp;Fassberg, Ms.&nbsp;Kozicz and Ms.&nbsp;Nelson are independent under the applicable provisions of
the NASDAQ listing standards and Rule <FONT STYLE="white-space:nowrap">10A-3.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of Mr.&nbsp;Dumont, Mr.&nbsp;Fassberg, Ms.&nbsp;Kozicz and
Ms.&nbsp;Nelson qualifies as an &#147;audit committee financial expert&#148; as such term is defined in the regulations under the Exchange Act and meets the requirements for financial literacy and financial sophistication required under applicable
rules and regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee is responsible for, among other things, the oversight of the integrity of our financial statements and system
of internal controls, the qualifications and independence of our independent registered accounting firm and the performance of our internal audit function and independent auditor. The Audit Committee also has the sole authority and responsibility to
select, determine the compensation of, evaluate and, when appropriate, replace our independent registered public accounting firm. In addition, the Audit Committee will review reports from management, legal counsel and third parties relating to the
status of compliance with laws, regulations and internal procedures. The Audit Committee is also responsible for reviewing and discussing with management our policies with respect to risk assessment and risk management. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee held eight meetings during the last fiscal year. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Nominating and Corporate Governance Committee </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Current Members:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Members During 2018:</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andr&eacute; Choulika (Chair)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andr&eacute; Choulika
(Chair)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Philippe Dumont</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Philippe Dumont</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kimberly K. Nelson<SUP STYLE="font-size:85%; vertical-align:top">(2) </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alain Godard<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Choulika serves as Cellectis&#146;s designee to the Nominating and Corporate Governance Committee. As
a controlled company, Calyxt is not required to have a Nominating and Corporate Governance Committee comprised entirely of independent directors. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ms.&nbsp;Nelson was appointed to the Nominating and Corporate Governance Committee on March&nbsp;4, 2019.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr. Godard served on the Nominating and Corporate Governance Committee until March&nbsp;4, 2019 when he was
succeeded by Ms. Nelson. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Nominating and Corporate Governance Committee is composed of Dr.&nbsp;Choulika (Chair),
Mr.&nbsp;Dumont&nbsp;and Ms.&nbsp;Nelson. The Nominating and Corporate Governance Committee is responsible for, among other things, matters of corporate governance and matters relating to the practices, policies and procedures of our Board,
identifying and recommending candidates for election to our Board and each committee of our Board, and reviewing, at least annually, our corporate governance principles. The Nominating and Corporate Governance Committee also advises on and
recommends director compensation, which is approved by the full Board. As a &#147;controlled company,&#148; we are not required to have director nominations selected by a nominations committee comprised solely of independent directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The policy of our Nominating and Corporate Governance Committee is to identify director candidates, including nominees submitted by stockholders, based on
criteria established by the Nominating and Corporate Governance Committee and approved by the Board, which includes the criteria set forth in our Corporate Governance Guidelines. The Nominating and Corporate Governance Committee considers not only
the director candidate&#146;s qualities, performance and professional responsibilities, but also the current composition of the Board and the challenges and needs of the Board at that time. In addition, the Stockholders Agreement provides Cellectis
with certain rights relating to the composition of our Board. See &#147;Certain Relationships and Related Party Transactions&#151;Relationship with Cellectis&#151;Stockholders Agreement.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Nominating and Governance Committee held seven meetings during the last fiscal year. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Compensation Committee </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Current Members:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Members During 2018:</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Yves J. Ribeill (Chair)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Yves J. Ribeill (Chair)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andr&eacute; Choulika<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alain Godard (Former Chair)<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Philippe Dumont</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andr&eacute; Choulika<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher J. Neugent<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Philippe Dumont</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher J. Neugent<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Ribeill was appointed to the Compensation Committee on October&nbsp;8, 2018 at which time he was also
appointed to serve as the Chair of the Compensation Committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Choulika serves as Cellectis&#146;s designee to the Compensation Committee. As a controlled company,
Calyxt is not required to have a Compensation Committee comprised entirely of independent directors. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Neugent was appointed to the Compensation Committee on October&nbsp;8, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr. Godard served on the Compensation Committee (and as the Chair thereof) until October&nbsp;8, 2018 when he
was succeeded by Dr. Ribeill. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Compensation Committee is composed of Dr.&nbsp;Ribeill (Chair),&nbsp;Dr.&nbsp;Choulika,
Mr.&nbsp;Dumont and Mr.&nbsp;Neugent. The Compensation Committee is responsible for, among other things, reviewing and approving our overall compensation philosophy and overseeing the administration of related compensation benefit programs, policies
and practices. The Compensation Committee is also responsible for annually reviewing and approving the corporate goals and objectives relevant to the compensation of our Chief Executive Officer and other executive officers and evaluating their
performance in light of these goals, reviewing the compensation of our executive officers and other appropriate officers, and administering our incentive and equity-based compensation plans. The Compensation Committee may delegate all or a portion
of duties and responsibilities to a subcommittee of the Compensation Committee. As a &#147;controlled company,&#148; we are not required to have a compensation committee comprised entirely of independent directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Compensation Committee held seven meetings during the last fiscal year. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Governance Guidelines </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board has adopted
written Corporate Governance Guidelines that serve as a framework for our Board and its committees. These guidelines cover a number of areas including the size and composition of the Board, membership criteria for the Board and director
qualifications, director responsibilities, board agenda, the responsibilities of the Chair of the Board and the Chief Executive Officer, the appointment of a presiding director, meetings of <FONT STYLE="white-space:nowrap">non-management</FONT>
directors, the role of committees of the Board, access of directors to management and independent advisors, third-party communications, director compensation, director orientation and continuing education, management evaluation and succession and
annual performance evaluations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Corporate Governance Guidelines are reviewed at least annually by our Nominating and Corporate Governance Committee,
and changes are recommended to our Board, as warranted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct and Ethics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have adopted the Calyxt Code of Business Conduct and Ethics, which is applicable to all of our employees, executive officers and directors. Any amendments
to our Code of Business Conduct and Ethics and any waivers of its requirements will be disclosed on our website or in filings under the Exchange Act, as required by the applicable rules and exchange requirements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Governance Materials </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Corporate Governance
Guidelines, Code of Business Conduct and Ethics, and charters for each of our standing Board committees are posted on the Investors section of our website under &#147;Corporate Governance&#148; at www.calyxt.com/corporate-governance/. In addition,
stockholders may obtain a print copy of our Corporate Governance Guidelines, Code of Business Conduct and Ethics as well as the charters of our standing Board committees by writing to our Investor Relations Department at: Calyxt, Inc., Investor
Relations, 2800 Mount Ridge Road, Roseville, MN 55113, or by calling (651) <FONT STYLE="white-space:nowrap">683-2807.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth information concerning our current executive officers: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="border-bottom:1.00pt solid #000000" ALIGN="center"><B>Age</B> <P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Position</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James A. Blome</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">56</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William F. Koschak</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">50</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debra H. Frimerman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">39</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General Counsel</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Manoj Sahoo</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">42</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Commercial Officer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel F. Voytas</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">56</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Science Officer</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>James A. Blome</I></B> has served as our Chief Executive Officer since October 2018. Prior to joining
Calyxt, Mr.&nbsp;Blome served as the President and CEO for Bayer CropScience, LP (North America) since June 2011. Prior to his position at Bayer CropScience LP, he held executive positions at Valent (Sumitomo Chemical) and Agriliance LLC.
Mr.&nbsp;Blome also serves as the Chairman of CropLife America, the Chairman of US Farming and Ranching Foundation, and the Independent, <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Chairman of Concentric Ag Technologies, Inc.
Mr.&nbsp;Blome is the 2013 recipient of the Henry A. Wallace Award from Iowa State University for outstanding leadership and service to agriculture. Mr.&nbsp;Blome is a graduate of Iowa State University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>William F. Koschak</I></B> has served as our Chief Financial Officer since January 2019. Mr.&nbsp;Koschak previously served as the Vice
President, Finance of the Brain Therapies business unit of Medtronic plc (NYSE: MDT), a global medical technology company, from June 2017 through January 2019. During this time, Mr.&nbsp;Koschak also served as interim Vice President and General
Manager, Brain Modulation from May 2018 through October 2018. Prior to joining Medtronic plc, Mr.&nbsp;Koschak served as the Executive Vice President and Chief Financial Officer of Young America Holdings, LLC, a privately held digital services firm,
beginning in December 2014. Earlier in his career, Mr.&nbsp;Koschak held various finance positions including Vice President, Finance for Convenience and Foodservice and Vice President, Financial Reporting at General Mills, Inc. (NYSE:GIS), where he
was employed from May 2005 until December 2014. Prior to General Mills, Mr.&nbsp;Koschak was an audit partner at KPMG LLP. Mr.&nbsp;Koschak is a director of 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> Financial Bank USA and has a
Bachelor of Arts degree from Augsburg College. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Debra H. Frimerman</I></B><B> </B>has served as our General Counsel since February
2019. Ms.&nbsp;Frimerman holds a J.D. from the University of Minnesota Law School and a Bachelor of Arts degree in economics from the University of California, Santa Barbara. Before joining Calyxt, Ms.&nbsp;Frimerman was Associate General Counsel
for Syngenta North America. Throughout her seven years at Syngenta, she provided counsel for executive leadership teams and contributed to the closing of numerous global transactions; launching new products into new markets; and developing
regulatory, compliance and corporate policies. Prior to her role at Syngenta, Ms.&nbsp;Frimerman practiced law at Stoel Rives LLP and Lindquist&nbsp;&amp; Vennum PLLP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Manoj Sahoo</I></B> has served as our Chief Commercial Officer since March 2017. He holds a MBA from the Tuck School of Business at
Dartmouth College and a B.S. in Chemical Engineering from the National Institute of Technology in India. Prior to joining Calyxt he was Assistant Vice President for Food Ingredients and <FONT STYLE="white-space:nowrap">Bio-industrial</FONT>
Enterprise at Cargill. His prior roles at Cargill included Business Development Director for Starches and Sweeteners North America and a role in the Corporate Strategy&nbsp;&amp; Development Group. Mr.&nbsp;Sahoo serves on the Industry Advisory
Board of the Larta Institute. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Daniel F. Voytas</I></B>, Ph.D., has served as our Chief Science Officer since May
2010. Dr.&nbsp;Voytas graduated summa cum laude from Harvard College in 1984 and received his Ph.D. in genetics from Harvard Medical School in 1990. He is one of our <FONT STYLE="white-space:nowrap">co-founders</FONT> and one of the inventors of the
TALEN technology. He continues to optimize the use of TALEN for the targeted modification of plant genomes. In addition to his role at Calyxt, Dr.&nbsp;Voytas is a professor in the Department of Genetics, Cell Biology and Development at the
University of Minnesota (UMN), which he joined in 2008, and Director of the UMN&#146;s Center for Genome Engineering and Director of the UMN&#146;s Center for Precision Plant Genomics. In 1992, Dr.&nbsp;Voytas joined the faculty at Iowa State
University. Prior to this, he conducted postdoctoral research at Johns Hopkins University School of Medicine. Dr.&nbsp;Voytas is an elected Fellow of the American Association for the Advancement of Science. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx718407_5"></A>STOCKHOLDER COMMUNICATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stockholders may contact our Board of Directors about bona fide issues or questions about Calyxt by sending a letter to the following address: Calyxt, Inc.,
2800 Mount Ridge Road, Roseville, MN 55113, Attention: Board of Directors. Each communication should specify the applicable addressee or addressees to be contacted, the general topic of the communication and the number of shares of our stock that
are owned of record (if a record holder) or beneficially. If a stockholder wishes to contact the independent members of the Board, the stockholder should address such communication to the attention of the &#147;Independent Directors&#148; at the
address above. Our General Counsel will initially receive and process communications before forwarding them to the addressee, and generally will not forward a communication that is unrelated to the duties and responsibilities of the Board, including
a communication the General Counsel determines to be primarily commercial in nature, is related to an improper or irrelevant topic, or is a request for general information about us or our products or services. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx718407_6"></A>PROPOSAL NO. 2 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RATIFICATION OF SELECTION OF INDEPENDENT PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Appointment of Ernst&nbsp;&amp; Young LLP </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ernst&nbsp;&amp; Young LLP (&#147;EY&#148;) has served as our independent registered public accounting firm since 2015. EY audited our financial statements for
2018 and 2017 and also audited our financial statements for fiscal year 2016, when we were a wholly-owned subsidiary of Cellectis. The Audit Committee has approved the engagement of EY to perform audit and audit-related services with respect to the
fiscal year ending December&nbsp;31, 2019, and the Board has directed that management submit the selection of EY as Calyxt&#146;s independent registered public accounting firm for ratification by the stockholders at the Annual Meeting. The Audit
Committee&#146;s selection process includes consideration of the following factors: continuity of experience with our business, internal controls and technical accounting experience; independence; history of and reputation for thoroughness,
accuracy, excellence and integrity; and reasonableness of fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Representatives of EY will be present at the Annual Meeting. They will be given an
opportunity to make a statement, if they desire to do so, and they will be available to respond to appropriate questions after the meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT
STYLE="white-space:nowrap">Pre-Approval</FONT> of Accounting Services </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee has established a policy regarding <FONT
STYLE="white-space:nowrap">pre-approval</FONT> of audit and permissible <FONT STYLE="white-space:nowrap">non-audit</FONT> services provided by our independent registered public accounting firm. Under that policy, the Audit Committee must approve the
services to be rendered and fees to be charged by our independent registered public accounting firm. Unless a type of service has received general <FONT STYLE="white-space:nowrap">pre-approval,</FONT> it will require specific <FONT
STYLE="white-space:nowrap">pre-approval</FONT> of the Audit Committee if it is to be provided by the independent auditor. The Audit Committee may establish <FONT STYLE="white-space:nowrap">pre-approval</FONT> fee limits for all services to be
provided by the independent accountant. The Audit Committee must then approve, in advance, any services or fees exceeding those <FONT STYLE="white-space:nowrap">pre-approved</FONT> levels, subject to the de minimis exception set forth in
Section&nbsp;10A(i)(1)(B) of the Exchange Act. EY did not perform any <FONT STYLE="white-space:nowrap">non-audit</FONT> or tax services for Calyxt in fiscal year 2018 or fiscal year 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee has delegated to its Chair the authority to grant separate <FONT STYLE="white-space:nowrap">pre-approvals</FONT> of services and fees in
accordance with the <FONT STYLE="white-space:nowrap">pre-approval</FONT> policy. The Audit Committee may further delegate <FONT STYLE="white-space:nowrap">pre-approval</FONT> authority from time to time to one or more of its other members in its
discretion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fees Billed by Independent Registered Public Accounting Firm for Fiscal Years 2018 and 2017 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Audit Fees </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents aggregate fees
for services rendered by EY in the fiscal years ended December&nbsp;31, 2018 and December&nbsp;31, 2017: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Audit Fees (1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">370,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,215,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">370,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,215,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Audit Fees include fees associated with the audit of our financial statements, review of our quarterly
financial statements, and services that are normally provided by EY in connection with statutory and regulatory filings or engagements for those fiscal years. Fees for 2018 include fees billed for professional services rendered of $85,868 in
connection with our registration statement related to our <FONT STYLE="white-space:nowrap">follow-on</FONT> public offering in May 2018. Fees for 2017 also include fees billed for professional services rendered of $898,030 in connection with our
registration statement related to our initial public offering in July 2017. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE BOARD OF DIRECTORS RECOMMENDS A VOTE
&#147;<U>FOR</U>&#148; THE RATIFICATION OF THE APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM. </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx718407_7"></A>TRANSACTION OF OTHER BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are properly brought
before the Annual Meeting, it is the intention of the persons named in the accompanying proxy to vote on such matters in accordance with their best judgment. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx718407_8"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2018 Summary Compensation Table </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table sets forth total compensation for the years ended December&nbsp;31, 2018 and December&nbsp;31, 2017, as applicable, for our named executive officers (&#147;NEOs&#148;), including our current principal executive officer, James A.
Blome (Chief Executive Officer since October&nbsp;1, 2018), and our former principal executive officers, Yves J. Ribeill (Interim Chief Executive Officer from August&nbsp;22, 2018 until October&nbsp;1, 2018) and Federico A. Tripodi (Former Chief
Executive Officer until August&nbsp;22, 2018); and our next two highest paid executive officers who were serving on December&nbsp;31, 2018, Manoj Sahoo (Chief Commercial Officer) and Daniel F. Voytas (Chief Science Officer). </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Name and Principal</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal<BR>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus&nbsp;($)(5)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards&nbsp;($)(6)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)(7)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)(8)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Current Executive Officers</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James A. Blome (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">158,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">119,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,860,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,579,759</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,353,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Manoj Sahoo</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">257,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">135,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 407,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Commercial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">197,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">105,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">784,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">212,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,300,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel F. Voytas (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">186,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 96,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 282,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Science Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">180,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">106,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">804,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">520,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,611,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Former Executive Officers</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Yves J. Ribeill (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 73,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,056,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,668,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,789,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Former Interim Chief Executive Officer&nbsp;&amp; Current Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federico A. Tripodi (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">227,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">541,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 768,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Former Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">345,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">189,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,568,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">465,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,568,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr. Blome was appointed as Chief Executive Officer effective October 1, 2018. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr. Voytas provided his services through a consulting agreement with us. The amount in the &#147;Salary&#148;
column represents the consulting fee that he received under this agreement. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr. Ribeill served as our Interim Chief Executive Officer from August 22, 2018 through October 1, 2018. He is
also a director of Calyxt, joining the Board on July 3, 2018. Dr. Ribeill earned cash compensation of $27,500 for his role as a director, which is included in the &#147;Salary&#148; column for 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr. Tripodi previously served as our Chief Executive Officer and resigned that position effective August 22,
2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The annual cash bonus payouts for fiscal year 2018 for Mr. Blome and Mr. Sahoo are $119,063 and $135,000,
respectively. At target, Mr. Blome receives a bonus of 75% of his base salary and Mr. Sahoo receives a bonus equal to 50% of his base salary. Under his consulting agreement, Dr. Voytas is also eligible for a scientific bonus and a commercial bonus
at the discretion of the Compensation Committee, which was $96,000 for fiscal year 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This column reflects the fair value of Restricted Stock Units (&#147;RSUs&#148;) granted in 2018 and 2017 based
on the stock price on the date of grant. These amounts reflect our accounting expense for these awards, and do not correspond to the actual value that will be realized by the NEOs. Mr. Blome&#146;s stock awards were originally granted on September
17, 2018 when he became a consultant to the Company. The awards were remeasured on October 1, 2018 when he became CEO. As a result, the grant date fair value for Mr. Blome&#146;s RSUs was $2,860,200 and after taking into consideration awards that
vested on October 1, 2018, the remeasured date fair value for the RSUs on October 1, 2018 was $2,002,050. Dr. Ribeill&#146;s stock awards were originally granted on August 21, 2018 in connection with his appointment as interim CEO. The awards were
modified on October 8, 2018 to accelerate their vesting. As a result, the grant date fair value for Dr. Ribeill&#146;s RSUs was $1,056,600 and the modification date fair value for the RSUs was $854,400. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This column reflects the fair value of options granted in 2018 and 2017 based on their grant date fair value.
These amounts reflect our accounting expense for these awards, and do not correspond to the actual value that will be realized by the NEOs. Dr. Ribeill&#146;s 2018 option grant originally included an incorrect strike price that has been corrected by
the Company. The grant date fair value for Dr. Ribeill&#146;s 2018 option grant was $1,668,491. The awards were subsequently modified on October 8, 2018 to accelerate their vesting. The modification fair value of the award as of October 8, 2018 was
$1,641,633. The assumptions used in the calculation of the amounts are described in Note 6 &#147;Stock-Based Compensation&#148; to our audited financial statements included in our Annual Report on Form 10-K filed with the SEC on March 12, 2019.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr. Blome&#146;s other compensation for the year ended December 31, 2018 includes relocation benefits of
$18,989 and an associated tax-gross up of those relocation benefits of $15,917. The relocation benefits included $10,989 of temporary living and transportation expenses and $8,000 for the movement of household goods. Mr. Sahoo&#146;s other
compensation for the year ended December 31, 2018 includes $10,639 of matching contributions under our 401(k) benefit plan. Mr. Tripodi&#146;s other compensation for the year ended December 31, 2018 includes $360,000 of severance, $228,923 of which
will be paid in 2019; a cash severance amount equal in value to what would have been his 2018 bonus of $144,000; severance payments for unused vacation of $24,695 and $10,465 of matching contributions under our 401(k) benefit plan.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Outstanding Equity Awards at 2018 Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information regarding outstanding equity awards of our NEOs as of December&nbsp;31, 2018. The market value of the shares
in the following table is the fair value of such shares as of December&nbsp;31, 2018. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Vesting<BR>Commencement<BR>Date <FONT STYLE="white-space:nowrap">(1-8)</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>(#)<BR>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>(#)<BR>Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares&nbsp;or<BR>Units of<BR>Stock&nbsp;That<BR>Have Not<BR>Vested (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market<BR>Value of<BR>Shares or<BR>Units of<BR>Stock That<BR>Have Not<BR>Vested<BR>($)(9)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Current Executive Officers:</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James A. Blome</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Oct.&nbsp;8,&nbsp;2018</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Oct.&nbsp;8,&nbsp;2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Sept.&nbsp;17,&nbsp;2018</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,398,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Manoj Sahoo</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">June&nbsp;14,&nbsp;2017</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">June&nbsp;14,&nbsp;2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">659,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Commercial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel F. Voytas</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">June&nbsp;14,&nbsp;2017</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">June&nbsp;14, 2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">885,189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Science Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">April&nbsp;7,&nbsp;2016</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">April&nbsp;7, 2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Sept.&nbsp;9,&nbsp;2015</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Sept. 9, 2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">May&nbsp;18,&nbsp;2015</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">May&nbsp;18,&nbsp;2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Sept.&nbsp;8,&nbsp;2015</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Sept. 8. 2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Dec.&nbsp;3,&nbsp;2014</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Dec. 3, 2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Former Executive Officers</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Yves J. Ribeill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Aug.&nbsp;21,&nbsp;2018</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Aug.&nbsp;21,&nbsp;2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">414,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Former Interim Chief Executive Officer&nbsp;&amp; Current Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federico A. Tripodi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Former Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The option grant vesting schedule is as follows: (i) 15% of the total number of options vest on the first
anniversary of the grant date, (ii) 15% of the total number of options vest on the second anniversary of the grant date and (iii) 5% of the total number of options vest on the last day of the next 14 calendar quarters beginning March 31, 2021.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The RSU award vesting schedule is as follows: (i) 25% of the total number of shares vested on October 1, 2018;
(ii) 15% of the total number of shares vest on October 1, 2019; and (iii) 5% of the total number of shares vest on the last day of the next 12 calendar quarters beginning December 31, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The vesting schedule is as follows: (i) 20% of the total number of shares underlying the options and RSUs
vested on June 14, 2017; (ii) 10% of the total number of shares underlying the option and RSUs vest on the second anniversary of the grant date and (iii) 5% of the total number of shares underlying the option and RSUs vest on the last day of the
next 14 quarters which began September 30, 2018 with an additional 25% vesting immediately upon a Triggering Event. A &#147;Triggering Event&#148; means a sale, transfer or disposition of all or substantially all of our assets through a merger,
consolidation or other business combination transaction of Calyxt with or into another corporation. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The vesting schedule is as follows: (i) 15% of the total number of shares underlying the option and RSUs vested
on the June 14, 2018; (ii) 15% of the total number of shares underlying the option and RSUs vest on the second anniversary of the grant date; and (iii) 5% of the total number of shares underlying the option and RSUs vest on the last day of the next
14 quarters, beginning September 30, 2019 (with an additional 25% vesting immediately upon a Triggering Event). A &#147;Triggering Event&#148; means a sale, transfer or disposition of all or substantially all of our assets through a merger,
consolidation or other business combination transaction of Calyxt with or into another corporation. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The vesting schedule is as follows: (i) 20% of the total number of shares underlying the option vested April 7,
2016; (ii) 10% of the total number of shares underlying the option vested on April 7, 2017; and (iii) 5% of the total number of shares underlying the option vest on the last day of the next 14 quarters, which began September 30, 2017 (with an
additional 25% vesting immediately upon our initial public offering). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This award is fully vested. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Warrants granted by Cellectis on May 8, 2015 and September 8, 2015 vested in equal installments over the first,
second and third anniversaries of the grant date. On May 28, 2015, Dr. Voytas was granted warrants to purchase 50,000 common shares of Cellectis with an exercise price of &#128;29.58 per share, or $33.91 per share using the exchange rate of USD
1.1467 for 1 euro, which was the exchange rate on December 31, 2018. On September 8, 2015, Dr. Voytas was granted warrants to purchase 50,000 common shares of Cellectis with an exercise price of &#128;28.01 per share, or $32.12 per share using the
exchange rate of USD 1.1467 for 1 euro, which was the exchange rate on December 31, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The vesting schedule is as follows (i) 33.3% of the total number of shares underlying the option and awards
vested October 10, 2018; (ii) 33.3% of the total number of shares underlying the option and RSUs vest on October 10, 2019; and (iii) 33.4% of the total number of shares underlying the option and RSUs vest on October 10, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Value of unvested RSUs is based on our closing price per common share of $10.36 on December&nbsp;31, 2018.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Agreements with Named Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following provides a discussion of the employment agreements among Calyxt and our NEOs. Each of these agreements provides for <FONT
STYLE="white-space:nowrap">at-will</FONT> employment and generally includes the NEO&#146;s initial base salary, an indication of eligibility for an annual cash inventive award opportunity and equity awards. In addition, we have entered into an
independent contractor agreement with Dr.&nbsp;Voytas. Dr.&nbsp;Ribeill entered into an employment agreement in connection with his appointment as Interim Chief Executive Officer, which terminated in accordance with its terms upon the appointment of
Mr.&nbsp;Blome as our Chief Executive Officer. Mr.&nbsp;Tripodi resigned from his position as Chief Executive Officer on August&nbsp;22, 2018 and his separation agreement, which became effective in connection with his resignation, is described
below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>James A. Blome </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are
party to an employment agreement with our Chief Executive Officer, James A. Blome, dated as of September&nbsp;17, 2018. Pursuant to his employment agreement, the term of Mr.&nbsp;Blome&#146;s employment began on October&nbsp;1, 2018 and will end
upon the termination of Mr.&nbsp;Blome&#146;s employment due to his death, permanent disability or resignation or a termination by us with or without Cause, as defined in Mr.&nbsp;Blome&#146;s employment agreement. Mr.&nbsp;Blome is entitled to
receive the following compensation and benefits in connection with his service as our Chief Executive Officer: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an annual base salary of $635,000; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a <FONT STYLE="white-space:nowrap">one-time</FONT> <FONT STYLE="white-space:nowrap">sign-on</FONT> bonus of
$1,000,000, payable in two installments, with a repayment schedule if employment terminates under certain conditions under the repayment period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">eligibility to receive an annual cash performance bonus with a target value of 75% of his base salary (prorated
for the number of days of his employment during 2018), based on his achievement of individual and/or company performance goals as determined by the Compensation Committee of the Board; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a <FONT STYLE="white-space:nowrap">one-time</FONT> lump sum payment of $10,000 in connection with the movement of
household goods to Roseville, Minnesota, reimbursement of relocation expenses up to $125,000 incurred in his relocation to Roseville, Minnesota, which are subject to repayment in certain circumstances, and a payment not to exceed $20,000 in the
event any of the relocation expenses subject to reimbursement are not tax deductible; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">participation in our benefit plans and programs in which substantially all of our employees participate, as may
be in effect from time to time, accrual of 20 days of vacation per year, and reimbursement for reasonable and necessary business expenses. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, on September&nbsp;17, 2018, Mr.&nbsp;Blome received two RSU unit grants in his capacity as a consultant to Calyxt pursuant to the terms of our
equity incentive plan and award agreements thereunder: (i)&nbsp;a grant of 100,000 RSUs and (ii)&nbsp;a grant of 80,000 RSUs (collectively, the &#147;September 2018 RSUs&#148;). <FONT STYLE="white-space:nowrap">One-quarter</FONT> of the September
2018 RSUs vested on October&nbsp;1, 2018, an additional 15% of the September 2018 RSUs will vest on October&nbsp;1, 2019, and the remaining September 2018 RSUs will vest in increments of 5% on the last day of each calendar quarter beginning with the
fourth quarter of 2019, or December&nbsp;31, 2019. On October&nbsp;8, 2018, in accordance with the terms of Mr.&nbsp;Blome&#146;s employment agreement, we granted Mr.&nbsp;Blome 200,000 stock options pursuant to our equity incentive plan and a stock
option award agreement, which stock options vest 15% on October&nbsp;8, 2019 and 15% on October&nbsp;8, 2020, with an additional 5% of the stock options vesting on the last day of each calendar quarter commencing with the first fiscal quarter of
2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Blome&#146;s employment agreement provides that for each calendar year during which Mr.&nbsp;Blome is employed by Calyxt, he will be
eligible to receive an annual performance award comprised of 50,000 RSUs and 125,000 stock options. The annual equity awards will be subject to the achievement of performance metrics, the annual RSU awards will vest in accordance with the vesting
schedule described above for the September 2018 RSUs, and the annual stock option awards will vest in accordance with our equity incentive plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Blome&#146;s employment agreement also provides for severance benefits in the event that
Mr.&nbsp;Blome&#146;s employment is terminated by us (i)&nbsp;without Cause or (ii)&nbsp;without Cause or for Good Reason (as defined in his employment agreement) within 36 months following a Change in Control (as defined in his employment
agreement), in each case subject to Mr.&nbsp;Blome&#146;s timely execution and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of a release of claims against us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of a termination without Cause, Mr.&nbsp;Blome will be entitled to receive a <FONT STYLE="white-space:nowrap">pro-rata</FONT> portion of his
annual performance bonus, calculated as the maximum annual performance bonus target amount, and the sum of 18 months&#146; base salary (24 months, if the termination occurs after the first year of employment), payable in accordance with our normal
payroll practices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of a termination without Cause or for Good Reason within 36 months following a Change in Control, Mr.&nbsp;Blome will be
entitled to receive 24 months&#146; base salary, at the amount applicable as of the date of the Change in Control, payable in the normal course of our payroll practice, and two times his maximum annual performance bonus, payable within 10 days of
the Change in Control. Mr.&nbsp;Blome&#146;s employment agreement also includes customary <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> <FONT STYLE="white-space:nowrap">non-compete,</FONT> intellectual property and confidentiality
provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Yves J. Ribeill </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with his appointment as Interim Chief Executive Officer, we entered into an employment agreement with Dr.&nbsp;Ribeill, dated as of
August&nbsp;22, 2018. Pursuant to his employment agreement, the term of Dr.&nbsp;Ribeill&#146;s employment ended on October&nbsp;1, 2018 in connection with the appointment of Mr.&nbsp;Blome as Chief Executive Officer. Dr.&nbsp;Ribeill was entitled
to receive the following compensation for his service as Interim Chief Executive Officer of Calyxt: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an annual base salary of $400,000; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">eligibility to receive an annual cash performance bonus with a target value of 60% of his base salary, prorated
for the number of days of his employment, based on his achievement of individual and/or company performance goals, as determined by the Compensation Committee of the Board; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">customary executive benefits, as determined by the Board, vacation and expense reimbursement, including
reimbursement of certain costs for accommodations in Minneapolis, Minnesota. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with his appointment, Dr.&nbsp;Ribeill
received stock options to purchase 180,000 shares of our common stock and 60,000 RSUs. <FONT STYLE="white-space:nowrap">One-third</FONT> of each of the stock options and RSUs vested on October&nbsp;10, 2018, an additional <FONT
STYLE="white-space:nowrap">one-third</FONT> will vest on October&nbsp;10, 2019, and the remaining <FONT STYLE="white-space:nowrap">one-third</FONT> will vest on October&nbsp;10, 2020, which reflects an acceleration of the original vesting schedule
applicable to Dr.&nbsp;Ribeill&#146;s stock options. Dr.&nbsp;Ribeill&#146;s employment agreement also included customary <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> <FONT STYLE="white-space:nowrap">non-compete,</FONT> intellectual
property and confidentiality provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Manoj Sahoo </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are party to an offer letter with our Chief Commercial Officer, Manoj Sahoo, dated February&nbsp;3, 2017. Pursuant to his offer letter, the term of
Mr.&nbsp;Sahoo&#146;s employment began on March&nbsp;1, 2017 and will end upon the termination of Mr.&nbsp;Sahoo&#146;s employment due to his death, permanent disability or resignation or a termination by us with or without Cause, as defined in
Mr.&nbsp;Sahoo&#146;s employment agreement. Mr.&nbsp;Sahoo&#146;s offer letter provides that his employment is <FONT STYLE="white-space:nowrap">at-will</FONT> and may be terminated at any time, with or without cause. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the offer letter, Mr.&nbsp;Sahoo&#146;s initial base salary was established at $250,000. In addition, Mr.&nbsp;Sahoo is eligible to receive an
annual cash bonus with a target value of 50% of his base salary based on his achievement of individual and/or company performance goals as determined by the Board if he remains employed through the bonus payment date. Mr.&nbsp;Sahoo&#146;s base
salary and his target bonus percentage are subject to periodic review. Mr.&nbsp;Sahoo&#146;s offer letter also provides for the payment of $20,000 milestone bonuses in connection with each of the first commercial retail sale of a food product
containing Calyxt ingredients and the execution and delivery of a deal with a leading food or ingredient company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While Mr.&nbsp;Sahoo&#146;s offer
letter provides that his employment is <FONT STYLE="white-space:nowrap">at-will</FONT> and may be terminated at any time, with or without cause, his offer letter also provides that he will be entitled to severance benefits in the event his
employment is terminated by us without cause (as defined in his offer letter). Upon such a termination he will be eligible to receive a pro rata bonus and 12 months of base salary severance paid in installments, provided that, upon our request, he
executes a release in favor of us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Sahoo&#146;s offer letter also included customary <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> <FONT
STYLE="white-space:nowrap">non-compete,</FONT> intellectual property and confidentiality provisions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Daniel F. Voytas </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Voytas entered into a consulting agreement with us, dated January&nbsp;1, 2010, as amended on December&nbsp;21, 2012, and spends 10 days per month
providing his service to us under this agreement. Under the agreement, he renders support and advisory services including providing scientific support during business development missions, running the scientific advisory board and strategic planning
services and analyses relating to project review, agricultural research and development and new technologies. Under the agreement, Dr.&nbsp;Voytas receives a monthly fee, which may be adjusted from time to time, for 10 days of service per month.
Dr.&nbsp;Voytas&#146;s monthly consulting fee is currently $16,000 per month. In addition, Dr.&nbsp;Voytas is eligible to receive an annual bonus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
initial term of the agreement with Dr.&nbsp;Voytas expired on January&nbsp;1, 2013 and was extended for a period of one year, with automatic renewals for an additional year unless Calyxt delivers written notice of nonrenewal. We may terminate the
consulting agreement at any time for any reason or no reason, subject to the payment of the termination payment described below, or upon thirty days&#146; notice in the event of a material breach of the agreement. We may also terminate the agreement
with immediate effect if Dr.&nbsp;Voytas does not obtain all necessary approvals to provide services to us from any college and university at which he is a faculty member or otherwise affiliated, in which case we will have no obligation to make any
termination payments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The agreement provides that if we terminate his agreement prior to the end of the term (other than as specified above in connection
with a failure to obtain required approvals), we will pay Dr.&nbsp;Voytas a lump sum equal to three months of consultation fees, provided that he executes and does not revoke a release in favor of us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of Dr.&nbsp;Voytas&#146; consulting agreement, he has agreed to maintain the confidentiality of proprietary or confidential information of us
and our subsidiaries at all times during his service and thereafter. He has assigned to us all of the intellectual property rights in any work product created or developed by him in the course of his performance of the services described in his
consulting agreement. Furthermore, he has agreed to not participate in a business that competes with us or solicit any of our customers or employees for the <FONT STYLE="white-space:nowrap">12-month</FONT> period following his termination of his
consulting term. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Federico A. Tripodi </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During his service as our Chief Executive Officer, we were party to an offer letter with Federico A. Tripodi dated May&nbsp;6, 2016. Pursuant to the offer
letter, Mr.&nbsp;Tripodi&#146;s initial base salary was established at $345,000. In addition, Mr.&nbsp;Tripodi was eligible to receive an annual cash bonus with a target value of 50% of his base salary based on his achievement of individual and/or
company performance goals as determined by the Board of Directors if he remained employed through the bonus payment date. Mr.&nbsp;Tripodi&#146;s base salary and his target bonus percentage were subject to periodic review, with any modification that
would result in a reduction of such compensation subject to Mr.&nbsp;Tripodi&#146;s approval. On April&nbsp;7, 2016, in accordance with the terms of his offer letter, Mr.&nbsp;Tripodi was granted an option to purchase 208,250 shares of our common
stock at an exercise price of $3.59 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The offer letter established Mr.&nbsp;Tripodi&#146;s principal place of employment as New Brighton,
Minnesota and required that he relocate to within 50 miles by car of our headquarters. In exchange for his relocation, the offer letter provided for relocation assistance of up to $78,000, which included reimbursement of home sale assistance, travel
relating to house hunting, temporary living and transition expenses, home purchase closing costs, moving expenses and an additional payment of 30% of any amount of reimbursed home sale assistance costs that are not tax deductible, up to $20,000. The
offer letter required Mr.&nbsp;Tripodi to repay all relocation-related amounts paid by us if he had not relocated by November&nbsp;22, 2016 and he was required to repay a prorated portion of these sums if, prior to May&nbsp;23, 2019, he resigned or
his employment was terminated for &#147;cause.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While Mr.&nbsp;Tripodi&#146;s offer letter provided that his employment was <FONT
STYLE="white-space:nowrap">at-will</FONT> and may be terminated at any time, with or without cause, his offer letter also provided that he would be entitled to severance benefits in the event his employment was terminated by us without cause (which
did not include a termination due to Mr.&nbsp;Tripodi&#146;s death or disability). Upon such a termination, he was eligible under the offer letter to receive a pro rata bonus and 12 months of base salary severance paid in installments, provided
that, upon our request, he executes a release in favor of us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of Mr.&nbsp;Tripodi&#146;s offer letter, he agreed to maintain the
confidentiality of our proprietary or confidential information at all times during his employment and thereafter. He also assigned to us all of the intellectual property rights in any work product created or developed by him during the term of his
employment. Mr.&nbsp;Tripodi also agreed to notify us prior to starting a new position after which we may exercise an election to restrict him from competing for a restricted period of up to 12 months after termination. If Mr.&nbsp;Tripodi is
receiving severance at this time, the severance payments would cease and he would be entitled to receive his base salary during the restricted period. If he breaches the <FONT STYLE="white-space:nowrap">non-competition</FONT> provision, he is
required to reimburse us for all severance and <FONT STYLE="white-space:nowrap">non-competition</FONT> payments he has received. Furthermore, he has agreed not to solicit any of our customers, employees or prospective customers of any of our
subsidiaries for the <FONT STYLE="white-space:nowrap">24-month</FONT> period following his termination of employment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;11, 2018, we entered into a Separation Agreement and Release with Mr.&nbsp;Tripodi,
pursuant to which we agreed to pay him (a)&nbsp;any base salary that had accrued but was unpaid as of August&nbsp;21, 2018, (b) any reimbursable expenses that had been incurred but were unpaid as of August&nbsp;21, 2018, (c)&nbsp;an amount equal to
$24,695.40, which represents payment for all of Mr.&nbsp;Tripodi&#146;s unused vacation days that had accrued as of August&nbsp;21, 2018, and (d)&nbsp;an amount equal to $144,000, less any applicable deductions, which represents <FONT
STYLE="white-space:nowrap">a&nbsp;pro-rata&nbsp;portion</FONT> of Mr.&nbsp;Tripodi&#146;s 2018 annual bonus. We also agreed to pay Mr.&nbsp;Tripodi his base salary at the annual rate of $360,000 (less any applicable deductions (e.g., tax
withholdings)) for a period of twelve (12)&nbsp;months following August&nbsp;21, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, Mr.&nbsp;Tripodi&#146;s separation agreement
provided, in accordance with the terms of the applicable award agreements and our equity plans, that (i)(A) 200,287 options to purchase shares of our common stock that had vested and remained unexercised as of August&nbsp;21, 2018 continued to be
held by Mr.&nbsp;Tripodi and remained exercisable until November&nbsp;21, 2018, and (B) 301,963 options, all of which were unvested as of August&nbsp;21, 2018 were forfeited and cancelled on August&nbsp;21, 2018; and (ii) (A) 166,600 RSUs granted to
Mr.&nbsp;Tripodi that remained unvested as of August&nbsp;21, 2018 were forfeited; and (B)&nbsp;Mr.&nbsp;Tripodi shall continue to be entitled to all rights and benefits with respect to 29,400 shares of our common stock that were received with
respect to RSUs that vested prior to August&nbsp;21, 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>2018 Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the amount of compensation we paid to our directors during our fiscal year 2018. Our directors each receive a cash stipend of
$50,000 per year for Board service, and each committee chair also receives an additional $15,000 of cash compensation for service as a committee chair in that year. Cash compensation is pro-rated based upon the date a director joins the Board.
Directors also receive equity compensation upon joining the Board. As of December 31, 2018, there was no annual equity award for Board service. Mr. Arthaud has elected to not receive compensation for his Board service. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees<BR>Earned<BR>or&nbsp;Paid&nbsp;in<BR>Cash&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards<BR>($)(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andr&eacute; Choulika</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">65,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">65,000</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laurent Arthaud</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Philippe Dumont</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">65,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">65,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jonathan B. Fassberg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,750</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">279,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">236,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">534,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alain Godard</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anna Ewa Kozicz-Stankiewicz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher J. Neugent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,500</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">279,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">236,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">528,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In 2018, Mr.&nbsp;Fassberg and Mr.&nbsp;Neugent each received RSUs for 19,600 common shares. This column
reflects the fair value of RSUs granted in 2018 based on their grant date fair value. These amounts reflect our accounting expense for these awards, and do not correspond to the actual value that will be realized by the director. The assumptions
used in the calculation of the amount are described in Note 6 &#147;Stock-Based Compensation&#148; to our audited financial statements included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed with SEC on
March&nbsp;12, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In 2018, Mr.&nbsp;Fassberg and Mr.&nbsp;Neugent each received options to purchase an aggregate of 29,400 common
shares at an exercise price of $14.24. This column reflects the fair value of options granted in 2018 based on their grant date fair value. These amounts reflect our accounting expense for these awards, and do not correspond to the actual value that
will be realized by the director. The assumptions used in the calculation of the amount are described in Note 6 &#147;Stock-Based Compensation&#148; to our audited financial statements included in our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> filed with SEC on March&nbsp;12, 2019. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EQUITY COMPENSATION PLAN INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth, as of December 31, 2018, certain information related to our compensation plans under which shares of our
common stock are authorized for issuance: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="middle" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Plan Category</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities&nbsp;to&nbsp;be<BR>Issued Upon<BR>Exercise of<BR>Outstanding<BR>Options</B><br><B>Warrants&nbsp;and<BR>Rights</B><br><B>(a)</B></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Exercise&nbsp;Price<BR>of&nbsp;Outstanding<BR>Options,<BR>Warrants&nbsp;and<BR>Rights</B><br><B>(b)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Remaining<BR>Available&nbsp;for<BR>Future&nbsp;Issuance<BR>Under
Equity<BR>Compensation<BR>Plans&nbsp;(Excluding<BR>Securities&nbsp;Reflected<BR>in Column&nbsp;(a))</B><br><B>(c)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans approved by security holders<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,214,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">$</P></TD>
<TD VALIGN="bottom"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">10.68</P></TD>
<TD NOWRAP VALIGN="bottom"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">2,696,680</P></TD>
<TD NOWRAP VALIGN="bottom"> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans not approved by security holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,214,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,696,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes the Initial Plan and the Omnibus Plan. </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the weighted average exercise price of options outstanding under the Initial Plan and the Omnibus
Plan. The weighted average exercise price does not take restricted stock units into account. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Of these shares, no shares are available for future issuance under our Initial Plan and 2,696,680 remain
available for future issuance under our Omnibus Plan. All of these shares are available for issuance other than upon the exercise of options, warrants or rights. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity-Based Awards </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe our ability to grant
equity-based awards is a valuable and necessary compensation tool that aligns the long-term financial interests of our personnel with the financial interests of our stockholders. In addition, we believe that our ability to grant stock options and
other equity-based awards helps us to attract and retain top talent, and encourages them to drive company performance to promote the success of our business. Pursuant to the Stockholders Agreement, for so long as Cellectis beneficially owns at least
50% of our outstanding common stock, any grant of stock-based compensation requires the prior approval of Cellectis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The material terms of our equity
incentive plans are described below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Calyxt Equity Incentive Plan (the &#147;Initial Plan&#148;) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>General </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We adopted the Initial Plan on
December&nbsp;13, 2014. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Awards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Awards granted under the Initial Plan may consist of incentive stock options or <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options. Each award
is subject to the terms and conditions set forth in the Initial Plan and to those other terms and conditions specified by the committee and memorialized in a written award agreement. The options will only become exercisable in the event that a
triggering event occurs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Shares Subject to the Initial Plan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to adjustment in certain circumstances as discussed below, the Initial Plan authorizes up to 2,037,175 shares of our common stock for issuance pursuant
to the terms of the Initial Plan. The maximum number of shares available for issuance of incentive stock options is 2,037,175. If and to the extent awards granted under the Initial Plan terminate, expire, cancel or are forfeited without being
exercised and/or delivered, the shares subject to such awards will again be available for grant under the Initial Plan. Additionally, to the extent any shares subject to an award are tendered and/or withheld in settlement of any exercise price
and/or any tax withholding obligation associated with that award, those shares will again be available for grant under the Initial Plan, but shares issued under the Initial Plan and later repurchased by us pursuant to a repurchase right shall not be
available for grant under the Initial Plan in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of any stock split, reverse stock split, stock dividend, combination, consolidation,
recapitalization or reclassification of the shares, rights offering, reorganization, merger, <FONT STYLE="white-space:nowrap">spin-off,</FONT> <FONT STYLE="white-space:nowrap">split-up,</FONT> change in corporate structure or similar event or
transaction, adjustments will be made by the administrator of the Initial Plan to: (i)&nbsp;the aggregate number, class and/or issuer of the securities reserved for issuance under the Initial Plan; (ii)&nbsp;the number, class and/or issuer of
securities subject to outstanding awards; (iii)&nbsp;the exercise price of outstanding options and (iv)&nbsp;any repurchase price per share applicable to shares issued pursuant to an award, in each case in a manner that reflects equitably the
effects of such event or transaction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Administration </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board or, to the extent authority is delegated by the Board, its Compensation Committee or other committee (in either event, the &#147;Initial Plan
Administrator&#148;) will administer the Initial Plan and determine the following items: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">designate participants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">determine the fair market value of common stock, provided that the determination is applied consistently to
participants under the Initial Plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">determine the types of awards to grant, the number of shares to be covered by awards, the terms and conditions of
awards, whether awards may be settled or exercised in cash, shares, other awards, other property or net settlement and the circumstances under which awards may be canceled, repurchased or forfeited and vesting will be accelerated or forfeiture
restrictions waived; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interpret and administer the Initial Plan and any instrument or agreement relating to, or award made under, the
Initial Plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">amend the terms or conditions of outstanding awards, including to accelerate the time or times at which an award
becomes vested, unrestricted or may be exercised and to accommodate differences in local law, tax policy or custom which deviate from the terms and conditions of the Initial Plan, provided that the amendment does not materially and adversely affect
the rights of any participant without his or her consent; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">implement an option exchange program; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any other determination and take any other action that it deems necessary or desirable to administer the
Initial Plan. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Eligibility </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Employees, directors, consultants and other of our service providers that provide services to us or our affiliates are eligible to participate in the Initial
Plan. Only our employees or employees of our subsidiaries are eligible to receive incentive stock options. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Options </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Term, Purchase Price and Vesting. The exercise price of any stock option granted under the Initial Plan will be not less than the fair market value of our
common stock, par value $0.0001 per share, on the date the option is granted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Initial Plan Administrator may determine the term for each option,
provided that the term of any option may not exceed ten years from the date of grant. The vesting schedule for each option will be determined by the Initial Plan Administrator. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Effects of Termination of Service </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless
otherwise provided in an award agreement, all unvested awards under the Initial Plan will terminate and be forfeited in the event of any termination of employment. Generally, unless provided otherwise in the award agreement, the right to exercise
any vested option terminates three months following termination of the participant&#146;s relationship with us for reasons other than death, disability or termination for cause. If the participant&#146;s relationship with us terminates due to death
or disability, unless provided otherwise in the award agreement, the right to exercise a previously vested option will terminate nine months or six months, respectively following such termination. If the participant&#146;s relationship with us is
terminated for cause, any option not already exercised will automatically be forfeited as of the date of such termination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Buyout
Provision </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Initial Plan contains a provision that permits the Initial Plan Administrator to buy out using cash or common stock an option that was
previously granted under the Initial Plan pursuant to the terms and conditions provided in the option award agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment and Termination of the Initial Plan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Initial Plan will terminate on the tenth anniversary of the effective date. Our Board of Directors may amend, alter or discontinue the Initial Plan at any
time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Change of Control </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the
event of a dissolution, liquidation or change in control of us, our Board of Directors has discretion to cash out all or any portion of outstanding awards, provided that the successor company will assume all or a portion of outstanding awards or
substitute for equivalent awards, any combination thereof or, if the successor company does not agree to such treatment, the outstanding awards will terminate upon the transaction and, unless otherwise provided in the award agreement, the
administrator may accelerate the vesting and exercisability of outstanding options to be terminated prior to the change in control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A change of control
will be deemed to have taken place upon: (i)&nbsp;the acquisition of all or substantially all of our assets, other than to an entity where the majority of its combined voting power is owned by us, where it is owned by the holders of our capital
stock in substantially the same proportions as their ownership in us or where the majority of the voting capital stock retains majority voting power; (ii)&nbsp;a merger, consolidation or other business combination that results in the current holders
of a majority of voting stock to cease to hold a majority of such stock following the transaction; or (iii)&nbsp;the acquisition by any person or group of persons other than the current, directly or indirectly, of more than 50% of the voting power
of us or more than 50% of our equity interests, excluding transactions that are determined to be capital raising transactions by the Board of Directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2017 Omnibus Incentive Plan (the &#147;Omnibus Plan&#148;) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>General </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We adopted the Omnibus Plan on
June&nbsp;14, 2017. We have granted awards of RSUs and stock options to our employees, certain employees of Cellectis, directors, officers and consultants and those of our parent or affiliates. The following is a summary of the material terms of the
Omnibus Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Purpose </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purpose
of the Omnibus Plan is to motivate and reward those employees, directors and consultants who are expected to contribute significantly to our long-term success and to further align employee interests to those of our stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Plan Term </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Omnibus Plan is scheduled
to expire after 10 years. The term will expire sooner if, prior to the end of the <FONT STYLE="white-space:nowrap">10-year</FONT> term or any extension period, the maximum number of shares available for issuance under the Omnibus Plan has been
issued or our Board terminates the Omnibus Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares and Award Limits </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to adjustment, 4,900,000 shares of our common stock were initially available for awards to be granted under the Omnibus Plan (other than substitute
awards; that is, awards that are granted in assumption of, or in substitution for, an outstanding award previously granted by a company or other business acquired by us or with which we combine). The total number of shares available for issuance
under the Omnibus Plan will be increased on the first day of each Company fiscal year following the effective date of our initial public offering in an amount equal to the least of (i) 4,900,000 shares, (ii) 5% of outstanding shares on the last day
of the immediately preceding fiscal year of (iii)&nbsp;such number of shares as determined by the Board in its discretion. Based on and subject to the foregoing, including such annual increases as approved by our Board for fiscal years 2018 and
2019, 4,329,125 shares of our common stock were authorized for issuance pursuant to the Omnibus Plan. An individual who is a <FONT STYLE="white-space:nowrap">non-employee</FONT> director may not receive an award under the Omnibus Plan that relates
to more than $5,000,000 for any calendar year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to adjustment, the maximum number of shares of our common stock that may be granted to any single
individual during any calendar year is as follows: (i)&nbsp;stock options and SARs that relate to no more than 200,000 shares of our common stock; (ii)&nbsp;restricted stock and RSUs that relate to no more than 200,000 shares of our common stock;
(iii)&nbsp;performance awards denominated in shares and other share-based awards that relate to no more than 200,000 shares of our common stock; (iv)&nbsp;deferred awards denominated in shares that relate to no more than 200,000 shares of our common
stock; (v)&nbsp;deferred awards denominated in cash that relate to no more than $5,000,000; and (vi)&nbsp;performance awards denominated in cash and other cash-based awards that related to no more than $5,000,000; provided that no participant may
receive awards that related to more than 200,000 shares of our common stock during the fiscal year of any participant&#146;s initial year of service with Calyxt. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an award is forfeited, expires, terminates or otherwise lapses or is settled for cash, the shares covered
by such award will again be available for issuance under the Omnibus Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Administration </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board or, to the extent authority is delegated by the Board, its Compensation Committee or other committee (in either event, the &#147;Omnibus Plan
Administrator&#148;) will administer the Omnibus Plan and determine the following items: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">determine the fair market value of the common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">select the participants to whom awards may be granted; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approve forms of agreements, amend or modify outstanding awards or award agreements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">correct any defect, supply any omission and reconcile any inconsistency in the Omnibus Plan or any Award, in the
manner and to the extent it will deem desirable to carry the Plan into effect; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish, amend, suspend or waive rules and regulations and appoint agents, trustees, brokers, depositories and
advisors and determine such terms of their engagement as it will deem appropriate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">construe and interpret the terms of the plan, any award agreement and any agreement related to any award; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any other determination and take any other action that it deems necessary or desirable to administer the
Omnibus Plan. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent not inconsistent with applicable law, the Omnibus Plan Administrator may delegate to one or more of our
officers the authority to grant stock options or SARs or other awards in the form of share rights under the Omnibus Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Types of
Awards </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Omnibus Plan provides for grants of incentive and <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options, SARs, restricted
stock, RSUs, performance awards, deferred awards, other share-based awards and other cash-based awards: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Stock Options</I>. A stock option is a contractual right to purchase shares at a future date at a specified
exercise price. The per share exercise price of a stock option (except in the case of substitute awards) will be determined by the Omnibus Plan Administrator at the time of grant but may not be less than the closing price of a share of our common
stock on the day prior to the grant date. The Omnibus Plan Administrator will determine the date on which each stock option becomes vested and exercisable and the expiration date of each option. No stock option will be exercisable more than ten
years from the grant date, except that the Omnibus Plan Administrator may generally provide for an extension of such <FONT STYLE="white-space:nowrap">ten-year</FONT> term in the event the exercise of the option would be prohibited by law on the
expiration date. Stock Options that are intended to qualify as incentive stock options must meet the requirements of Section&nbsp;422 of the Internal Revenue Code. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>SARs</I>. A SAR represents a contractual right to receive, in cash or shares, an amount equal to the
appreciation of one share of our common stock from the grant date over the exercise or hurdle price of such SAR. The per share exercise price of a SAR (except in the case of substitute awards) will be determined by the Omnibus Plan Administrator but
may not be less than the closing price of a share of our common stock on the day prior to the grant date. The Omnibus Plan Administrator will determine the date on which each SAR may be exercised or settled and the expiration date of each SAR.
However, no SAR will be exercisable more than ten years from the grant date. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Restricted Stock</I>. Restricted stock is an award of shares of our common stock that are subject to
restrictions on transfer and a substantial risk of forfeiture. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>RSUs</I>. An RSU represents a contractual right to receive one share of our common stock at a future date,
subject to specified vesting and other restrictions. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Performance Awards</I>. Performance awards, which may be denominated in cash or shares, will be earned upon
the satisfaction of performance conditions specified by the Omnibus Plan Administrator. The performance conditions for awards that are intended to qualify as &#147;performance-based compensation&#148; for purposes of Section&nbsp;162(m) of the
Internal Revenue Code may include, but not be limited to, the following: return measures (including total stockholder return; return on equity; return on assets or net assets; return on risk-weighted assets; and return on capital (including return
on total capital or return on invested capital)); revenues (including total revenue; gross revenue; net revenue; and net sales); income/earnings measures (including earnings per share; earnings or loss (including earnings before or after interest,
taxes, depreciation and amortization); gross income; net income; operating income (before or after taxes); <FONT STYLE="white-space:nowrap">pre-or</FONT> <FONT STYLE="white-space:nowrap">after-tax</FONT> income or loss (before or after allocation of
corporate overhead and bonus); <FONT STYLE="white-space:nowrap">pre-</FONT> or <FONT STYLE="white-space:nowrap">after-tax</FONT> operating income; net earnings; net income or loss (before or after taxes); operating margin; gross margin; and adjusted
net income); expense measures (including expenses; operating efficiencies; and improvement in or attainment of expense levels or working capital levels (including cash and accounts receivable)); cash flow measures (including cash flow or cash flow
per share (before or after dividends); and cash flow return on investment); share price measures (including share price; appreciation in and/or maintenance of share price; and market capitalization); strategic objectives (including market share;
debt reduction; customer growth; employee satisfaction; research and development achievements; mergers and acquisitions; management retention; dynamic market response; expense reduction initiatives; reductions in costs; risk management; regulatory
compliance and achievements; recruiting and maintaining personnel; and business quality); and other measures (including economic value-added models or equivalent metrics; economic profit added; gross profits; economic profit; comparisons with
various stock market indices; financial ratios (including those measuring liquidity, activity, profitability or leverage); cost of capital or assets under management; and financing and other capital raising transactions (including sales of our
equity or debt securities; factoring transactions; sales or licenses of our assets, including its intellectual property, whether in a particular jurisdiction or territory or globally; or through partnering transactions)). These performance criteria
may be measured on an absolute (e.g., plan or budget) or relative basis, may be established on a corporate-wide basis or with respect to one or more business units, divisions, subsidiaries or business segments, may be based on a ratio or separate
calculation of any performance criteria and may be made relative to an index or one or more of the performance goals themselves. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Deferred Awards</I>. The Omnibus Plan Administrator is authorized to grant awards denominated in a right to
receive shares of our common stock or cash on a deferred basis. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Other Share-Based Awards</I>. The Omnibus Plan Administrator is authorized to grant other share-based awards,
which may be denominated in shares of our common stock or factors that may influence the value of our shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Other Cash-Based Awards</I>. The Omnibus Plan Administrator is authorized to grant other cash-based awards
either independently or as an element of or supplement to any other award under the Omnibus Plan. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Adjustments
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that the Omnibus Plan Administrator determines that, as result of any stock split, reverse stock split, stock dividend, combination,
consolidation, recapitalization (including a recapitalization through a large nonrecurring cash dividend) or reclassification of the shares, repurchase, exchange or subdivision of the shares or other securities of Calyxt, a rights offering, a
reorganization, merger, <FONT STYLE="white-space:nowrap">spin-off,</FONT> <FONT STYLE="white-space:nowrap">split-up,</FONT> change in corporate structure or other similar occurrence, in each case excluding any triggering event, i.e., a change in
control to an entity of which Calyxt is not a majority owner, or is not a majority owner of Calyxt, an adjustment is appropriate to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the Omnibus
Plan, the Omnibus Plan Administrator will, subject to compliance with Section&nbsp;409A of the Internal Revenue Code, adjust equitably any or all of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number, type and class of shares or other stock or securities: available for future awards and covered by
each outstanding award; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the grant, purchase, exercise or hurdle price covered by each such outstanding award; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any repurchase price per share applicable to shares issued pursuant to any award, or, if deemed appropriate, will
make a provision for a cash payment to the holder of an outstanding award. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the Omnibus Plan Administrator may adjust the
terms and conditions of, and the criteria included in, outstanding awards in recognition of events affecting Calyxt or the financial statements of Calyxt, or changes in applicable laws, regulations or accounting principles, whenever the Omnibus Plan
Administrator determines that such adjustments are appropriate in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the Omnibus Plan, subject, in all such instances, to compliance with
Section&nbsp;162(m) of the Internal Revenue Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>No Repricing </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as provided in the Omnibus Plan&#146;s adjustment provisions, no action will directly or indirectly, through cancellation and regrant or any other
method, reduce, or have the effect of reducing, the exercise or hurdle price of any award established at the time of grant thereof without approval of our stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Termination of Service and Change of Control </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Omnibus Plan Administrator will determine the effect of a termination of employment or service on outstanding awards, including whether the awards will
vest, become exercisable, settle or be forfeited. In the event of a change of control, except as otherwise provided in the applicable award agreement, the Omnibus Plan Administrator may provide for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assumption or substitution with equivalent awards of outstanding awards under the Omnibus Plan by us (if we are
the surviving corporation) or by the surviving corporation or its parent or subsidiary; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">termination of outstanding awards under the Omnibus Plan in exchange for a payment of cash, securities and/or
other property equal to the excess of the fair market value of the portion of the awards stock that is vested and exercisable immediately prior to the consummation of the corporate transaction over the per share exercise price;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any combination of assumption, substitution or termination of outstanding awards under the Omnibus Plan as above;
<I>provided</I> that outstanding awards of stock options and SARs may be cancelled without consideration if the fair market value on the date of the change in control is greater than the exercise or hurdle price of such award; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acceleration of the vesting (including the lapse of any restrictions, with any performance criteria or conditions
deemed met at target) and exercisability of outstanding awards in full prior to the date of the change of control and the expiration of awards not timely exercised by the date determined by the Omnibus Plan Administrator. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment and Termination </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board may
amend, alter, suspend, discontinue or terminate the Omnibus Plan. The Omnibus Plan Administrator may also amend, alter, suspend, discontinue or terminate, or waive any conditions or rights under, any outstanding award. However, subject to the
adjustment provision and change of control provision, any such action by the Omnibus Plan Administrator that would materially adversely affect the rights of a holder of an outstanding award may not be taken without the holder&#146;s consent, except
to the extent that such action is taken to cause the Omnibus Plan to comply with applicable law, stock market or exchange rules and regulations, or accounting or tax rules and regulations, or to impose any &#147;clawback&#148; or recoupment
provisions on any awards in accordance with the Omnibus Plan. Calyxt will also seek, to the extent necessary and desirable to comply with applicable laws, the approval of holders of capital stock with respect to any amendment of the Omnibus Plan.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Sub-Plan</FONT> for French Employees and Directors </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Omnibus Plan authorizes the Omnibus Plan Administrator to adopt procedures and forms relating to the Plan as it deems advisable with respect to foreign
participants. Accordingly, the Board has established a <FONT STYLE="white-space:nowrap">sub-plan</FONT> of the Omnibus Plan for the purpose of granting to qualifying employees and directors who are resident in France for French tax purposes equity
awards which may qualify for favorable tax and social security treatment in France under the French Commercial Code. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx718407_9">
</A>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RELATED STOCKHOLDER MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information regarding beneficial ownership of our common stock as of April&nbsp;3, 2019 for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person whom we know to own beneficially more than 5% of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each director and named executive officer individually; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all directors and executive officers as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the following table sets forth certain information regarding beneficial ownership of Cellectis&#146; ordinary shares as of February&nbsp;28, 2019
for each of our directors and named executive officers individually and all of our directors and executive officers as a group. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with the rules of the SEC, beneficial ownership includes voting or investment power with
respect to securities and includes the shares issuable pursuant to stock options that are exercisable within 60 days of the date for which information is presented. Shares issuable pursuant to stock options are deemed outstanding for computing the
percentage of the person holding such options but are not outstanding for purposes of computing the percentage of any other person. The percentage of beneficial ownership for the following table is based on 32,697,089 shares of Calyxt common stock
outstanding as of April&nbsp;3, 2019 and 42,430,069 Cellectis ordinary shares outstanding as of December&nbsp;31, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, the
address for each listed director and named executive officer is c/o Calyxt, 2800 Mount Ridge Road, Roseville, MN 55113. The address of Cellectis is 8, rue de la Croix Jarry, 75013, Paris, France. The address of Fidelity Management&nbsp;&amp;
Research Company is 245 Summer Street, Boston, Massachusetts 02210. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Calyxt&nbsp;Common&nbsp;Stock&nbsp;Beneficially&nbsp;Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage<BR>of&nbsp;Class</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5% Beneficial Owners:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cellectis S.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,713,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fidelity Management&nbsp;&amp; Research Company(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,885,854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Calyxt Common Stock<BR>Beneficially Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Cellectis Ordinary Shares<BR>Beneficially Owned<SUP STYLE="font-size:85%; vertical-align:top"><FONT STYLE="font-size:5pt">&#134;</FONT></SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage<BR>of<BR>Class</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage<BR>of<BR>Class</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Directors and Named Executive Officers:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andr&eacute; Choulika (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">308,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,702,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.01</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laurent Arthaud</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Philippe Dumont (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jonathan B. Fassberg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alain Godard (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anna Ewa Kozicz-Stankiewicz (5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kimberly K. Nelson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher J. Neugent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Yves J. Ribeill (6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James A. Blome</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debra H. Frimerman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William F. Koschak</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Manoj Sahoo (7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel F. Voytas (8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federico A. Tripodi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Directors and current executive officers as a group (14 persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">742,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,904,627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.49</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts presented with respect to beneficial ownership of Cellectis ordinary shares were reported by Cellectis
on its Annual Report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> for the year ended December&nbsp;31, 2018 and are presented here solely in reliance upon such information. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents beneficial ownerships of less than one percent of our outstanding shares of common stock.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts beneficially owned by FMR LLC were reported pursuant to a Schedule 13G amendment filed with the SEC on
February&nbsp;13, 2019 by FMR LLC and Abigail P. Johnson. FMR LLC is the parent company of Fidelity Management&nbsp;&amp; Research Company (&#147;FMR Co.&#148;), which carries out the voting of shares owned by various Fidelity funds under written
guidelines established by the Fidelity funds&#146; boards of trustees. Amounts presented here are presented solely in reliance upon such information. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Calyxt amounts include 287,385 shares of Calyxt common stock that Dr.&nbsp;Choulika has the right to acquire
upon the exercise of stock options within 60 days of April&nbsp;3, 2019. Cellectis amounts include 219,173 Cellectis ordinary shares that Dr.&nbsp;Choulika has the right to acquire pursuant to stock options granted in March 2015 under the Cellectis
2015 Stock Option Plan, 175,000 Cellectis ordinary shares that Dr.&nbsp;Choulika has the right to acquire pursuant to stock options granted in September 2015 governed by the Cellectis 2015 Stock Option Plan, 120,525 Cellectis ordinary shares that
Dr.&nbsp;Choulika has the right to acquire pursuant to stock options granted in March 2016 under the Cellectis 2015 Stock Option Plan, 141,548 Cellectis ordinary shares that Dr.&nbsp;Choulika has the right to acquire pursuant to stock options
granted in October 2016 under the Cellectis 2016 Stock Option Plan and 50,625 Cellectis ordinary shares that Dr.&nbsp;Choulika has the right to acquire pursuant to stock options granted in October 2017 under the Cellectis 2017 Stock Option Plan.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Calyxt amounts include 4,410 shares of Calyxt common stock that Mr.&nbsp;Dumont has the right to acquire upon
the exercise of stock options within 60 days of April&nbsp;3, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Calyxt amounts include 30,870 shares of Calyxt common stock that Mr.&nbsp;Godard has the right to acquire upon
the exercise of stock options within 60 days of April&nbsp;3, 2019. Cellectis amounts include 50,000 Cellectis <FONT STYLE="white-space:nowrap">non-employee</FONT> warrants which are exercisable since March&nbsp;27, 2016, 50,000 Cellectis <FONT
STYLE="white-space:nowrap">non-employee</FONT> warrants, which are exercisable since September&nbsp;8, 2016, 40,175 Cellectis <FONT STYLE="white-space:nowrap">non-employee</FONT> warrants, which are exercisable since March&nbsp;14, 2017, 26,667
Cellectis <FONT STYLE="white-space:nowrap">non-employee</FONT> warrants, which are exercisable since October&nbsp;28, 2017 and 13,333 Cellectis <FONT STYLE="white-space:nowrap">non-employee</FONT> warrants, which are exercisable since
October&nbsp;10, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Calyxt amounts include 4,410 shares of Calyxt common stock that Ms.&nbsp;Kozicz has the right to acquire upon
the exercise of stock options within 60 days of April&nbsp;3, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Calyxt amounts include 59,940 shares of Calyxt common stock that Dr.&nbsp;Ribeill has the right to acquire upon
the exercise of options exercisable within 60 days of April&nbsp;3, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Calyxt amounts include 66,150 shares of Calyxt common stock that Mr.&nbsp;Sahoo has the right to acquire upon
the exercise of options exercisable within 60 days of April&nbsp;3, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Calyxt amounts include 223,383 shares of Calyxt common stock that Dr.&nbsp;Voytas has the right to acquire upon
the exercise of options exercisable within 60 days of April&nbsp;3, 2019, and 400 shares of common stock acquired in the IPO directed share program. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx718407_10"></A>SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;16(a) of the Exchange Act requires our directors and officers and persons who own more than 10% of our common stock to file reports of ownership
and changes in ownership with the SEC, and to furnish us with copies of the reports. Specific due dates for these reports are prescribed by SEC rules and we are required to report in this Proxy Statement any failure by directors, officers, or 10%
holders to file such reports on a timely basis. Based on our review of such reports and written representations from our directors and officers, we believe that all such filing requirements were timely met during 2018, except for: (1)&nbsp;a late
report for Alain Godard with respect to the exercise of stock options for 10,000 shares of common stock and the subsequent sale of 10,000 shares of common stock, which was reported on a Form 4 filed on March&nbsp;13, 2018; (2) a late report for Yves
J. Ribeill with respect to the grant of 180,000 shares of common stock underlying stock options and 60,000 RSUs, which was reported on a Form 4 filed on October&nbsp;10, 2018; and (3)&nbsp;a failure to file a Form 4 for James A. Blome with respect
to the withholding of 15,536 shares of common stock in connection with the accelerated vesting of RSUs, which was reported on a Form 5 filed on February&nbsp;14, 2019. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx718407_11"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS, AND DIRECTOR </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEPENDENCE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the named
executive officer and director compensation arrangements discussed in &#147;Executive Compensation&#148; above, we describe below transactions and series of similar transactions since the beginning of our 2018 fiscal year and currently proposed
transactions, to which we were a party or will be a party, in which: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amounts involved exceeded or will exceed $120,000; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any of our directors, executive officers or beneficial holders of more than 5% of any class of our capital stock
had or will have a direct or indirect material interest. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other than as described below, there have not been, nor are there any
currently proposed, transactions or series of similar transactions meeting these criteria to which we have been or will be a party other than compensation arrangements, which are described where required under &#147;Executive Compensation.&#148;
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Relationship with Cellectis </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the completion
of our initial public offering, we were a wholly owned subsidiary of Cellectis. As of April&nbsp;3, 2019, Cellectis owned approximately 69.5% of our common stock. As of the date of this Proxy Statement, Cellectis continues to beneficially own a
majority of our outstanding common stock, and as a result Cellectis will continue to have significant control of our business, including pursuant to the agreements described below. Currently, Cellectis consolidates our financial results in its
financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with our initial public offering, we and Cellectis entered into certain agreements that relate
to our relationship with Cellectis and provide a framework for our ongoing relationship. Of the agreements summarized below, the material agreements are filed as exhibits to our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT>
filed with the SEC on March&nbsp;12, 2019 and summaries of these agreements set forth the terms of the agreements that we believe are material. These summaries are qualified in their entirety by reference to the full text of such agreements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Management Services Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
are party to a management services agreement dated January&nbsp;1, 2016 that we entered into with Cellectis and Cellectis, Inc., a Delaware corporation and wholly owned subsidiary of Cellectis, pursuant to which Cellectis and Cellectis, Inc. provide
certain services to us, including certain general management, finance, investor relations, communication, legal, intellectual property, human resources and information technology services. In consideration for such services, we pay to Cellectis and
Cellectis, Inc. certain fees, consisting of reimbursement of all costs and expenses reasonably incurred by Cellectis and Cellectis, Inc. in connection with the provision of such services, payment of a <FONT STYLE="white-space:nowrap">mark-up</FONT>
corresponding to a percentage of certain of the costs and expenses, which range from zero to 10%, and reimbursement of costs and expenses of services that are subcontracted by Cellectis on our behalf. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The management services agreement is automatically renewed for <FONT STYLE="white-space:nowrap">one-year</FONT> periods, which commence on January 1st of each
year. Each party has the right to terminate the agreement at the anniversary date of the agreement by giving three months prior notice. We also entered into an amendment to the agreement in connection with our initial public offering to provide that
the agreement may otherwise be terminated by a party in connection with certain material breaches by the other party, upon prior written notice, subject to limited cure periods, and certain change of control, sale and bankruptcy events, or certain
judgments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2018, we made payments to Cellectis for services provided under our management services agreement of
$2,258,286, which exclude direct <FONT STYLE="white-space:nowrap">re-invoicing</FONT> and royalties paid to Cellectis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Stockholders
Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;25, 2017, we entered into the Stockholders Agreement with Cellectis and other holders of our common stock. Pursuant to the
Stockholders Agreement, Cellectis has certain contractual rights for so long as it beneficially owns at least 50% of the then outstanding shares of our common stock, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve any modification to our or any future subsidiary&#146;s share capital (e.g., share capital increase or
decrease), the creation of any subsidiary, any grant of stock-based compensation, any distributions or initial public offering, merger, <FONT STYLE="white-space:nowrap">spin-off,</FONT> liquidation, winding up or
<FONT STYLE="white-space:nowrap">carve-out</FONT> transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve the annual business plan and annual budget and any modification thereto; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve any external growth transactions exceeding $500,000 and not included in the approved annual business
plan and annual budget; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve any investment and disposition decisions exceeding $500,000 and not included in the approved annual
business plan and annual budget (it being understood that this clause excludes the purchase and sale of inventory as a part of the normal course of business); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve any related-party agreement and any agreement or transaction between the executives or stockholders of
Calyxt, on the one hand, and Calyxt or any of its subsidiaries, on the other hand; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve any decision pertaining to the recruitment, dismissal/removal, or increase of the compensation of
executives and corporate officers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve any material decision relating to a material litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve any decision relating to the opening of a social or restructuring plan or <FONT
STYLE="white-space:nowrap">pre-insolvency</FONT> proceedings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve any buyback by us of our own shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve any new borrowings or debts exceeding $500,000 and early repayment of loans, if any (it being
understood that Cellectis will approve the entering into of contracts for revolving loans and other short-term loans and the repayment of such for financing general operating activities, such as revolving loans for inventory or factoring of
receivables); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve grants of any pledges on securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to develop new activities and businesses not described in the annual business plan and annual budget;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve entry into any material agreement or partnership; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve any offshore and relocation activities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, Cellectis has the following rights for so long as it beneficially owns at least 15% of the then outstanding shares of our common stock,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to nominate the greater of three members of our Board or a majority of the directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to designate the Chair of our Board and one member to each Board committee; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve any amendments to our Certificate of Incorporation or our Bylaws that would change the name of our
company, its jurisdiction of incorporation, the location of its principal executive offices, the purpose or purposes for which our company is incorporated or the Cellectis approval items set forth in the Stockholders Agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve the payment of any regular or special dividends; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve the commencement of any proceeding for the voluntary dissolution, winding up or bankruptcy of Calyxt
or a material subsidiary; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve any public or private offering, merger, amalgamation or consolidation of us or the spinoff of a
business of ours or any sale, conveyance, transfer or other disposition of our assets; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to approve any appointment to, or removal from, our Board to the extent permissible by the laws of the State of
Delaware. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, for so long as Cellectis beneficially owns at least 15% of the then outstanding shares of our common stock,
(i)&nbsp;Cellectis is entitled to certain information rights, including the right to consult with and advise senior management, to receive quarterly and annual financial statements and to review our books and records and (ii)&nbsp;we are also
required to cooperate with Cellectis in connection with certain sales and pledges of our shares or grants of security interests in respect thereof, including in connection with margin loans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Stockholders Agreement also provides Cellectis with certain registration rights, as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Demand Registration</I>&#151;Cellectis may request that we register for resale all or a portion of their
Calyxt shares. Any such request must cover a quantity of shares with an anticipated aggregate offering price of at least $25.0&nbsp;million. To the extent we are a well-known seasoned issuer, Cellectis may also request that we file an automatic
shelf registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that covers the registrable securities requested to be registered. Depending on certain conditions, we may defer a demand registration for up to 90 days in any <FONT
STYLE="white-space:nowrap">12-month</FONT> period. Cellectis will agree pursuant to a contractual <FONT STYLE="white-space:nowrap">lock-up</FONT> not to exercise any of its rights under the registration rights agreement during a <FONT
STYLE="white-space:nowrap">90-day</FONT> restricted period. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Piggyback Registration Rights</I>&#151;In the event that we propose to register any of our securities under
the Securities Act of 1933, as amended, or the Securities Act, either for our account or for the account of our other security holders, Cellectis is entitled to certain piggyback registration rights allowing it to include its shares in the
registration, subject to certain marketing and other limitations. As a result, whenever we propose to file a registration statement under the Securities Act, Cellectis is entitled to notice of the registration. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Expenses; Indemnification</I>&#151;The registration rights provide that we must pay all registration expenses
(other than the underwriting discounts and commissions) in connection with effecting any demand registration or shelf registration. The registration rights contain indemnification and contribution provisions. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Term</I>&#151;The registration rights remain in effect with respect to any shares covered by the Stockholders
Agreement until (i)&nbsp;all of Cellectis&#146; shares have been sold pursuant to an effective registration statement under the Securities Act; (ii)&nbsp;all of Cellectis&#146; shares have been sold to the public pursuant to Rule 144 under the
Securities Act; or (iii)&nbsp;Cellectis owns less than 10% of the then outstanding shares of our common stock. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Separation Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;25, 2017, we entered into a separation agreement with Cellectis. The separation agreement sets forth certain agreements between Cellectis and us
that govern our relationship, including with respect to the following matters: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">guarantees; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insurance policies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">mutual releases and indemnification matters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">accounting, financial reporting and internal control issues; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the filing of documents with the SEC; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">confidentiality; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ability of the parties to compete with each other; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">settlement of intercompany accounts. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The separation agreement will terminate upon the earlier of (i)&nbsp;mutual written consent of Cellectis and us and (ii)&nbsp;the date on which Cellectis and
its affiliates cease to hold at least 15% of the then outstanding shares of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>License Agreement with Cellectis
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;25, 2017, we entered into a license agreement with Cellectis, pursuant to which we received an exclusive, worldwide license (subject
to existing licenses granted by Cellectis to third parties) to use, commercialize and exploit certain intellectual property in the field of researching, developing and commercializing agricultural and food products, including traits, seeds, and feed
and food ingredients (excluding any application in connection with animals and animal cells), except that such license is <FONT STYLE="white-space:nowrap">non-exclusive</FONT> in such field for any activities relating to researching, developing or
commercializing certain modified or mutated <FONT STYLE="white-space:nowrap">I-CreI</FONT> homing endonucleases. We were granted a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license to use the TALEN trademark in connection with our
exploitation of licensed products under the agreement. Any improvements we make to the licensed intellectual property are owned by us but licensed back to Cellectis on an exclusive basis for any use outside of our exclusive agricultural field of
use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In consideration for the license from Cellectis, we pay Cellectis, on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, a royalty of 3% of net sales of any
products that are covered by the patents licensed from Cellectis. In addition, we pay Cellectis 30% of revenue we receive for sublicensing our rights under the agreement to third parties. Our payment obligations to Cellectis expire upon the
expiration of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> valid claim of the patents licensed to us by Cellectis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under our license agreement with Cellectis, and as between the parties, Cellectis has the first right to control the prosecution, maintenance, defense and
enforcement of the licensed intellectual property and we have the right to step in and assume such control with respect to the patents owned by Cellectis and exclusively licensed to us under the agreement if Cellectis elects to not prosecute,
maintain, defend or enforce such patents. In certain circumstances, if Cellectis elects to abandon any patents owned by Cellectis and exclusively licensed to us under the agreement, we will have the right to assume ownership of such patents. In
addition, some of the intellectual property that is licensed to us by Cellectis consists of an exclusive sublicense, subject to existing sublicenses granted by Cellectis to third parties, of intellectual property originally licensed to Cellectis by
the University of Minnesota to exploit such intellectual property in our agricultural field of use. Therefore, as to such sublicensed intellectual property, our license from Cellectis is subject to the terms and conditions of the license agreement
between the University of Minnesota and Cellectis, and to the extent our activities under such sublicense violate any terms and conditions of the license agreement between Cellectis and the University of Minnesota, we are responsible for any damages
that Cellectis may incur. In addition, we reimburse Cellectis for payments made by Cellectis to the University of Minnesota pursuant to the license agreement between the University of Minnesota and Cellectis to the extent that any such payments are
as a result of our applicable activities. Under the license agreement between Cellectis and the University of Minnesota, the University of Minnesota has the first right to control the prosecution and maintenance of the licensed intellectual
property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our license agreement with Cellectis is perpetual. However, it may be terminated upon the mutual written agreement of both parties, either
party&#146;s uncured material breach of the agreement, or upon certain bankruptcy and insolvency related events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31,
2018, we made payments to Cellectis under our license agreement of $70,835. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Relationship with the University of Minnesota </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are party to several licensing agreements with the University of Minnesota, including exclusive sublicense rights pursuant to our license agreement with
Cellectis, in the field of researching, developing and commercializing agricultural and food products. Our Chief Science Officer, Dr.&nbsp;Daniel&nbsp;F. Voytas, is employed by the University of Minnesota as a Professor and serves as the Director of
the University of Minnesota&#146;s Center for Genome Engineering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2018, Calyxt paid approximately $487,089 to the
University of Minnesota pursuant to such agreements, including amounts paid for licensing fees, legal and patent expenses and research and development related expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directors &amp; Officers Insurance </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our directors and
officers are insured pursuant to a &#147;directors and officers&#148; insurance policy, which provides protection against un-indemnified losses arising from certain wrongful acts in their capacities as directors and officers and reimburses us for
losses incurred by us in response to securities claims involving directors and officers. The policy contains various customary exclusions for policies of this type. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board has adopted a
policy to enter into indemnification agreements with each of our directors and officers. Such indemnification agreements and our Certificate of Incorporation and Bylaws will require us, subject to certain exceptions, to indemnify and hold harmless
our directors and officers to the fullest extent permitted by Delaware law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policy Concerning Related Person Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain a written related person transaction approval policy, for the review of any transaction, arrangement or relationship in which we are a participant,
if the amount involved exceeds $120,000 and one of our executive officers, directors, director nominees or beneficial holders of more than 5% of our total equity (or their immediate family members), each of whom we refer to as a related person, has
a direct or indirect material interest. This policy was not in effect when we entered into the agreements with Cellectis described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of the
agreements between us and Cellectis that were entered into in connection with our initial public offering, and any transactions contemplated thereby, were and will be deemed approved under and not subject to the terms of such policy. Any future
amendment to such agreements would be subject to our related person transaction approval policy. If a related person, other than Cellectis and its affiliates, proposes to enter into such a transaction, arrangement or relationship, which we refer to
as a related person transaction, the related person must report the proposed related person transaction to the chair of our Audit Committee for so long as the controlled company exception applies and the Nominating and Corporate Governance Committee
thereafter (for purposes of this paragraph only, we refer to each of these committees as the Committee). The policy calls for the proposed related person transaction to be reviewed and, if deemed appropriate, approved by the Committee. In approving
or rejecting such proposed transactions, the Committee will be required to consider relevant facts and circumstances. The Committee will approve only those transactions that, in light of known circumstances, are deemed to be in our best interests.
In the event that any member of the Committee is not a disinterested person with respect to the related person transaction under review, that member will be excluded from the review and approval or rejection of such related person transaction;
provided, however, that such Committee member may be counted in determining the presence of a quorum at the meeting of the Committee at which such transaction is considered. If we become aware of an existing related person transaction which has not
been approved under the policy, the matter will be referred to the Committee. The Committee will evaluate all options available, including ratification, revision or termination of such transaction. In the event that management determines that it is
impractical or undesirable to wait until a meeting of the Committee to consummate a related person transaction, the chair of the Committee may approve such transaction in accordance with the related person transaction approval policy. Any such
approval must be reported to the Committee at its next regularly scheduled meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx718407_12"></A>REPORT OF THE AUDIT COMMITTEE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This report of the Audit Committee is required by the Securities and Exchange Commission (SEC) and, in accordance with the SEC&#146;s rules, will not be
deemed to be part of or incorporated by reference by any general statement incorporating by reference this Proxy Statement into any filing under the Securities Act or under the Exchange Act, except to the extent that we specifically incorporate this
information by reference, and will not otherwise be deemed &#147;soliciting material&#148; or &#147;filed&#148; under either the Securities Act or the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The principal purpose of the Audit Committee is to assist the Board in its general oversight of our accounting practices, system of internal controls, audit
processes and financial reporting processes. The Audit Committee is responsible for appointing and retaining our independent auditor and approving the audit and <FONT STYLE="white-space:nowrap">non-audit</FONT> services to be provided by the
independent auditor. The Audit Committee&#146;s function is more fully described in its charter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management is responsible for preparing our
financial statements and ensuring they are complete and accurate and prepared in accordance with generally accepted accounting principles. EY, our independent registered public accounting firm for 2018, was responsible for performing an independent
audit of our consolidated financial statements and expressing an opinion on the conformity of those financial statements with generally accepted accounting principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee has reviewed and discussed our audited financial statements for the year ended December&nbsp;31, 2018 with management and with EY. These
audited financial statements are included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2018 (Annual Report). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee has also discussed with EY the matters required to be discussed by the Statement on Auditing Standards No.&nbsp;61, as amended (AICPA,
Professional Standards, Vol. 1, AU Section&nbsp;380), as adopted by the Public Company Accounting Oversight Board (United States) in Rule 3200T regarding &#147;Communication with Audit Committees.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee also has received and reviewed the written disclosures and the letter from EY required by applicable requirements of the Public Company
Accounting Oversight Board regarding EY&#146;s communications with the Audit Committee concerning independence, and has discussed with EY its independence from us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the review and discussions described above, the Audit Committee recommended to the Board of Directors that the audited financial statements be
included in the Annual Report for filing with the SEC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THE AUDIT COMMITTEE </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Philippe Dumont (Chair) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Jonathan B. Fassberg
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ms.&nbsp;Anna Ewa Kozicz </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ms.&nbsp;Kimberly&nbsp;K. Nelson
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Company Website </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the
information about Calyxt contained in this Proxy Statement, additional information about Calyxt can be found on our website located at <U>www.calyxt.com</U>, including information about our management team, products and services and our corporate
governance practices (including the charters for our Audit Committee, Nominating and Corporate Governance Committee and Compensation Committee).&nbsp;The content of our website is available for information purposes only, and should not be relied
upon for investment purposes, and is not deemed to be incorporated by reference into this Proxy Statement. We make available through our internet website under the heading &#147;Investors,&#148; our Proxy Statement for the Annual Meeting, our Annual
Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> and amendments to those reports, after we
electronically file such materials with the SEC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx718407_13"></A>OTHER MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are properly brought
before the Annual Meeting, it is the intention of the persons named in the accompanying proxy to vote on such matters in accordance with their best judgment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">By Order of the Board of Directors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">ANDR&Eacute; CHOULIKA </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Andr&eacute; Choulika </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Chair of the Board of Directors </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: April&nbsp;22, 2019 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Calyxt&#146;s Annual Report on
Form <FONT STYLE="white-space:nowrap">10-K</FONT> (which is not a part of Calyxt&#146;s proxy soliciting materials), excluding exhibits, is being mailed to stockholders together with this Proxy Statement.&nbsp;A copy of exhibits to the Form <FONT
STYLE="white-space:nowrap">10-K</FONT> will be furnished to any stockholder, without charge, upon receipt of a phone call or written request from such stockholder.&nbsp;Such request may be made to our Investor Relations Department by writing to
Calyxt, Inc., Investor Relations, 2800 Mount Ridge Road, Roseville, MN 55113, or by calling (651) <FONT STYLE="white-space:nowrap">683-2807.</FONT> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g718407ig1.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="91%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">Using a <B><U>black ink</U></B> pen, mark your votes with an <B>X</B> as shown in this example. Please do not write outside the designated areas.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><FONT STYLE="font-size:20pt">&#9746;</FONT></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
</TABLE> </DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:24pt">&nbsp;


<IMG SRC="g718407pc2.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:24pt; font-size:10pt; font-family:Times New Roman"><B>&nbsp;Your vote matters &#150; here&#146;s how to vote! </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:24pt; font-size:8pt; font-family:Times New Roman">&nbsp;You may vote online or by phone instead of mailing this card. </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="73%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="middle"><FONT STYLE="font-size:10pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">


<IMG SRC="g718407pc3.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Votes submitted electronically must be received by 1:00 AM, Central
Time, on May 17, 2019.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g718407pc4.jpg" ALT="LOGO">
</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Online</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Go to
<B>www.investorvote.com/CLXT</B> or scan the QR code &#150; login details are located in the shaded bar below.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g718407pc5.jpg" ALT="LOGO">
</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Phone</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Call toll free 1-800-652-VOTE (8683)
within the USA, US territories and Canada</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="center">


<IMG SRC="g718407pc6.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Save paper, time and money!</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Sign up
for electronic delivery at www.investorvote.com/CLXT</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g718407pc7.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B></B><FONT STYLE="FONT-FAMILY:'WINGDINGS 3'">&#113;</FONT><B></B><B>&nbsp;&nbsp;IF VOTING BY MAIL, SIGN,
DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE.&nbsp;&nbsp;</B><FONT STYLE="FONT-FAMILY:'WINGDINGS 3'">&#113;</FONT><B></B><B> </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt dashed #ff00ff">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#000000"><FONT COLOR="#FFFFFF"><B>&nbsp;A&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#d8d8d8">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" BGCOLOR="#d8d8d8"><B>Proposals &#150; The Board of Directors recommends a vote <U>FOR</U> all the nominees listed and <U>FOR</U> Proposal 2.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="20"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:14pt">
<TD VALIGN="bottom"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">1.</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="19"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Election of Directors: To elect 7 directors for a term
of one year and until their successors have been elected and qualified.</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="right"><B><FONT STYLE="font-size:24pt">&nbsp;&nbsp;</FONT><FONT STYLE="font-size:30pt">+</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>For</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Withhold</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>For</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Withhold</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>For</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Withhold</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">01 - Dr. Andr&eacute; Choulika</P>
<P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:18pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:18pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">02 - Mr. Philippe Dumont</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:18pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:18pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"><FONT STYLE="white-space:nowrap">03&nbsp;-&nbsp;Mr.</FONT> Jonathan Fassberg</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:18pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:18pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.88em; text-indent:-1.88em; font-size:8pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">04&nbsp;-&#8201;Ms.&nbsp;Anna&nbsp;Ewa&nbsp;Kozicz-Stankiewicz</FONT></P> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:18pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:18pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"><FONT STYLE="white-space:nowrap">05&nbsp;-&nbsp;Ms.</FONT> Kimberly Nelson</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:18pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:18pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"><FONT STYLE="white-space:nowrap">06&nbsp;-&nbsp;Mr.</FONT> Christopher Neugent</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:18pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:18pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">07&nbsp;-&nbsp;Dr.</FONT> Yves
Ribeill</P> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:18pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:18pt">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>For</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Against</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Abstain</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="font-size:8pt">2.</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:8pt">Ratification of the appointment of Ernst &amp; Young LLP as independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2019.</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:8pt"><FONT STYLE="font-size:18pt">&#9744;</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:8pt"><FONT STYLE="font-size:18pt">&#9744;</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:8pt"><FONT STYLE="font-size:18pt">&#9744;</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="98%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#000000"><FONT COLOR="#FFFFFF">&nbsp;<B>B</B>&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#d8d8d8">&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#d8d8d8"><B>Authorized Signatures &#150; This section must be completed for your vote to count. Please date and sign below.</B></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="100%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">Please sign exactly as name(s) appears hereon. Joint owners should each sign. When signing as attorney, executor, administrator, corporate officer, trustee, guardian, or custodian, please give full title. If a corporation,
partnership or other business entity, write in the full corporation, partnership or other business entity name.</TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Date (mm/dd/yyyy) &#150; Please print date below.</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">&nbsp;&nbsp;Signature&nbsp;1&nbsp;&#150;&nbsp;Please&nbsp;keep&nbsp;signature&nbsp;within&nbsp;the&nbsp;box.</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">&nbsp;&nbsp;Signature&nbsp;2&nbsp;&#150;&nbsp;Please&nbsp;keep&nbsp;signature&nbsp;within&nbsp;the&nbsp;box.</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:20pt" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:20pt">
<TD VALIGN="top" STYLE="BORDER:1.50pt solid #000000; padding-left:8pt"><FONT STYLE="font-size:24pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/</FONT> <FONT STYLE="font-size:24pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.50pt solid #000000; BORDER-TOP:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.50pt solid #000000; BORDER-TOP:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g718407pc8.jpg" ALT="LOGO">
 </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13pt; font-family:Times New Roman" ALIGN="center"><B>2019 Annual Meeting Admission Ticket </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2019 Annual Meeting of Calyxt, Inc. Stockholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>May 17, 2019, 10:00am CT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>To be held at 90 South Seventh Street, Ste. 4950 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Minneapolis, MN 55402 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Upon arrival, please present this admission ticket and photo identification at the registration desk. </B></P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Important notice regarding the Internet availability of proxy materials for the Annual Meeting of Stockholders. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The material is available at: www.edocumentview.com/CLXT </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g718407p2.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B></B><FONT
STYLE="FONT-FAMILY:'WINGDINGS 3'">&#113;</FONT><B></B><B>&nbsp;&nbsp;IF VOTING BY MAIL, SIGN, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE.&nbsp;&nbsp;</B><FONT STYLE="FONT-FAMILY:'WINGDINGS 3'">&#113;</FONT><B></B><B> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt dashed #ff00ff">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:14pt" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:14pt">
<TD VALIGN="top" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-BOTTOM:2.00pt solid #000000" BGCOLOR="#d8d8d8"> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:14pt; font-family:Times New Roman"><B>&nbsp;&nbsp;Calyxt, Inc.</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:14pt; font-family:Times New Roman" ALIGN="right"><B><FONT STYLE="font-size:24pt">+</FONT></B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Notice of 2019 Annual Meeting of Stockholders</B> </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><B>Proxy Solicited by Board of Directors for Annual Meeting &#150; May 17, 2019, 10:00 AM (CT)</B> </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">James Blome, William Koschak and Debra Frimerman, or any of them, each with the power of substitution, are hereby authorized to represent and vote the shares
of the undersigned, with all the powers which the undersigned would possess if personally present, at the Annual Meeting of Stockholders of Calyxt, Inc. to be held on May 17, 2019 or at any postponement or adjournment thereof. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shares represented by this proxy will be voted as directed by the stockholder. If no such directions are indicated, the Proxies will have authority to vote
FOR the election of the Board of Directors and FOR Proposal 2.</B> </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>In their discretion, the Proxies are authorized to vote upon such other business as
may properly come before the meeting.</B> </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Items to be voted appear on reverse side) </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="98%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" BGCOLOR="#000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><FONT COLOR="#FFFFFF">&nbsp;<B>C</B>&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" BGCOLOR="#d8d8d8">&nbsp;</TD>
<TD VALIGN="top" BGCOLOR="#d8d8d8"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Non-Voting Items</B></P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Change of Address</B> &#150; Please print new address below.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Comments</B> &#150; Please print your comments below.</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:20pt">
<TD VALIGN="top" STYLE="BORDER:1.50pt solid #000000; padding-left:8pt"><FONT STYLE="font-size:24pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size:20pt">
</FONT><FONT STYLE="font-size:24pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:20pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1.50pt solid #000000; BORDER-TOP:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1.50pt solid #000000; BORDER-RIGHT:1.50pt solid #000000; BORDER-BOTTOM:1.50pt solid #000000; padding-right:2pt">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:14pt" ALIGN="center">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:18pt">
<TD VALIGN="top"><FONT STYLE="font-size:14pt"><B></B>&#11035;<B></B><B></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B><FONT STYLE="font-size:26pt">+</FONT></B></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g718407g62g95.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g718407g62g95.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X4&6:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!'26UG/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R]I;6<O(CX*(" @(" @(" @/'AM
M<#I-;V1I9GE$871E/C(P,3@M,#0M,3=4,#@Z-3(Z-#0K,#4Z,S \+WAM<#I-
M;V1I9GE$871E/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C Q."TP-"TQ
M-U0P.#HU,CHT,RLP-3HS,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX
M;7 Z365T861A=&%$871E/C(P,3@M,#0M,3=4,#@Z-3(Z-#0K,#4Z,S \+WAM
M<#I-971A9&%T841A=&4^"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^061O
M8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO>&UP.D-R96%T;W)4;V]L
M/@H@(" @(" @(" \>&UP.E1H=6UB;F%I;',^"B @(" @(" @(" @(#QR9&8Z
M06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z=VED=&@^,C4V
M/"]X;7!'26UG.G=I9'1H/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIH
M96EG:'0^.#@\+WAM<$=);6<Z:&5I9VAT/@H@(" @(" @(" @(" @(" @(" \
M>&UP1TEM9SIF;W)M870^2E!%1SPO>&UP1TEM9SIF;W)M870^"B @(" @(" @
M(" @(" @(" @(#QX;7!'26UG.FEM86=E/B\Y:B\T04%14VM:2E)G04)!9T5!
M4T%"24%!1"\W44%S54=H=F1'.7IA1SEW241-=4U!0311:VQ.02LP04%!04%!
M0D%!4T%!04%!14$F(WA!.T%10DE!04%!05%!0B\K-$%$:T9K8C)*;$%'5$%!
M04%!068O8D%)44%"9U%%0D%514)G549"9VM'0E%92D-W9T="9V=,1$%O2T-W
M;TLF(WA!.T1"04U$07=-1$%W441!-%!%03A/1$)-5$9"451%>'=B1WAS8TAX
M.&9(>#AF2'@X9DAW14A"=V-.1$$P645"05E':%521E)O9DAX.&8F(WA!.TAX
M.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X
M9DAX.&9(>#AF2'@X9B\X04%%46=!5T%%04%W15(F(WA!.T%!25)!44U2068O
M14%A24%!04%(05%%0D%114%!04%!04%!04%!449!=TE'05%!2$-!:TM#=T5!
M06=)1$%114)!445!04%!04%!04$F(WA!.T%104-!=U%&0F=C24-1;TQ%04%#
M05%-1$%G44-"9V-$0D%)1T%N34)!9TU20D%!1DE227A15D5'13)%:6-9155-
M<$=H0GA7>%%I4$(F(WA!.U5T2&A->%II.$-2>6=V16Q1>E)4:W%+>5DS4$-.
M55%N:S9/>DYH9%5:2%1$,'5)24IO34I#:&=::$I21E)Q4S!6=$Y62T)R>30O
M4$4F(WA!.S%/5#!:6%=&;&%7,7AD6&PY5UHR:'!A;71S8E<U=EDS4C%D;F0T
M95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\K0VLU4U9L<&59;5HF(WA!.W%B
M;DHR96XU2VIP2U=M<#9I<'%Q=7-R839V;U)!04E#05%)1$)1545"45E%0T%-
M1&)114%!:$5$0D-%4TU514954DYH26=:>&=:17DF(WA!.V]B2'=&34A2-%-.
M0T962FEC=D5Z2D121&=H85-5>5=I63=,0T(S4%-.94I%9WAD56MW9TI#:&=:
M2FI:1D=I9&MD1E4S.'%/>G=Y9W F(WA!.S K4'IH2E-K=$U453504FQD65=6
M<&)81C%E6#%2;%IM9&]A5W!R8D<Q=6(R4C%D;F0T95AP-V9(,2MF,T]%:%EA
M2&E);4MI-'E.:F\F(WA!.RM$;$I75VPU:5IM<'5C;EHV9FMQ3VMP86%N<4MM
M<7$V>71R<2MV+V%!07=$05%!0T5135)!1#A!.54T<3=&6%EQ-T9867$W1EA9
M<3<F(WA!.T9867$W1EA9<3@O+T%$9C@T834U83 W5#5D26Q31U,U;&1*2%I&
M8S!645)13E5D.'=T8FYL:D$T5W9*26IK.'%(-7EF;4E(-4A61DDF(WA!.R]K
M3G9B,"]#3W8T-7)F>C)8=CA!<T14-&MN;U U8V9N1%!R5W!2-DYR:U5C5C-0
M55=T,T965F1X=G=D4U11;G-2.'%:;3986$=:-%HF(WA!.V,R,D=3.6DY57I:
M3G)"=GI,.'I75VAX45-Z-G(Y5TQG<6)*1U!Q3U U=VEF15(R4&),8U=->35"
M,S-9=6AN;DI%66-8.4QP."M4>G4F(WA!.WDX+RM83#8U5T583%)Y>4=I=$UP
M544O-C(T2# U9DQ45$%U;G!-=EDK9DA'-G-$=65L*U5.96XK<T14-VU1>5)Y
M1#EW>D=P5F@K>E4F(WA!.SEI37AP0C5F=$13:F@T-&IL>EIL:TA3=7A6,DMU
M>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU
M>%8F(WA!.S)+=7A6,DMV2F8X06Y)6"]!2357:B\X04=E6"]!26=-,6YA6$E.
M3V)K.%!Z54Y#9F519BM5,C!0+VU/9R]W0U1G>3=4+W="-4@S<V\F(WA!.V-W
M*W%,:4XU8F573T]6;TI(4FQ36D%P6D-244UO64UT5C8W9VI/:T1M=VM!45-,
M.'4Y.' O;58U33AZ*UAT8FMM,6U6-RM/-V-T1'$F(WA!.W)665-N<E)I4V5,
M1"M5+U)T;38P,E=-:%$R<F\K=3EI9'!A9E4T9TU1141(;D1U+U=03F@K6D1U
M,V\S-60K94I)-6].3G9:8512<T0F(WA!.UDS1$AU<'%),E X07A(-W9$3415
M-F8X06E$>2]B4%I124]303)0,40Y4#8S,&Y9,V-D,UIW,TMF6FQ53E1W4&-F
M46,Q:C5J;'AM16HF(WA!.T4Y1F9&<F1I<G-69&ER<U9D:7)S5EEV*UHQ,V0R
M9FM85F)M,&UK=#=I3DDO5&UI66\V,6U11VI+45)S8W@Y6$EJ1U-'12M4-7%B
M5W0F(WA!.UI:*V)8.7=Z+W=!>&QC;F(S<FY0.&-U.'5.6EI6-4\O3F)Z3&]L
M+T-,,CAL,413>7=7-'0U,DUJ0D]H84YM<7EL97=R5$UN0G)*=T\F(WA!.S5S
M330U0T@P:DA):VMA>5)S1U)W1U)H,$E)<41M+T)C;$E03DAM6%5T1FYS:W0Y
M3$8Y1F944C)S8W8Q:%EA5'EK.%5+;$<R;W8R<V\F(WA!.WI:5$%I:&0K8D=2
M<$I,<C@R3%,P,#=72C=Q=V%/.3!I-%,Q3FM*43-Q<S595E8K4%%E;3ED=C)C
M<$]T04)*1SA3>#A2;FU:<EEG=%8F(WA!.S%V4CE*9SEF53=Y1WII4#)43318
M;%1S;T\W2#5:0V53365:<$))1$5R<C@V=DE%1#A%=35B:GAA2T=3;B]$:$UX
M:G(X439S4$5#*WDF(WA!.R]/8GE"8W1W82ME,EEM9SEE1U%!+W=#>55/0CE*
M>&IR<U(V<$=1379S9%%S3E%T;'5B1S1J=7)D+W-Y=W-(52]3<$]:55I#47-'
M,EDF(WA!.TM)>5-P6')(;6YY-V]W+S-+86I"8713;VED>#9H2&E)>%9Z.4%Y
M=65A15!Q3DE-9T=-,U@U,65125<T<&1Y,TAV1D)*5"]H=VU9-3$F(WA!.RM)
M9%=(:5)5-&9Z=CAH4U!X864T:4@X-W=-4B]W=DDO:&='=G@K82M+1U0V2#5V
M.',V-71P5V]W,TUG1E1#0U9L<#0K;316-F92;5(F(WA!.VIZ=VXY2EII44MB
M-6%L-4PO=T$U0R\X04A+,&8O:E!,+W=!44=A>G1,:T=N3GEE2#5Q1VA0=DE0
M+TMB84@O>DA19CA!2G=:9' O-WDF(WA!.U!V6E$U:#E086QR,FEA5TLV:F8R
M.6Y55D%M;%)#4C=":4-F;WIO6C5)>#5K0GEI44=--G8U,R]++U=B2UA3.5,Q
M2S)U8E<T1DAJ8U F(WA!.W@V-T5.>"M&9V1W83%'5G@Q=4]*<U,S8F1.<DI9
M6FEE3UA$25!$9E O=T-75GAO22]3=6I3:E9F3%4U2FAV65-*9E,O>5I3;%(O
M<RLF(WA!.VYY3V(S4S9U3U%C.2]V9E5U=R]A2$AQ-#A-<6IL-W8U,W4O57=:
M95A)8V$X<3=5-C%Z365J3#96+TQ(>DQQ1VTK5&A*-7EP<&-A4%,F(WA!.WAN
M=3)%8VLV16)K4G-E9%%F8F5T8S!/<VYJ:$QM2V9*=F%73VYJ<4QW>4)V;EA1
M*R]W1$9-:V@O379Y2$Y*=U17<F--5%-R;&M(+T(F(WA!.T]&1UE9,65)+W=!
M5'IV1T\Y4#1B*WAN='9R54YZ1DQA,'(V-D]R4C!(*U5$5$QH245897I+,&YV
M4'I!.&Q78CA*.6%T3V9D56M%:$@F(WA!.WHY4&Q42W!A;D=0-&=X-'=Q-E(U
M,#AQ87A.-D=M-G!"8U1K5D5)8FI)4C$R4G5,2#9-34TX2F)!<4I!<#%L>DI+
M.5DX,"M89$=+<G$F(WA!.VUO=U=J=G5S8VIJ;5(T:$)6<64Y37)N;6A$-FI3
M1$E"05=N-6HK4G)T,5-,5W)933-4,5<Y3#A:06U6>#%732]X0DA'3SE!+VUL
M4$(F(WA!.U K6$=R5%%33$Q%.&-:4U)#1U5J,3 V16)(239S9S1J6#0S4FLK
M;#AZ6GHW:75X5CE/-DXU*SAL=S9067A3-C%A2DI(8GA+-D=15D0F(WA!.TMG
M0D)Z;TUE<'AI23E1-4]52FIV4FXQ=GEV-7-E,U-Z,49,<'1,=5EB-$,R9%-1
M.&9,9TAQ1RM%,5 X05A*,T1,5DAK8E1S541Q2#4F(WA!.U@K6$PK-6YU6C-U
M4DYC1S9,<W)O3C=U=DML55 R3V)C2SE/4C8U0U=K9U1E+U@W54=!55!Z3B]-
M4U!Y<%E*0F%H6F1:=7=48GAT=7,F(WA!.V%6;UI82&9F6E(S4'EW8795*T=+
M2#%&6GIP.#=A<'$R<&%R95!E-FIC=F1856XR<%I$52])9&=",D$R>E)4;5I'
M>6),:D4R:$UI:#(F(WA!.TMS:#AJ*V%T5CAV83EB5#)C:F5H3$MI6%9Q0U-S
M<UIA:$)8*V%H*T4Y<W8P*V%52D%H;$-61C=V*V)(;5!5=$(X;U-83VUS63=Q
M95HF(WA!.TQC5&=!;4Y81$9M1F4Y1C1G*RMB:E=:5$-&:FTU1U-60C@Q5'IZ
M5'I03E!),',P:$Q34T]3>DUX-FMK-VLU;U-B8U9:9U8R2W(T2C4F(WA!.S=E
M6DHT2D=I;6I)84]20U9:5TA19VIC2$-$4W9P3#AQ9D]S,VUF44@K=6M.<61G
M=VEU;4%P>E9G5$A*46)!=%%G*S1Z9F%04#1K9"LF(WA!.UEC<DA+=WAR+VY)
M6"]J;&%0+WAN;"\T9TUX*S!U45E:=51W+TY1,$HY-4(O-51B42]W1&U/9R\U
M3T1,=% O95(Y-TM(35!1=BMC9W0F(WA!.T0T,T=M835'3G!&87IN3D\V,6MJ
M*VMG=CDR6C-A5U!C4RM$6FU(5C0O;7)A5V$O;%(U<75D1S@P5S%M.&A/;6%N
M271T9'=-9F<U4V8F(WA!.T%J,$\Q5EEI<#A+-6PV4$U95$$V1G-X5$E,-D)K
M,&)Y,7 U;#%0.$%2,7!"2D-H:VQU:V=J5U%,1T-X4$E,>3)Z9GEM44YZ<S='
M5W,F(WA!.WI'4$-:>4UE-VE.4&U(>EHU;78O041*<F1X<60R>"]E35)B>$4O
M1$9%1#A#3#AH,3A4=FY.6G-P>5-S=7)L2WEK*U9)938K4B])5G(F(WA!.W$S
M-51F54QN.3-0<6MK;#5&3%1E3U94=VAB,TA&0E5E0D]B:E0V8U-W565U-VM2
M:&-8:5=O-F9D-F1F5#).,T=9<FTR9&\U55!:;$XF(WA!.TTQ36]M2F]U3U)3
M;$1.3$1+:S!,=$A,1W=A3U)347ES1%5%161#34%.2SDS,"\X04YD=BM665,V
M>DTV=G)D<W=S4W!P.&1W=R]D>6,F(WA!.V9!<#A:.7=2;31J<E S4$8O1GEC
M9UI05&)W>3EV<G4K=35B>3AL864U;EEV3$LU<7I-8S X<$5M>30U3%9N85A.
M-611,FQT1UIB:60F(WA!.S%J:&I8<7IS84%$-F-99VLP1D%E.659+TLY=C5:
M+TIU+W="3&EO,'%X>'E856\O8FUE85!M,WDR;U!91$YZ;'=J2&=)8VE586DK
M9C@F(WA!.S!R:G5X5C)+=EAF*V-E9BM/:')8+T=+2"]I5#5S*WI/8VTW1#%E
M,C5T,CDX<&5E9&1M,7IZ5G%/;T\S2D=L84\S2%E1>&YH1T(O<U(F(WA!.U4K
M*V,S<4UN2$UL>$IM>6M757-762]L,2M85C$U=G5P;F59,G5M,G1"4$]">5IN
M8F-)9TY"5VY5.7-Y=$QP:FQ08T%Z:$,S;SDO.$$F(WA!.S@T+RM7,W1Y3$A5
M3'5#-$$K1C5J2$MH4'5Q<D=F=4]:.'5Z659S4S)N0T=/*U10>6DQ,C X.%)$
M5TE2*VIT3TEU:&-P.%55-TMF,V$F(WA!.TE34#5H5FQ)-D0S1U593D9)6E!6
M>41'3TTS=3EJ.'AA2%HV-V]T,W!6,R]C,U-C95$S2TU$5DA(=7)!2$YP;'AI
M8U1%='A&:#5X;VXF(WA!.S5%8499>$<V.'A8-UA006-N:FI0;U%+4#AP>CA:
M*V16>D%X.6YX1SAY,41%3W%95%(O:UAP;TU,+V\Q=5!8:51C;B]G;#E1+VIL
M:"\F(WA!.TQ2-W9V6F5G4$M0>D=4>55.66EK.'!Y0G)/4TMT>$5O:T-P2T=0
M,F9604\V,#)'83-5*TAX96IK,'IQ.6U+6FI-2'%8+T]0='DV*UHF(WA!.W12
M=&=4=VQS:DE2,G)(2VEJ+VLT8S)06G Y6DAK,C1E869F.#5#+SAC<E(O*TTX
M=B]%0FPS85A)37,S2C1F;6]A12LX9R\X04MB84@F(WA!.R]W07@P2"]*=UID
M<"]W0SAJ-S)53UEF468U;F%)3EDX:S9L8G%V2V5#4#8Q0E1R>F<K3V<Y,E5&
M9G!Z9#9V2'A9>4A);4Q$-65Z;FXF(WA!.T98=WI01$Y(3D=A4U)S2%$K0E4Q
M1T5';&942&XW6%58.'1B+T%&2TDX5G9B3D9I1F%M;#-X4V<O,DUM8B]5-5 S
M2E!E4'9C<5HY3#4F(WA!.VMZ;C-&5DQA,VQU3&E+,VE(2U=:,6IJ6'A::E%$
M-WIH07,P<C8Y,'5W:C O5$Q3=VDO=3=31T]"1# R:E5+4#%:,#A).$E!-VY-
M064F(WA!.U@O;F@U2"MT5V<X>E=-9BMK5WEH3E)59%AI1WEY9354;V8X04HK
M5V$W=$14,D]-9D9Q>7@V=D1S,411=45K9VI-65EI3FE'6DMM:$LF(WA!.V=G
M16IX2$DT<71X5C=&*U)F:W9M-RMA3#)0-%4U439A<D1Q,S):2E(X=G-$-F,R
M;EHK1"M-+T)U>%(V<S<O3FHO=T%L-W)(*W!&+WDF(WA!.V5437I79C-28DUN
M,'9M3$]F8U8R2W96<D@X9W(K-W-R939'<U)+3&E.2E%P:%EK0C%$52LQ-S5S
M;SEN16DW8FAH6GHK5S,U8EA0;$,F(WA!.S5V<'!R-4QS6&%2;T%K6E1J=TI0
M8W0O3FU:<&1+8U)/.3)Z:$1H6C-M63)0:EA/5F-*,DMV;V(X:59J2&MD:6Q/
M5%AK>&MP+TYX46(F(WA!.R]W0WA!>F5D;B\S9GAC;D9Y96E:;DYJ<U99<BM9
M4&YU,#AP855S>%%4-FAC:W):5WA.05-V,FYE;C=+,49F2' W-6IA;E5$1DAZ
M650F(WA!.VY4-3$X=V5A.68X04U&>5HY5G9*2CDV<$17:U-E>5)J-%)M:7E:
M<%1.>4QJ1U)+5S(Q=&,S57EW5S!4>GI/84I&1W!D:69:5G%4:T$F(WA!.T-E
M4T9B571+,4Q42GAB-FIB4U=K-TM(155Y;$@T:VM!.%1V,G=Y9UEM:4M34E-&
M>4M(<&XU068X<&QE9CES-E0O:R]$;7<W3B]V1#<F(WA!.W8Q3G5(;7E4+VY)
M6"]J;&%0+WAN;"\T9TUV-U,U0FQM-5!$.#%$46XS:T@O04I48E$O.$%M3V<O
M-4]$3'10.$$S:V9E>6AZ1#9S24(F(WA!.T)"1E%D:41N4T]7*U1F3T=I3F]N
M;695=$TT.%5T-6TY14@O9E1F2$=F*T%96GI79DAW5$EC4U%O<%!L5$8V8C5P
M.'@O5V9Y8SAU5V8F(WA!.T]S,&MX:&LS-DI:.&M#+V,P6GI96G-T-$EJ.&).
M<W!E:U!-<S$W57I$.'!D2D]P964Y3T)&67)2;74U1#1E:4MO9CA!:UIX>DLP
M8T\F(WA!.TQ)4$QD;FI&;#E.6C!$;$Q:66\U63-I;%502$EP5C!95D)5:6A"
M0CAC0D9Q*U4O4$=K-F1P2&UR5610,#995%=C17!%6D<O0V]"84TF(WA!.VYU
M67EE4#!:>FUO9TEZ24A*>$II:6ME57-54G P3G)0<49T0F1Z9E8W5U=616YU
M2U8Y3TYM05HV9C5),WE544-29DI1*W5D3G-R3W@F(WA!.S K,W,W2E93,&=J
M5DE&6&-C04YT*SEF2$]M:$5!041K-6=$1R]W03)0+TIE-G@O<5)F.$%*-4UX
M.5HO9$9J:RML.'A:>C=I=7A6.64F(WA!.V%$+WAW=$\O-6A99BM4834P*U V
M4C=N34A*2%I.3'-69DEV;4A42DY+,3(O,#9156$Q;FMI2'5Q<V5**VQA2$]9
M>5$T6D5D>FAY1D8F(WA!.TPX9V@V9"M49C5G-F9O3#-':C9T2C9&:&1/2F],
M:S%+>'DP0W-(<#!6=V\S-U4Y.#)':#%):&-:8VDR-#4Q<UAS5C$U,CAO5S%U
M,7@F(WA!.TQR5FPV4VET56YJ9&HO<7%H6FTK9UIT1'%-648X46)U24I"-5DO
M3G)1=DU0;5=44G)A2C1O>6A.;&-Y:T0Q;5-P9&5(-U!W-W)5-RLF(WA!.S)5
M-'1B1V,K14U9-4%45'I,.#EB>5=B>G-)1U W=3)T66MJ2&(T:7IK+SA!1%IR
M*S!*6&LY=V%S=DXU,VU#,79D=GE!=$Y-1V=8,3,F(WA!.T=Q2%5Z8VU+9#EV
M55=)27))=G-P4$DK-2M78FIS,DDT4V5T=5)I-4U*+U!'94=8>C V>'5(84<R
M:%-503$T=#A455!V4F=C>$\P1&4F(WA!.U0T3F58;3@O>D-A,W!N-4%F.'!L
M968X06)/:R\U4'<U<T]Z9C=W*S<Y5&)H-7-K+S5Y1B\T-5=J+W=$1V58+VE!
M>2]T3&M'5V)K.% F(WA!.WI53D-F95%F*U4R,% O;4]G+S5/1$QT4"]E4CDW
M2TA-4'%Z3VMC=#1D+WIK0F]F;S9R<"MS>'%!;#%%8F59:B]!2#5%95-K+S9Y
M=E0F(WA!.R]9-7 K,'-D4T5U.6]Z1'$X;7I7=$M);'8W:5=W=#=&,G)"8E-3
M>7A,-$Y-140O.&UH:VI),5,R:#AI<C)B+VY(=E-.=%<Q:#$O:W,F(WA!.S18
M+S5+4VHO04EH;3$W3FAZ;#A'+T-/<C)43G$S34TO3DAZ=79L:E%3='4T+U,Q
M.$=J<S$W;TMF1DM2+VM6,CDV6FEA=E5E2$AB-FDF(WA!.W=N2V<K85=:;EEU
M-4Q->$I::6%K:SE35&UG8U9R1EA9<3DX+TI0>G8K:SE,3V=8<VQB-U0Q<F%S
M>#-K='AS0C@T*VYY<#<U=61"<4\F(WA!.TEC2C5J-VY)>%-V6FM0-7-!;CAV
M9%EP=BLW:B]!3U1Y6F9R4#=O<W-N,'9M3$]F8U8R2W9O6'DW*V-(:W%0>35:
M:3EV1W0W>3-G:FDF(WA!.VUT5$9)>D8P44ME0E93<$)),C,K96)V1G)C9D%,
M3S=K:DE+5%AY3BM:5VUE8F(R+W1B84(W6C=4:3A#>6M&-5E4<UA+:EIE3&12
M53DF(WA!.U)L=6XQ47EK9V1%>&YB34UY;6)Y5#@V9GDK=6(X+S1K,'%)>3-%
M84).4F=15EIK45575E(S2VI:=F%N9V,Q;78P>%!R:CA7;DI#.7<F(WA!.SA1
M>E5.1'-69&EQ8BM54F9N>E1P4#%!13-N,75%=V=E26-(9C)P,3ES='<S>&EU
M9'!J>F5J+VXW-6)U0F4R;FU'1D,Q<SA9=&)O:F8F(WA!.V<V<U-J2"]71%4K
M:C-Z3S=2>$=X2G1Y>#9V26,Q:E-R5VPY93)B;5,P=4I,9'E+1C1N6D-2-%95
M:D-*16-L0E4U2DI*2&%34FDW<V$F(WA!.W,W1W!*4&-K-$97-'$Y1R])8353
M3'IT3$<S5S1S<%DP*UEE3U0Y4TA-+W,T,6LK1&)I-7-X+S5Y0G-P-5!,,FY8
M84M7:70W:W)+4C(F(WA!.SE24&A*.7%R5$UR=$M*-%%F3FYM1WIW:DY--#9F
M95%F*U4R,% O;4]G+S5/1$QT4"]E4CDW2TA-4'%Z3VMC=&@O=T-B5V@O<&)Y
M4&8F(WA!.W%O<DY:05AS4'IH0C4O.$%*371M3')C9D9J4&QU=WE#=RM:8S4Y
M>%A9<3=&6# S*U4R:V9O>GE*<'%S=D=7-U9R=5=V8WI'<4@O:U@F(WA!.WAZ
M;TY(1&AX:GHS8W)'2T1*=%0Q1WHP>E0W:2]V2D)&83)Y1U-6>C)!.%!%;F]"
M;5)/46E,4$IK5%0U6C@T*V%,>GI.<C%X<6QX5E4F(WA!.UDX3&%'=%)(0W K
M0E T;C-Z;DTK535*8U)C5U5R2U-:57AE;F%H*U9%,70K5V-/<FE.:G)C6DXW
M9%(Y>&)/05!4<#1O;T1N=RM)6G,F(WA!.TIA3W-01B]&>BM$86-F<&59-7(R
M<$AA2').-V]U<E=U<5=48V)M,6-/=F=W-DUJ52]:6F%G*S)4>'I-2D%J;VM'
M:2MN16XP,WIR-4TF(WA!.VM.=7<K<F%R8E!(=G59<$-#2TY4.7%.+S%:,$9J
M3&HR-FAY=G%$-68Q4%1B,U1.46XP*SEJ34XQ8D]9-550:4\T.%%E;U!C6GHP
M-&TF(WA!.TIO.#-&27!#-49$<U9:="M46G90*U9G-F8Y5W)X2WIF5V5T4%,Y
M2G$X<68U6$=N=E1-=E$S-&]P;FHU=G!43BLU5'-665HU;B]+8GDF(WA!.VAR
M,'(S3%%.63-R,4PS1F]1;DEN=39%1D0W;6=*.&-X375J:%!F:U=%<UE,1$QR
M+T%*>#1A=&)86$%26#=-='9U0B]R3$IV.3)9<#<F(WA!.TTW<&99,2M$-7)R
M4"]N2&AE44XU<EI+,3-31T-H<"]R334O-&IJ2'-Z=FMK669.-D(U52],-WEX
M-5EQ*VY7-64V66-7=DIY2DII4$$F(WA!.T=G0RLO141-,T1P;UDK6$YS:D%"
M4#=Q,71R=3-K=')Q2DHW955C6DEP1D1+=U!99S=:95%#2TQ*-7AR2#5$959R
M=59P9%!U6CE/3%8F(WA!.U!P0VLP67(P;TAO+R]$6F=4-T]G95)P<4])24\P
M+S5X-S!D2D%B=E9R:5I+-W)&1VM2*SEJ3"MR25(W3FHQ2U!"1$PT+W=!<W9*
M:V4F(WA!.VA484UL9V]T-39'5V%P335D9#%F,50X5E905'0W57I+1VMX.%!$
M5%!G1E5W>68X035X-3 Q<%=.=G)-,&-8-TM347$W1#5S1U%(-W,F(WA!.WA4
M,EE/:VU(9W U-5$O2C-3=DQM<E%A<W5O6$9Z95<O3#!X4DDT>GI1;S-*84]4
M<W@O87DS1&]9=VQX5V):4GAG1S)C,SEH6C,Y;DPF(WA!.UI8<TMZ,G,V;$I9
M6$9664A->552255E5%E1.'HQ3"]N2"]12G!M97<Q1S1T16)C4D]Q>DMV<T0X
M1%4K6D]9175Z66YK86%J:$-,.'0F(WA!.R]K:&\R:C9N839L3'%&>&181G!)
M<S!+:%5I5&UH<4]1*TUK9E1K<U=G:D5G,V1,2$5!.4EZ4&)6:G!&3D4X8F=3
M4G5'4C$V9VIO=U F(WA!.S9S2$Y8:R]N,SAU=GDX.'5E5TQZ54)B>4ID.%1&
M67$P.&@U5'9S;$9*,S0O84DX0FUT,4=M>%DT13E7;6-)9U!%33%$46DY23 R
M9E4F(WA!.SE6=$Y/9T@W,C=M4T90675W5W8P5G)K;U)-:4%/<5%,3#8W=')E
M2S-T-')E16-9;U573TYF0E9&05!U1V1/0E%P>D5N.#-E56),>E(F(WA!.W V
M869F6%9Z8C)Q=4I(4S):135K9EHU.#!K<4(Q<&Q78D--9V]K,'AL1S)(+W=$
M2V=02G8O3%IQ4"])>40O<6IM3"]*=5!V4#0K1$0F(WA!.W=1:4Q$.&DO2G1N
M97=89G(S='@V16EY0T=:-%=J8W%A:%A!:55L9D56>55E>CA93C=P1TE04D=6
M5U5Q=T)5:6A",T)">D]B2&UM=B\F(WA!.T%*12M7.5%U,W5D4'5:9$U-:$Q0
M06EI5T5%.65#:W%6*UA+;FAM=GED;G=K8D)P<4])1D$R=CA!>FHQ<$MY03-E
M<GIY>#DQ:6I322\F(WA!.V5X:R]6:T(R8DAQ565#2&]8;&YY=&\O;')4>EEA
M5VIP0WIM4U%Y3WIL;DE!3$=P;T111#=)1UHR3$1(1TMI,GAI06=F3B\U92M8
M4$XF(WA!.TMQ*V]23DAE24]-9#=!47-O6')X3E%6669-9DQ)6CE.1$IZ-6]L
M048U-V,O.#0X4S@V,G5U2U5.9'!B8V=J=S-743$K-%IG;G-Z=6PF(WA!.SEJ
M5C10;7(R2"]/4$YS<DLQ+W)4>4HK,4A"0TEZ.41U>B\X045C;$AS=V1:2D=&
M-DPU63AM95AV3%5$4F%68D-.-4%"3F-/96-S;% F(WA!.S5M4#9H45IN67-%
M8UDY26))>$$U2C-L>DHR2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R
M2W5X5DM03C)T+V]0>3%Q3W%G07DF(WA!.U=S3$Y%1#!-:F9$2%@R-7--<7I:
M3T-":VE2;U!M0W<X,"M:3E!L:VQS=%1U8F0U;4UK=G!Y<T$W<V%L;5=T0V$K
M27IN;S5:>#5%=4DF(WA!.TI%2T=Q-C-R1W)43$YQ9#=.95-,54E:;EHK24\U
M0V=M:6HU64HU2E,U;3%*2E%745$Y5R]);GEM.7IQ:W9M2S51:3)S9UER36MB
M3D\F(WA!.S1O>D0O55$O969B3FPR9FAU6$=E:F1I:C%E-EIU1SDR2W5X5C)+
M=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8F(WA!.S)+
M=7A6,DMU>%8R2W5X5C)+=7A62G9/5V=.-6<X<V%H<$-/235,<4UE:S=F6D5I
M34I%-64S2D)82W,K4&IG67-:0WA4-7 Q8GE6-7(F(WA!.S!Q6F\W-U,W:5!I
M865O<V)34FXO049:135+9G9Z;C4T2G@U9W5-66M)3S,X=C8Y8WE#3S,P,C9M
M:U!216AK62]C0FM2:FME44M/17,F(WA!.S8X<&9K;#5I,4=E3V97;"]2;6YG
M9W5J14<T9&9"549E2'IB<#1(37I$;TIY4'$R1%I(151Z93AA8G!T:G!L:D19
M5TU+=U=L=79#2THF(WA!.V5G2%@V4U1U5#-/8FU%0D553U1E0E-*>5-867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98+SEK/3PO>&UP1TEM9SII;6%G
M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F
M.D%L=#X*(" @(" @(" @/"]X;7 Z5&AU;6)N86EL<SX*(" @(" @/"]R9&8Z
M1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T
M/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O
M96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC871I
M;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET;&4^
M"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI
M('AM;#IL86YG/2)X+61E9F%U;'0B/C$\+W)D9CIL:3X*(" @(" @(" @(" @
M/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" \+W)D9CI$
M97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70]
M(B(*(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@
M(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(CX*(" @(" @(" @/'AM<$U-
M.D1O8W5M96YT240^>&UP+F1I9#I!,S8V,T8Y,T5%-#%%.#$Q034Q,T%$1C)#
M-T(R1CDV-#PO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DEN
M<W1A;F-E240^>&UP+FEI9#I!,S8V,T8Y,T5%-#%%.#$Q034Q,T%$1C)#-T(R
M1CDV-#PO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I
M;F%L1&]C=6UE;G1)1#YU=6ED.F8T93@S9&%E+3<Y.3$M-#8T-"UB.61D+6(S
M9C$V8V,R.&$P-CPO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @
M(" \>&UP34TZ4F5N9&ET:6]N0VQA<W,^9&5F875L=#PO>&UP34TZ4F5N9&ET
M:6]N0VQA<W,^"B @(" @(" @(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC
M94E$/GAM<"YI:60Z03(V-C-&.3-%130Q13@Q,4$U,3-!1$8R0S=",D8Y-C0\
M+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @(#QS=%)E9CID;V-U;65N
M=$E$/GAM<"YD:60Z03(V-C-&.3-%130Q13@Q,4$U,3-!1$8R0S=",D8Y-C0\
M+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA
M;$1O8W5M96YT240^=75I9#IF-&4X,V1A92TW.3DQ+30V-#0M8CED9"UB,V8Q
M-F-C,CAA,#8\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @
M(" @/'-T4F5F.G)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+W-T4F5F.G)E;F1I
M=&EO;D-L87-S/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @
M(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$
M/GAM<"YI:60Z-S9#0C!%,D-$1#)&13<Q,4%!0D1&0D-&-3-!0D4P140\+W-T
M179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N
M/C(P,3<M,#4M,#-4,30Z,3<Z-#,K,#4Z,S \+W-T179T.G=H96X^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S
M=')A=&]R($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG
M960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D$S-C8S
M1CDS144T,44X,3%!-3$S041&,D,W0C)&.38T/"]S=$5V=#II;G-T86YC94E$
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#$X+3 T+3$W5# X
M.C4R.C0T*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I
M;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @
M(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @
M("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@
M(" @(" @(" \<&1F.E!R;V1U8V5R/D%D;V)E(%!$1B!L:6)R87)Y(#$P+C Q
M/"]P9&8Z4')O9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @
M(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X
M;6QN<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]T+W!G
M+R(*(" @(" @(" @(" @>&UL;G,Z<W1$:6T](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS(R(*(" @(" @(" @(" @>&UL
M;G,Z>&UP1STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O(CX*(" @
M(" @(" @/'AM<%109SI.4&%G97,^,3PO>&UP5%!G.DY086=E<SX*(" @(" @
M(" @/'AM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/D9A;'-E/"]X;7!4
M4&<Z2&%S5FES:6)L951R86YS<&%R96YC>3X*(" @(" @(" @/'AM<%109SI(
M87-6:7-I8FQE3W9E<G!R:6YT/D9A;'-E/"]X;7!44&<Z2&%S5FES:6)L94]V
M97)P<FEN=#X*(" @(" @(" @/'AM<%109SI-87A086=E4VEZ92!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=$1I;3IW/C<R,"XP
M,# P,# \+W-T1&EM.G<^"B @(" @(" @(" @(#QS=$1I;3IH/C4T,"XP,# P
M,# \+W-T1&EM.F@^"B @(" @(" @(" @(#QS=$1I;3IU;FET/E!O:6YT<SPO
M<W1$:6TZ=6YI=#X*(" @(" @(" @/"]X;7!44&<Z36%X4&%G95-I>F4^"B @
M(" @(" @(#QX;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @(" @/')D9CI3
M97$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^0WEA;CPO<F1F.FQI/@H@(" @
M(" @(" @(" @(" \<F1F.FQI/DUA9V5N=&$\+W)D9CIL:3X*(" @(" @(" @
M(" @(" @/')D9CIL:3Y996QL;W<\+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:3Y";&%C:SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^
M"B @(" @(" @(#PO>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(#QX;7!4
M4&<Z4W=A=&-H1W)O=7!S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P3F%M93Y$969A=6QT(%-W871C
M:"!'<F]U<#PO>&UP1SIG<F]U<$YA;64^"B @(" @(" @(" @(" @(" @(#QX
M;7!'.F=R;W5P5'EP93XP/"]X;7!'.F=R;W5P5'EP93X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @
M/"]X;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" \+W)D9CI$97-C<FEP=&EO
M;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ 20#7 P$1  (1
M 0,1 ?_$ !\   (" @,! 0$            *!PD&" 0%"P$" __$ $(0   &
M 0,# @($"0H'      $" P0%!@< "!$)$A,4(0H5%B(Q.!<Y071V>+.VMQ@C
M)#0W46%W@;0F*3)6=974_\0 '@$  00# 0$!              4&!P@" P0!
M"0K_Q !0$0 " @$" P,'!0L("0,%   ! @,$$0 %!A(A!Q,Q%"(R05%A<15R
M@9&A(S0U-D)28G2QL[0(%C-#=H*RM21$4W-UA)*BPPG!\%23PM'2_]H # ,!
M  (1 Q$ /P!_C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HU7UU/L[9/VX;/[SE3
M#]@1J][BI^CQD;-K0T+/E9MIRT1\9("2,L,?*1*RJC-=5-,[IBX!(QO(0H'*
M408_:)O.X[!PM<W+:IQ6NQ3TXXYC%#/RK-9CC?[G/')$258@%D.#UTG;K8EK
M4Y)H6Y)%:, \JMT9P#T8$>!]FE6&O5WZB+5\1_\ RBY!P<AP.9NZQ[B99BJ'
M/)DSLQH8( 0X<E'Q$34* \I'3,!3!6Y>U'CM7#_+KL<Y*M0VPH?<5\B P?=@
M^PC33&\[D#GRDGW&.''U=WIA?I3]2RR[T"W#%^7(6%CLO4.!;VI"<K+99A"W
M.H_,&D*^?N(E5=T6(G(>4D8E*0*T<!&R2<P@NP91H-%VYIR[-NT"QQ;Y5MVY
MPQ1[I2A6R)JZE(;=7O%A=VC);NIHI)(@X5N[D$H*)'R,"X]IW1KW/%,JB>->
M?F4861,A2<=>5E)7.#@\P( QC5JF4LF8[Q!1IZ^Y4NT)CZDPS10TK9YV32BV
MS3RD,1%%HJ<17=2KD_\ -1<<P2<R;]X*3:/:.7)TTC3#2I6]PLQU*->6U9E.
M$AA0NQ]I..BHOB[L51%RS, "=/\ X0X3XGXVX@V[AS@_8=PXEW^_,HI[3MU1
M[DTW(P9WF11W<-.)?/MVK+Q5*T >6S-%$K.%,,L=6C%[R]34=%FRYE2HM)=X
MWC;E,KI1RDI%D<G!K(,*_.R?K$"+-NPY&K\D*L0W*9FK8H  2U5[,-W:NKS6
M-NJSLH;R?,LG(V.JR2Q1% 0>F8^^7UACK[)\'?R*N,8N'J-JZW!7"&]34H)+
M6QTDDM+3MM$#-6L[EMU3R=V27F5IJK7XV'G+-*22;+ME6\:O3AZ_:J7;7$QC
M27?)1-J@7JJB:];<.!(591]$JJ*_)YB),JD\5%#E*28D'T[AVS<MG6F+OFQW
M=KL24[T'<V%'/&X\Z.=,]'BD&!)&^",]&1O-=5=645.[>.P_==J.X[+Q!LL=
M'BFE7>[M&XP*KQ;K%'S&,5KJ*@NT;@1X$[S#U;! EB@GBEAU?" @8 ,40$!
M! 0'D! ?<! 0]A 0]P$/MTU=?/@C'0]".A!]6ONC1HT:-&C1HT:-&C1HT:-8
ME;;_ $2@-4'U[NM2I3)T94K9Y;;)#5MJX,B"8K%0<3#UFDL9(%4A5!,YA3!1
M,3\=Y>>6U>I4E#W;=6HC9Y7M6(JZMC&<-*Z XR,X/3(U@\D<8S(Z(#X%V"@X
M\?$C6-53.6%+W(%B*/F#%MREC\@2,JF0*G8I W: B;M91$N\<F[0 1'A(>
M1'V#6BMO&T77$5/=-NMR'PCK7JT[G'L2*5V^S6*3P2'$<T3GV)(C'ZE).I2T
MHZVZ-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&C53?6P_%^9(_3#&'[[Q
M.HS[7/Q'W#]:V[^,BTD;Y^#I?GQ?O%TDGJH>F-J]'X?S[XF3/U;+;_$[$6ID
M[$/QJW'^S]K_ #':]+_#OWY-^K-^]BTQIO=V28KWS8G''.1%)"$FH1P[F,>W
MJ',8\G2[*NU],+[Y>=9%E.1+U(J;6:@WPD(^9ARR>1<HBQE65Q>&^)+W#-[R
MRF$DCD"QVZT@')9A#<W)SX+1.IZQRIU5O25T+(UI>P#M^XP_D]\9_P Z.&%K
M7Z&X1PT>)N'KP"U-^VJ.4RBOY2L;S[?<KNS34-PKAFKSG$\%RI)8ISHH;MMG
MN:MF.376-\P0 MR.!<NJA<XLJ[BGWR$05*F$O6Y11)(%#) HB63B'9&\Q"KK
M)(R3- %VJKBS>P\0;=Q%26YM\N2.46*SX%BK(1GNYD!/C@\DBYCD )1C@@?H
M=[%^W#@+MVX3AXIX(W(2-&(H=[V&V8XM\X=ONA8TMUJ*[\H?E<U+L+24;\:.
M]6>0QS)%C&W/<%:MO%];6F$%1_!/_"QM]8.L*;2P0Y5!,)0YY(WEF'>HXB)'
ML$[5<RB*@*L7;YJXPXBV"KQ!1:M-B.>/+U+07+UY<>OP+0R8"S1YPRX88D2-
ME4^U3LQV;M1X;EV?< M;<JW>6-CW=8PT^V7BH&3C#2TK/*L5ZKS!9HPLB<EB
M"O-$_=LFS]5=QVWBD7ZJS*<TW19E@'J_( [2<Q2::224B@)C*MY(C(S5.225
M^L223>I@90$^\U6=XVVUM.X6*-R(PS1-U4]5(/4.C>#QOZ2,.C*0?'('YONW
MGLXWGLN[2]_X:WJ@^WS-.=Q@CQF!XKC.[R5)  DM1IQ*U1TZ-4:!N5>;E&V>
MDS4.:-&C1HT:-&C1HT:-&C2Q_P 19_6MH/YOGK]IAO5>NW?QX6^&]_MVG37X
MD_U+_F?_  :6E;N'#1P@Z:KK-G399)PV<MU3HN&[A$Y5$5T%DS%42624*51)
M5,Q3IG*4Q3 8 '5?59D8,K%64AE920RD'(((P00>H(Z@Z:X)!R#@CP(Z'3LW
M1LW)WW<9M,5-DV8>V6WXJO<GC<]HE%U'<Q8H!M!U^P5]_-/E1%5]+-&\XO"+
MOEQ.[?-XAH^D%W4@Z=N5;=]E/$%W?N&2=PE>Q:VVY)0-B0EI9X5A@G@>9SU>
M55F,+.<NXB5W+.S,SYV6U)9I_=6+/#(8B[$DLH564L3XL W*2>IP">IUNMN=
ME,AU^APD[CB[2--E2Y+Q%57XL:[6K$60A\CY;H>/)A59"QQ$L#=6$A[-)2[!
M=H"!2OFR)Y '+%-5N=W<0R7H:<,U"X]23Y0VNL_)!7G#Q7]SI4925GBDY3#%
M8DE0KRCG4=YS("-=UII%C5HW*'O84.%5LK+-'$3YRG'*'+#'LZ]-5B[B]Y.[
M?%6/<[PU170E+O1,CJ3%.O[['S-TR5PO!WMKARPQCR.:,T(&0O*%^<U>;5,F
MV;$5K-\,XCVP)P*HHQ]OW%/$^VT=YBJLLENG?[VK=>BK(=IAN+M4\;(JB&2X
MMYJTIPJYK72R+B D)EBY;BCG52"Z2EDD,8QW"R"%EQZ)D[PH?5YDG3T3JV'/
M>X'%&V?',ME/,5J:U>JQABMD1,4SJ6G9==-51E 5R)1Y=S,V_!%44&38O"2"
M+E^]5:1K-Z];R3O6][;P_0EW+=;*UJT9"@X+232L"4@@B7SI9GP>5%'10SN5
MC1W55L6(:L1EF<(@Z>TL3X*H'4L?8/B< $A:#/'7\S38)9_'[>,:U''=6(HJ
MDQG[Z@O<KP\1*801?&8M9!A5()14H]RT6HUM143@!4Y=8H&$U?=Z[;=VGE=-
MBV^K1K D)/=4VKCCU/R*Z5H2?$QE;./ 2'UMBQQ#.Q(K1)&GJ:3SY#[\ A%^
M&'^.M.B=9CJ)D?>K-G..40[^[Y8?%&( 8]O//B[TZ*G(=GY.[U_EX^U4?8=-
M4=K''8?F^6(R,_T9VS:^3X9%,28_OY]^N+Y;W+.>_'P[F''^#/VZWTVR=?6\
M-+!%5W=70J[,U1XX0:.LB8V8O8>Q0*:IBD-*3%3<OI*+L;5$P][M*!4KSQ!H
M"BK-C*NDTV+EZ</=M=Q9XX.):4$M9V5&O;>CQ3PY..\EK,\D<ZCQ80F!U7)5
M)& 0J%7B%^8+;C4H>ADB!#+[RA)##V\I4^P'PTQ_=\XXMQ[AR3S[9[;'ML3Q
ME297<UN:^5\S?5Z60:+PCJ)3:D4<22T\,A'-X1JU24<23N09-FZ9E7!"C/=S
M>-NH[5)O5BTB[9'62WY2N71X)%5H6B"@F0S<Z"%5!,C.JJ,D:<KSQ1PFPSCN
M0@DYQU!4@%2,>/-D<N/$D:6NSO\ $"Y,DY9_&[<L2U6J5I-51%E9LH@^LUKD
M&X"/C?D@(&6B("O.#AQRQ</[<D0H"(NC&/VI0!O/;?N$DKQ[#M=:M7!(2QN7
M/8LR#U.(()8H8&/YC/:'Z77 ;-CB*4DBM"B+ZGERSGW\JD*OPR_Q]6M(97K-
M]1"1<&6:YMBH-(QA$&<5BK$ZC<@#]A2GF:7+O!*'Y.]V<?[Q'30E[6..I&RN
M[Q0C\R+;=M*CW9FJ2M];'WYUPG>]R/A.J^X0P_\ Y(Q^W6;T/KB;[ZF_;N+-
M9,>Y/9$4+ZF/MV/(.(!='D/(5-UCXM+706$G/B5'S)IJ"!U&ZY %(W92[8>,
MZSJUB>AN*#TDM48HN8>O#4?)"#[#U /BI'36<>_7T(YFCE'K#QA>GQCY,?;]
M.F+-@'4FQEOFB9:%0AE<=YBJD>E)V7'KV13E&[Z',LDT/9JA+@W9*2\*D\7;
MMI)NY8M)&#=O&C=TFY;.F,F^G?@CC[;^,8I(A$:.ZUD$EBB\@D5XLA38JRX4
MRPAF59%9%DA9E5@RLDCN3;]SBOJ0!W<R#+1$YR,XYD/3F7) /0%20#G()C_K
M8?B_,D?IAC#]]XG7#VN?B/N'ZUMW\9%K7OGX.E^?%^\722>JAZ8VKT?A_/OB
M9,_5LMO\3L1:F3L0_&K<?[/VO\QVK2_P[]^3?JS?O8M3?NDZW&Z[$^:<GXBK
MN(,-U ^.KO8Z@LK9$+A<I5XG!R;ADTE4'K6Q4^.]++M$D)1J(P9P,T=H&*;@
M>XRQQ)VO<2[9N^X[7!M>U530MSU2U@6K<K"&1E24.L]6/EE0+(OW$^:P(.M]
MO?+<,\L*P0H8W9/.YW/0D!LAD&",,/-]8]6H"+U:8/=1#C@WJ"X/Q];L.V=Z
M@B:]XP8SE<ON+Y17N;M+[!HRDQ:$W;Z#\YSJ)PXP[I:-.]:N&UA:+.*_**/!
M7\H3?=DWBM9W&O5BA+K'+:V])XRD3,.;RJI+-/'<K^!DB0PRJ/ND3&5$&I"[
M)^W3COL?XOH<8<&[HVT[G5/=6!&))*&YT'=6GVS>=O:3NMRVVQR+WD#E)8I%
MCMU)J]V"O/%GLW\.I<Y:<;2F+]T%#F,838-Y2$FK#5)DEA"OR1".V"R;>#>/
MH.>4]"LD=)^A)PC63 2N2-8]-8$4KVU.V*C+4CEEVF9IGB5U:K9B>K,&4,LB
M2. Z1R AE'++RJ1YS^)^OFR_^J5PP^R12<0=E>^)Q M=>\BV7?=OFV6U8"#,
ML5F[!#>I5YG\]8FJ[A)71@G?VBO>/^IS<A0>C2:W;7MJRKG.N8Y%Q"2V<,E9
M2?RA,<0-H;1Z@,:[3L:UB8CT&LFWC9 J\XZ&R.'C-8[&(F)BPKQWRZO5/[8^
MWRU-O8H;;MFW/;H1]W))()'AJ"7ED%:22-H9[MA5(=V[V"O69BB0M(TX7YK_
M ,J#^51Q+_*#XKV_=-TX?V#8:G#]>U2V3;]NA\HMU:=R6*>2+==\D2&[O-@/
M&K)YE';JI:4U-MKS6+DD^)U+K_;LHN124M^-\&VR'\@&<LV,+<:Q*F3 0[DV
M<LG<I=FV$2\@!W,'(<#P;M$ $IH:J]MO$T<@-K;]GM19\Y$BMUY<>Q)!;E1?
M[T+ZK$G$-L'SXH''L =#]!YV'UJ=6V[^NH[GG9]1<*VV+VX5]XTRW3XR0D;%
M9+G+R,/1<AKQ:,K+XVDHB)@(-T^<1[5;SQ<VK-PXV%%G+^GAF9HAWVR?QMQ[
MO/"U+:;4>P0NNYU8WDGL6Y7BI7FC$DM"2**"%G9%.8YC-%WX67EB0Q-I7W#<
MK%*.!Q64B9 2S.Q$<N,F(J%4G \&RO-AO-'*=4^I=??>8653>K4G;ZI' J!E
M89.G7A%!1#N^LF1X;)*SY-7LY BPK*$*?@YD%"@*8Q6.VSBOO0YI[&8\]815
MN 8]8#^7EP??DC/J/AI&_G#=SGNZ^/S>23]O>9_^?6Q'L'WUT7?-BY]:X6-^
MB-_I[II%9(H"SXLB>">ODEE8J7BG_A;*2-:GTVCTT8[6:MG*#MA)QCI(QV)7
M;N=>"N,J?&.W/9AC\EO562/<*1?G[EW#&.6)\*7KSA',;%58,DD; E.9G)M]
M^._$74<DB$"6/.>4G/*P/3*M@X. <@@CIDU3[R^NL_H60I_&VU2G4RVLJK(.
MH:8RG>PEI:#FI5DL9O($I<!!2T"9Q$LW"1T&UDD9=PVF#@HNQA_EI6<E(QMQ
M7VRO2O3T.&ZE2TE9VAEW*YWLD,LJ$J_DD$,D):)&!"V'E993DI%W?*\B3=W[
MNY&BJ(CA3@RODJ6&<\BJ5R!^<6P>N!C!.LV,^O3N^?6:$K\QAW#F1UYV6CXB
M-@JU#W6M6>7DY-VBR81<6\3M=C9"[?.ETFK5,:Z[4.X53*!3\]@M_;NVGBA[
M$,$NU;5?::1(HX:\5NO8EDD8(D<;"S83F=B%4=PQ)(^&N2+B"X756AAEYB%"
MH'1R2<  \S#)/Z)ZZE/X@AW-R$1LD?V6';5VQO:]F=W/U]E+!/-(.9<ML*K2
MD.UG 8Q@3#>->G79HR@1S 'Z:)70,VP*@B12[<&F>'@][$2P6'AW=IX$E[Y(
M9F79S)$LW)'WJQN2@D[M.<#FY5S@;N(BQ6@64*Q6<LH/,%8BOE0V!S 'IG S
MXX'AI;G4 Z;.K#]GG4OSSLEH]GH&**QBB<AK7:S7"1<7Z!MDM)(R9HB,A119
MK0%WJ[9-CZ6*;G!)9HX7\YUC^I\9B))OOA7M!WGA"G8H[;6VV>*S9\JD:[#9
MDD$ABCAPA@MUU"<L2G!5CS$^=C "E2W2>C&\<20LKOSDR!R0>4+TY748PH]6
M<YZZO:Z7G5 W ;U,_P!LQ7E6JXCA*]!8AG[\S=T*OVZ*F%)B*N-#K[=NX<3]
MZL[,\:=E:)!19%-@DY,Y1:'([323617F;LZ[1=[XNWNSMVY5ML@@@VN:ZK4H
M;4<IECM4X%5FGN6%[ODL.2 @8L%/, ""X-JW6>]8>*5(5586D'=AP2P>-1DL
M[#&&/J\<==7SZF?2]I'#JS;L9W<KNIN5>:2:YL782FIK'%#ATEC#'K/X5Z,=
M<;<*91\+A[9)YBN5L^*4!&N1\"V#DR"JJU/>TWB:;?\ B2U760_)VSS34*<0
M8\ADB?N[5K&<%YYD(5\9[B.%?$$EB;O;:U;=0?N4#-%&,]"5.'?WEF'0_FA1
MJK[4<Z2M6M8 Z-V\7<%CF&RA%H8YQS6[-'HR]60RA8YZ'F[##.TP683#.(K=
M2MCEC'R*)BKQZDY\I6>-#HOVZ"C!RU=+27L?93Q5OE"+<8Q0H5["++67<9YX
MIIX7',DRQ5ZUEDCD&#&9>[9U(<+R,K%7K;+<L1B4=W$K ,G>LP9E(R"%56P"
M/#FP3XXQUU 69>G;NUP7D>E8TNF+GSJ1R19HRHT"QU=<EAIEJGY9R1JRCF=A
M:$!*.>F.8ZZL=8$(>418H.))1B6/1.ZTB;MP)Q/LU^IM]O;F=[]B.K2L5F$]
M2S/*W*D:3J (W/4F.=8I @:0IR#FUSS[;<@E2)XB3(P2-D/,CL? !AX>\,%(
M )QCKIP_(FSAG>-@8[,#SB9G,?A*F8_A[*X\P-1N&/&$"]K,Z[(4IG!8L]NK
M4:^>M42>0L899JB0!["A:B_PJES@K^:9F&8]HJ48K!YN7RJC'"U>9NG-W?E,
M$;NH&>[RH'AIY2TA)M_D7-G$"1JQ_/C"E6^'.H)]W32WV#.A;NWR4H9YE)_4
M,#0*;I9N/SYXG<K:[(BL='UD=6JL\/&"T.*9S)C,6J#=*)BBJDU416*J$![-
MV-\3[@>?<I*NRP!BI[YA;M, <<\=>NW=\IP2.]LPL1@A"#G3:@V&Y+UF*5U_
M2(D<^\*AQ];J?=K=B1^'?JR<$N##=/-EL)&YC(O)'%L<G!*.2D$2E79(W@7S
M9NJ< *90DDY4;D,*@)N1)XSNZ3L*K"!N[XCF[\+YKR;=&("WZ2"V752?6)&*
M^.&Q@]QX<3EZ6VYL>)B'+GX<^0/I./?I:&YU62HMPME)F#ME)>G66=JLJ=FJ
M*S,\E7I1U$OCM%C$3%5L9RT5%!42$%1(2G$A1'@*^VZTE*W:IRE3+4L35I"A
M)0R02-$Y4D E2RGE) )&.@TUW0QN\;8YD9D;'AE20<>[(UM7T[\FRV)M[&VV
MSQ3I5L22RG5Z--%34,5-Q7,B2*-(G4G*8#VN$DH^>6>II*%,!7;1LX3 JZ"*
MA'+P)N,NV<7;!8C8J)-RK4YL'HT%^04Y@P\" DQ< ^#*K#J 1V;;*T-ZLX/C
M*D;>]9#R-]C9^(&FG.MA^+\R1^F&,/WWB=6/[7/Q'W#]:V[^,BTZ]\_!TOSX
MOWBZ23U4/3&U>C\/Y]\3)GZMEM_B=B+4R=B'XU;C_9^U_F.U:7^'?OR;]6;]
M[%KA=>/!WT W45O+\<S\,+G2DM7+Y<I.Q-2[X_*SK,X0H% "!W5E6D.3F'A1
M9RY=J' 1Y.;#MHV?R+B2ONB+B'>::ESC \KH\E>8>SK7-1L]"69SU\=>;_7[
MNVLX'FV$Z_/CPK?]I0_7\=4=ZA[2#IZGI>YC:W#IX88N-AD>?P<4ZQT^R.%5
M/(:/C\6RDQ#L 5.80]DJ;%PCL ,(=J2I"B/MW#<KL[W5;7 NTVYY/O"I/5L,
M3GD3;9)84R?=5BB;X'3]VN</MT#L?Z.-D;W"$E1_V*I^G20^1+I*9(O]XR'.
M**+3-ZMUDN$JHJH*JAY&RS#R9>"90?<X^H>*!S_<'L ![:J!?MR;A>N7YB3+
M=M6+4A)R>>Q*\K9/KZN=,65S+))(WC([N?B[%C]IU.6R?$7X=MV. L6JM?61
MMCR1 N+$V[.\%JE7%C6FX$$.!#WJ\++\&, D*/ G 2@("L\(;7\L\3[)MQ7G
MCGOPM.OCFM7)LVA[/O>&7QZ>W711A\HN5XL9#2*6'Z"^>_\ VJ=/8[G-O-)W
M2X3N^%+XB!8NUQI@C)A- B[^K69ERXKUIB@.)!!]"R)4EQ1!5(D@R%Y$NS&8
MR#I-2Y7$.QT^(]HN;1=7[G9C^YRA07K6$\Z"S'X>?#( V,@.G-$QY'8%^VJT
M=N"2"0=''0^M''57'O4_6,J>A.O/[S3B"[8#RG=\09$C1C+?1)QS"RB1>\6K
MLA *O'S$8JH1,SF'G(U9G,0[L4R>JC7S5<2$%02%I'N^U7-DW*YM5^/N[5*9
MHI!UY6'1HY8R0.:*:,K+$V!S1NK>O4>3PO7FDAD&'C8J?8?8P]S## ^PC6?;
M<=T&3-L$EDF3QL^](OD[%=MQ9,B995(6;6RMB%8V..%/DJ5@K,@BC(PKL2"9
M$PNFX&(D\7$>W8.(]PX=DW"2@_*=PVVSMTO4CE6=1R3ICPFKN \3>KSAT#'6
MVK;EJ&4QG^EB>)O'IS#HPP?24]0?C[=:XZ0-<NF'>AALJ^FER?[O<@Q'DJ^/
MWKJ Q"T?(\HS-\\/BF[<1)8O8NRIS)Q\OBG $51/9WZ[ENLA(U0P:G3L<X2\
MKMOQ3>BS7I.T&UHZ]);N,36@#XK41N[B;!!L.65EDK:<>PT>=S<D'FQDK""/
M2D];^\(,@?I'/BNI#^(L_K6T'\WSU^TPWKO[=_'A;X;W^W:=;>)/]2_YG_P:
M6?U7S37UM!@S9?N=W*UZ7M>#L32V0*] S0UZ6DH^8JT<DRF2L6DD+$Z4[.Q3
MDZ@,GS1QY$45$.U8"^7R%.0KBV;A+B+B""6SL^V2WH(9NXED26M&$EY%DY")
MIHV)Y'5L@$=?'.1KKKT;5I6>"$R*K<I(9!AL X\YE]1!Z>W5ZG1OV1[IMMNY
MZ[WG-V(9B@U24P79ZJPF)"9JDBBXL#Z^XTEFD:5&#GY1V55:.A)5R551N1N4
MK,Y3K%4.D129>RGA#B/8.(;ES>-KEI5I-GL5DE>6M(&G>[0D6/$,\C9*12-D
MJ%PIR<D K^RT;=6S(\\)C1H&0$LARQDC./-8GP!/LZ:9<U8'3FUYG\O(/):5
MDY60,<[^3D'L@^.ISWG>/'*KER8_=];O,LH<3<^_(CS[Z^?<KM+++(Y)>21W
M<GQ+.Q9B??DG48,2Q)/B22?B3DZRG&$1%V#)6/(";X^2S=YJ41+\F$@?*Y*?
MCV3_ ), E$H>D65Y,!@$ ]P$..==&W11S[A0AF_H9KE6*7U?<Y)T1^OJ\TG6
M<(#2Q*WHM(@;/3H6 /V:])%NW0:-T&K5%)LU;(I-VS=!,B*#=!$A4T444DP*
M1))),I2)ID*4A"% I0   -7[5550J@*J@*JJ %50,  #H !T '0#H-28!CH.
M@'0 >K7Z4116\?F235\2A5DO(0I_&L3GL53[@'L4)R/:<O!B\CP(<CH(!QD
MX.1D9P1X$>_WZ-0!N?W+8UVF8@L&8\H/5TX:),C'Q$-'@DI.6VS/R+&B*Q M
MUE$DU9&0%NNL=591-K'QS5_*OE4F+%RJ1$XBX@V_AG:Y]UW%V$,6$BB3!FLV
M'![JO"I(!D?E8DDA4C5Y'(1&(Y[5F*I"TTIPHZ #TG8YPBCUDX/P )/0'2?6
MY7J\[P\_RTFA7KW(8-H*RRI(RFXK?N(.329"8Q4@FKZV*VMTN^.@()OC-7T-
M"N#]QT(%F4XIZJUQ!VH\5;W+(L%Q]FI%CW=7;7:&0)X#OKJ\MJ5RO1^5XHF.
M2(5'33,M;S=L$A9#!&?!(25./TI/3)]N"JG\T:TAK-,W#;BYETWJ5:S!FZ<2
M.160^2QEQR$^:BN)A*XDEFR4J=F102G,+EZHDF/:<QE."F$&?7J;]OTK+5@W
M7>)ACG[J.W>=<YP9&42% <'SG('0]=<*I9M,>19K##QY0\I&?6<<V/B=0VX;
MK-5UVKE(Z#ALLHW<(*E$BB*R)S)JI*$'W*=-0IB'*/N4P" ^X:264JQ5AAE)
M5@?$$'!!^!Z:T'IT/B-3;M?^\MMX_P \\2_O]7]+'#GXP[%_QG:_XZ#714^^
MJWZQ#^\73?/6P_%^9(_3#&'[[Q.K1]KGXC[A^M;=_&1:>.^?@Z7Y\7[Q=))Z
MJ'IC:O1^'\^^)DS]6RV_Q.Q%J9.Q#\:MQ_L_:_S':M+_  []^3?JS?O8M7 =
M;7!WX5]ETQ=(YGZBQX,L\/D)J9)/O=*5IV<:Q<&A#<#VM$8^8;65][E_FZPF
M8##V=AY2[7MG^4N$I;:)S3[/8BO*0/.\G8^3VE'Z(259W]U<'U8*QOD'>T6<
M#+0.L@]O*?,<?##!C\W25VJDZ9&KY=B&XSZ!]*KJ&5,[[Q2%2% (?E7M<-PW
M%0C+%+3T(<]X>DE(9W(%\0#X'"ZC@W;W]VIIX,W[R+LUXXK<_+)5([HY/,OR
M["FW)R?-EA=QCT6)8^.G!M]GN]IW%,]4]'VCRE1$,?!E)^.J&M0MIOZOJZ >
M(OI3N/R;E]XU\T?B;')(:.6,3V;6K)$@9DS734$!#N+6*];FJA"_6[7Y#&,4
MO!5)J[$MK\IW[<=U=<IME 0QG'HV;[\JL#[J\%I2!UQ)XXZ%P</0\]F68^$,
M7*/GRG .?FJXQ[_=IN;5GM/#2]/7KVVX\EL557= G+0U9R54YB'QXZ:.3 @Z
MR;7IQPZ681+,A"&,\L506"1G&AS^(HU<;(#I=08^(0)!O;3P_1EVROQ&)(J^
MX598J+JWFMN$$S,4B4 'GGJGGF0G'^C>4<S'NXE#=X@JQM$EKF5)4(C(/]:K
M$D*/TDZL/T>;)Z+I475:=-'6:8WK$5=LA46FSEHC:3"VNWURN2UQF2J'B:M&
MS4NSCGM@D2I )Q91#=RH^<>Z9/$@;R+(I]ZI.S;ZT5R]3J368Z<-FU!!+;ES
MW5:.654>>3'7EB5B[> P.I ZC9$JO)&C,$5W56<^"!F +'W*#D_#7HKXCQ?3
M,*XSI&*<>QQ(NFT2O,*_!-2B0ZJC9HGRK(/5TR$!W*2SL[B4EGXE!1_)O';U
M7E5<XC>W:]NJ;1M]/;:,8CJ4H$@A48)*J.KN1CFDE8M)*_B\CLYZL=21#$D$
M4<,8PD:A5'N'K/M).23ZR2=+J?$6?UK:#^;YZ_:8;U!/;OX\+?#>_P!NTZ;?
M$G^I?\S_ .#2S^J^::^FW/A\?NSYI_ST5_<"FZL[V'?B]NW_ !D_P-33PX=^
M]9OU@_NX]7Z:FO3@T:-&O.[W<X@E<#;F,VXIE6:K/Z*Y"L1(8%""GZRJRCY2
M9J$HD @ >&5K$A$R"8%Y @./&(B8AM45XHVN39>(=XVV12ODUZ?NLC'/6E<S
M59![I*\D3CJ?2QZM1Q<A:O:GB88Y)&Q[T)YD/]Y"#].M>$%UFJZ+ELJH@X;J
MIKH+I',FJBLD<%$E4CE$#$43.4IR'*(&*8 $! 0TA E2&4D,I!!!P00<@@^H
M@]0=<VG*]KO6FVJY Q=7#9ZO(XCRU%1+-C<8Z6K5GD(&>EF;=-%[8JO+5N&F
M69(Z65+ZTL1)G82L:NNM'IH2+9JG*.[7<.=K7#=[;8#O5SY+W.*)$MQRU[$D
M,TJ+AYZTE>&5>[E(YQ%(4DC9C&!(%$C/6IO=22)?*).YF4 .&5RK$#JR%0PP
M?'!P0>F#XG#,H]>';97,ET6IXP@;'D:BO+,P:9(R:Z8R-7C(*L.C&:NI"HP$
MLQ1LEAD8U55.2=)2L9!-E&3-5DP%\YD$W4?R;CVS\/U]PI5=NAGOTWL(FX;@
MR25HX:[>:TE6&5!//)&2)'$D<*E$*(79PT>$N_U5EC2)6DC+@2RD%0J'IE%(
M#,0>IR%& 0,D@C6?XAFUOGL7M)AXQ^#BGSA,KVM-5FN"T;,/FS?'+6(?IJIF
M,@X!G%S3TS-=,3 *$TL8AA(J&F_VYV7>+AB*-^:I-\I605.8Y75:"Q.".AY8
MYGY"#Z,IQXZY>(W)6HH.4;O7Z>!($84_0&./B=+-:KWIKZ=IZ;V>=HN.]A^(
ME8[*&)Z(E6J<5UE5K+VFNP$XSR&4%%+D]L<>]>-Y=>0D9--56(47;K+2,,:'
M1B/.R!@D%O. =ZX8H\%[68]QVVF*]0-N2RV8(9DO=3;>PCNLIDDD!,1929(N
MZ$64Y!I\[98IQ[?"1+%&%3,H9U5A)_6%@3S9+>CD=5Y>7(QI+"R/&\C8IZ0:
M&$[5_-2CQL<Q3$$[=T^771,)#@!R"9,Y1$I@ Q1'@P ("&JD3L'GF=3E7ED9
M3[0SD@_2#ID-U9B/ L?VZEG:_P#>6V\?YYXE_?ZOZ5.'/QAV+_C.U_QT&MU3
M[ZK?K$/[Q=-\]; /^7YDG_"X8P$?\/\ CB(#W_U$ _UU:/M<_$?</UK;OXR+
M3QWS\'2_/B_>+I)/50],;5Z/P_GWQ,F?JV6W^)V(M3)V(?C5N/\ 9^U_F.U:
M7^'?OR;]6;][%IM2]TV$R+2+CC^RM_5UV\U>?J$\VX*/GA[)%.X>22#N 2@8
M[-XL4HB ]IA ?R:LW<J0WZ=JC87F@N5YZLR]/.BL1M%(.N1U1SCIIW2(LB/&
MW575D;X,"#]AUYR>3J#-XJR/?,965/QS^/KA8Z9,!V&3(:0K<N[B'*R13<B+
M==5H9=N<!,51!1-0ASD,4PT,W&C-ME^[MU@8GHVK%27V<]>5HF(_18KE3ZP0
M1J-I8VAEDB;THW=#\58K_P"VOD#D*RUREWVA1;HJ5=R1]%OI0U$#\N_H?*K3
M,)VB50I ].^744'R)J>P_4[!]]$%^Q7J7:4; 0;AY-Y0O7+>22F6''7'1V).
M0?HT+*RQR1CT9>3F]_(W,OVZP?7'K7IS'H6XB^@&S(]_>-?%*YJR#9+2FN<G
M8N:M5E1.CPC8X" '% LE!6.3:F-SY$I?RIB*2B8C:_L;VOR+A/RUEQ)NUZQ9
M#$8)KUR*<*_ /#/(I]8ESX$'3UV&'NZ/>$=9Y&?/Z*^8H^M6/TZN8=.FK%JY
M>O7*#-DS06=.W;I9-NU:M6Z9EG#ERX6,1)!!!(AU5EE3E323*8YS%*41"5V9
M45G=@J(I9F8@*JJ,LS$]   22>@'4Z6R0 23@#J2>@ 'B2=(U=4;? ZWCYY<
MI5:0<?@1Q<K(UO&3(#*)MYU05B)S^0'*!NTWJ;2X:HA%E6(FHSK3*'04;MWZ
MLH*].^T;C!N*MZ9:SGY'VUI*^W*,A9SD">\P/Y5EE'=9 *5TB!57,G,P]UOF
M[8/(?N$65B'J;\Z0CVN1T]B@>O.JSR)*J%5.FFH<B"8*KF(0QBHI"JF@"BIB
M@()IBLLBB!SB!15533 >\Y0&/@"<D D*,M@$X&0,GV#) R>F2!XD:2]?SUYH
MTY/T8][G\H3"XX+OTOZG+V#HEDS9N'J_>_N6+TS)1\#."90WE=2%64,VJ\^K
MP<XH&K<DZ<.'TRZ$EKNR?C#Y=VGY&NR\VZ[/$B*SG+V]N!"039)RTE8E:TYQ
MG'D\C,SS-AZ;)>\I@[B1LS0  $GJ\7@K>\IZ#>[E))+'6I7Q%,6Y49;29HB9
MS,VKK-T6X6 !\:;E^EBAVS3,;[ .NE&OC$#[1!NH(?\ 2/#8[=XV*<,2@>8K
M[Q&6]C2#;64?WA&Y'S3KDXD'FTSCP,XS\1$<?3C[-+&ZKQIK:O!Z3W4HP]LR
MI63\:YF@;HK$VNU,[O7K#38N/G#)2 0K6$E(F78/):(70(HA%QKB,=M#/2'5
M.]2>)M"E056F'LSX_P!JX3I[CM^[0VS'9LK<@GJ1I-A^Y6&2*5&EB*@B*-HV
M4N"2P8* "5[:-SAI)+%.'P[AU9 &Z\O*P(R,>B,$9SDYQC5Q^T7J\8SW<[FI
M'!<!0YJC0$G5'\IC>P6V18?2*WV& \LC.P[^"BU'T=#"I6RNI>+1;S4L<4H&
M5,Z=%4=M&B$J\+]J&W<4<0R;-!2FIPR5GDV^>U(G?VIX,R31/#'SQPDU^:6,
M+-+T@EYFRRJJS3WB*Y:,"QM&I0F)G(YG9>K J,A?-ZCSCZ)Z]0-7 :E+2SJH
M#JC],]+>5"QV3<6+14%N ID2:+;DDE"LH?)-9046=MZS,/\ M$D9-QKA=RI6
M9U<!:?TMQ#S1DX]9E*0,6]HW9\.*XDW';3'#O=2+NU$AY(MPKJ2RUY7_ *N:
M,EC7F/F><T4Q",LD*-NNU^6J)8L+80<HST61.IY6..C D\C>'4JW0@JGYE7"
MV6<'65Q4,NX\MF/;"W553!C9X=U'D>%1-VF<Q+XY!CIJ/,/!D)*(=OH]R0Q5
M&[E5,Q3#5K<MHW/9[#5=THV:,ZDCDL1,@?'Y43D<DJ'Q$D3.C#J&(TS9H)H&
MY)HGC;V.I&?>I\&'O4D>_48Z3M:M3O@3;/G#<S;6=.POCV?N#Y=TBWD)5LS6
M0J]<25,7O?VBS+D)#P3%%,WE,=\Z367X*@Q0=O%4&RJULO#V\<0VEJ;31FM.
M6 >54(KP _EV+!'=0H/'+L"W@@9B%/17JSVG"01LY)ZM@\BCVN_HJ![S[ADX
M&FU][_3GL.>MCV%\/U67:3>;-M%*I\?2Y5^N#)I>%J_2XFJ6VOJOWQBDC?I<
M2'92D8\?&313F8F(;23IFP</GJ%G.,. Y][X/VG:JTJ2[OP_4JI4E=N1+C05
M(JUF N_]'Y4(DDC9R%$L<0D9$+NKPO;:UBC#"A#3UD01DG <J@1UR?#GY003
M@9 YCC)TG3D'&F0L3V1[3\F4JST.SQZBB3J$M4*_A7Y?&<2>9%%\@CZIHH(=
M[=ZU%9FZ2,19LNJBH0YJJWMNO[98>KN-.Q2L(2&ALQ/$_0XR X',I\5=2R,.
MJL00=,N2*6%BDL;QL/%74J?M\0?41T/JUQJ/C^\Y,L3*I8[I]EO%GDE"ILH"
MJ0DC/2K@QC 3N(RC6[E<$B"8!57.0J*).5%E"$*8P8TZ-W<9TJT*MBY8D.$A
MK0O-(W]R-6./:2,#Q) UY'')*P2-&D8^"HI8_4 =3%N+VE9[VJ2U=B,VT1]5
M5;3 QT]$/TSIRD&L+U#RNH3Y_'BO#GL4&H!FLY$-WJZ[%4$U@,LQ=,GCE5W[
MAC>^&I((MWI/6-F%)HI 1)"><9:'OTS%W\)\V:)7)0X/5&1FW6:=BHRK/&4Y
ME#*?%3G\GF'3F7\I<Y'P()BK%=C6IV3\<VYNW<.UZK>ZC946K5(Z[EPI!6"/
ME"(MT$RF4665,T B29"F.<X@4H"(@&DW;9S5W&A:568UKM6P%499C#.D@"@9
M))Y< >W6J%N26)P"2DB, /$\K X'OZ:>]Z@6!YW=-LZRUBNBF;N;9/PT%9*4
MFNLFV0E)FJ6"'M[")!PY%)!JI8D(I:$;.72B#9JO)I+NUD6Z:IRW-XWV6;B/
MA7<]MI\K69X89Z8)"K)-6GBM1Q\S$*O?B(PJS$*ID#,0 3I_;C7:W2FAC]-E
M5D]A9&5P.N!YV.7)Z#.?5I"VXTJWX\L4G4+W5YZG6F&<':RM>LL4]A9A@NF8
M2F(Y82"*#E/D2B)#BGV*EX.F8Y! PTNMT[=">2K=K3U+,3%9(+$3PRH1ZF20
M*P]QQ@CJ,C4?NCQL4D1D=>A5@58?$'!U=K\/TP?&W;90DRLW1HU';M9V*L@5
MNL+%)ZXR3BEPW9J.P)X".ET&KE9%N90%E4FZZA"&(DH8LN]B"/\ SGW*3D;N
MQL-A#)RGD#MN&V,J%L<H9@K$+G)"L0, Z7N'0?*YC@X\F89]7]+%Z_H/U:;T
MU:+3PTHAUC-EF75MX$GDS$&(,CY K67*E 6B8<X_HEGMC*'N44B:JSC!\:O1
M<@FQ=/VD+#V$WJ3)&>.)EVJ0#F(L(5?[5>$MT;BA]QVK:[]VONE6&Q,U&E8L
MI%;B'DTR/W$3A&=(HICS8+M*S#/7#/WJC,;AEAADD69%9C'&SA7'FL#R@]2
MK=?$L=4<V2LV2G3DC6;?7YNJV2'6!M+5ZR13^#G(MP9,BP-Y&)DV[5^R6%%5
M)4$G+=)04U"' O:<HC#MBO8J325[4$U:Q$>66"Q$\,T;8!Y9(I%5T."#AE!P
M0? Z065D8HZLC+T96!5@?80<$?3KK6;-U(.VK!BW5=O7SE!FS:H$%1=RZ<JE
M1;MT4R@)CJK*G(FF0H")CF H!R.M:(TCJB L[LJ*H&2S,0%  ZDDD  >)UX
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M-H@D!R'AVVG$X/M#)"K ^_.M:U:R'*5X%/M6*-3]BC4UE*!0 I0 I2@!2E*
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<1HT:-&C1HT:-&C1HT:-&C1HT:-&C1HT:-&O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g718407ig1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g718407ig1.jpg
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M P,# P,# P,#_\  $0@ WP%H P$1  (1 0,1 ?_$ .X  0  !@,! 0
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MG1P?I$;OW4],VHRJ#[A+<IM[6F]PAVTNG"NY=#?T8A).(\KCRSK$;HD4,41
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M5"B8  P=2+R4N3_&E=5-%'D/HQ9990B2226VJ"HJJJH8")IIIDL F.H<X@
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ME>W<W15/^^/[@2ON#\\]@W&J6E:P<?=1&4U1QY10<+# NJO#G3"T;"C&BB:
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M0=.M<.]<2ECMSQ-#O!4T<QV!J2$*J(%$@+2!>H@)@ZE(6_G [[%:BPIUFO\
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M7U&C]JH'4JK9RF<HB4P#D%>-.HU"D<( (" @ @/@(" " @/T@(#X" X457?
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MFQZQOC1VS]G,BTC4UAUI,TZ7U\74KMNT4?R6T;\TGV$HVV.JD<!;-%$S-BG
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MOXH4ARL&PK*%((]>MW!BL=$6 0L<9;+I6G9O(ADKS/A9MU^(#M[MOY1T"V7
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MQ];:V:V65,Q5?M$EQ3;%.V#T9E1O+%;#OR/R@;7UK2=UP$9C8V*.-Q,<S_\
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M1P Q>X>T0 U,$P (?E$1SO?UOBAZG(XS7_JV7](O<9GG+]6[8-W._&H=H/\
MPVN?W+:^/W2.<O\ DA<[/]:Y1?[B\?6N)_YRQO\ HV;]*IO[<OU;?]?/&O\
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M!(YHV2LM3-EC:(F,,YC>R%VYCM.3C/MK?.K=0Z!UA&:T>!",:SP\8/UIND7
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M^XG1:#S_ )I/SW/19VQ796DBQ6-I;&N+@6XW'UL>V35P!W2MK"5S?1KGEH)
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MLIPO'M96:V(?D@!5'9B5R9,(F$3")A%1?M_B&EM?8$Y>3WD\&6P-(V(E8E.
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MK7M?H.2P3%RY(FJNUCDSBFF @F7"9TDY64%CF$;1HX ..C&C>X-Z!TGWW =
M7$:GU7'/-+WO\F9,2U)J<K# QS9HXHIY71UH6.MSQ0:PQSW2TW)HXRYK))W-
MW/(+C4#F(7+4PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB818CRO*FB>:I_SK;<#]H?P$?<G*(?:'P$H;(*!1#\
MG0,[]]'G'0UHOVE#]"O=)GA7DFP?Y$P7H/9P'^8+X_>IHG]]?;G^W]R?^,G(
M_2)_XM%^TH?H5-_8KR3_ #'@_P#<X#_,%DR<59YI:..6F[ Q?R,FTEZ+#/&\
MA+!= DGB:B1NB[S\17DA>!7/T\1E%U78_KF'.*YN,Q9:Q&X!I$AZ#9H/V@#/
MVH ^Q>/GFS&38;RSG\78BBAG@R4K',B^4[;2#Z-^18RGH/\ ]NQL7[$!5 9B
MERY,(F$3")A%)"W;OB:CN36VH'$'(O5;^PEW+ZU(+()PU.>E;O5J7%S9%0\T
M[G82E?F48X2&Z>?%*$, BH3,I7Q<EC&SY$.:!"0 W\IXU&\M^R/<PN^QX]Q7
M1\%XXO9WQ_E^>168HV8N6)K*Q#C+:87,%N2$CH&T1/5?/J/N66N'1KE3@PYI
MW!6K4V9D]#?"YK;L+1[#I.*#:42^B;K'7'8&O:$Z;6&?1JY'-)FJTIL^(?.4
M#1[]%9LJH""ZBB*A0S+N,UQ/+&RWNBKOD;,>T06%D<D@+6[M'AW:>T'<T@@:
M@ A=:L_J\X&/-9"A3Y-WL?@K%R#+R?3I62U)*M*]=:Z"$V"VW%8&.M0QO$\+
MFR-89(VLD:XS\K>ZY^PZ\O=@+K)^TV+KFSO:1:-;*VJ"]*UL[9&"DF[A.]+@
MUB#4]Q6;.PF3R1FY%T(U4XF:>I3%L.)FQD4-R*$S@TYHP]LFUVI:=PTV=3OW
M-<S;KH7 ?%M.Y<QR_CO%XKE>,Q9S$4G$\M39<KWQ6FW.KN,T;FFFW=+\TVQ7
MFJB /+'V&MTG[+Q,(VT[LIEN#6E4V1',?AS.T,G+E%LG(M9ED;T4B]BU'D/-
ML0(SGJ](JL3.(V02*1-^P51<%(0%.T+;)4G8Z[)2>=SF$=="#U .A:>K7#71
MS3]UP(U.BUSGW$+' N7WN(VY>[8I2-:7%CHG_'&R0-EA?J^&>,/#)X'$NAF;
M)$7.+-QF9EBM/3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A%BSJUK0WFJ=>4GNU /F'Z@7FYQ+ H?:'P*!M\
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A81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g718407p2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g718407p2.jpg
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M P,# P,# P,#_\  $0@ 1 (K P$1  (1 0,1 ?_$ *$  0 " P$! 0$!
M       ("04&!P0* P$" 0$! 0$                  0(#$   !@("  ()
M @,&! ,) 0 " P0%!@<!"  )$1(3%)2FUE@9:2H5%R(6&"$CM7=("B0YR8HQ
M0B5A<C-CDS2%9BD:$0$  0,# P,"!P$  P       1$A E%A$C$3(T&A W'!
M\(&Q(D*",Y'A,G+_V@ , P$  A$#$0 _ +@NI#J2ZX[^ZU].+DN/4^NI_9]A
M4TS2&:S-[4RO+O(WM0O<RSW)P$DD:5.-2864'&<A+#CP#C'AR0[?)GE&<Q$V
MJL6^AEU,?)!4WM,T^*N*,=S/4^AEU,?)!4WM,T^*N*'<SU/H9=3'R05-[3-/
MBKBAW,]3Z&74Q\D%3>TS3XJXH=S/4^AEU,?)!4WM,T^*N*'<SU/H9=3'R05-
M[3-/BKBAW,]3Z&74Q\D%3>TS3XJXH=S/4^AEU,?)!4WM,T^*N*'<SU/H9=3'
MR05-[3-/BKBAW,]3Z&74Q\D%3>TS3XJXH=S/4^AEU,?)!4WM,T^*N*'<SU/H
M9=3'R05-[3-/BKBAW,]3Z&74Q\D%3>TS3XJXH=S/4^AEU,?)!4WM,T^*N*'<
MSU/H9=3'R05-[3-/BKBAW,]3Z&74Q\D%3>TS3XJXH=S/4^AEU,?)!4WM,T^*
MN*'<SU/H9=3'R05-[3-/BKBAW,]3Z&74Q\D%3>TS3XJXH=S/4^AEU,?)!4WM
M,T^*N*'<SU/H9=3'R05-[3-/BKBAW,]3Z&74Q\D%3>TS3XJXH=S/4^AEU,?)
M!4WM,T^*N*'<SU/H9=3'R05-[3-/BKBAW,]3Z&74Q\D%3>TS3XJXH=S/4^AE
MU,?)!4WM,T^*N*'<SU/H9=3'R05-[3-/BKBAW,]3Z&74Q\D%3>TS3XJXH=S/
M4^AEU,?)!4WM,T^*N*'<SU/H9=3'R05-[3-/BKBAW,]3Z&74Q\D%3>TS3XJX
MH=S/4^AEU,?)!4WM,T^*N*'<SU/H9=3'R05-[3-/BKBAW,]3Z&74Q\D%3>TS
M3XJXH=S/4^AEU,?)!4WM,T^*N*'<SU/H9=3'R05-[3-/BKBAW,]3Z&74Q\D%
M3>TS3XJXH=S/4^AEU,?)!4WM,T^*N*'<SU/H9=3'R05-[3-/BKBAW,]3Z&74
MQ\D%3>TS3XJXH=S/4^AEU,?)!4WM,T^*N*'<SU/H9=3'R05-[3-/BKBAW,]3
MZ&74Q\D%3>TS3XJXH=S/4^AEU,?)!4WM,T^*N*'<SU/H9=3'R05-[3-/BKBA
MW,]3Z&74Q\D%3>TS3XJXH=S/4^AEU,?)!4WM,T^*N*'<SU/H9=3'R05-[3-/
MBKBAW,]3Z&74Q\D%3>TS3XJXH=S/4^AEU,?)!4WM,T^*N*'<SU/H9=3'R05-
M[3-/BKBAW,]3Z&74Q\D%3>TS3XJXH=S/4^AEU,?)!4WM,T^*N*'<SU/H9=3'
MR05-[3-/BKBAW,]3Z&74Q\D%3>TS3XJXH=S/4^AEU,?)!4WM,T^*N*'<SU/H
M9=3'R05-[3-/BKBAW,]3Z&74Q\D%3>TS3XJXH=S/4^AEU,?)!4WM,T^*N*'<
MSU/H9=3'R05-[3-/BKBAW,]3Z&74Q\D%3>TS3XJXH=S/4^AEU,?)!4WM,T^*
MN*'<SU/H9=3'R05-[3-/BKBAW,]3Z&74Q\D%3>TS3XJXH=S/4^AEU,?)!4WM
M,T^*N*'<SU/H9=3'R05-[3-/BKBAW,]3Z&74Q\D%3>TS3XJXH=S/4^AEU,?)
M!4WM,T^*N*'<SU4,?3<T<_J(_E'^G*$?RU]>O^EK]']8D?JG]/GTM_WP_:KP
M_7/2?RO^[/\ Z[Y/-Z7UW_S^3^#EHZ\LJ=?X5]U]'1A_RB]!O\@6#_$G?DCH
MY?+_ *3]5K_*P_!4J2H4JE<N4IT:)&G.5+%BHXM.E2I4Y8CE"E2H.$ HA.04
M#(AC%G 0AQG.<XQC@5%S7NXTJ32Y]KO7E%L%OK/XLMRW2>.Z&4-.-CVF/+<>
M;Q3/%HL*9MI9$:#(<X,"*2^8G./[S /[/$-9^LFI8O\ C[.ZL.W>KXJ'(1JI
MBOU)8K#:&I'XX](XO373%L63,&]&0#/F,%^F&" '&?'&/#@3DU/WWU W@9G=
MVU?O:&V<LC(O1S&&$C<8S9\#4>GRERFGU4S%!'['A)WK8!$A_4VM*$PP @@R
M+PSP)>\!P' <!P' <!P' <!P' <!P' <!P' <"F_NNN[9JA-=*MFE$32P*BK
M,V^8DU;;7W4-8M%Q6I1>NZIFD(WFPXM GQJ?F]8WM\H*;"W99A"J.0MXQC #
M^T0L&_CB)FD]:61!L7NJDFFE<5'&5T36]F"-DTOA.WUN[D5'*ZRI6,2&II5=
M*RET<O9JS7?J9#G("WY2VICF]O5$C,5&G"-*18*/"4:CX^59Z7I1TZ3=XS_$
M-<[5MN5:<@A-KT7LS(]:K>I*R=NM?JX0Q9Y8ZL;;>1/;/;,M4M\;GRR0QIX3
M)4;*PHW!S-=3/0! (KP4"';B9I6U-$%;:[5MCK/M1[G-,V9+:ZIRQS^B1\KV
M!+&>)_JT-A.Z-JS9;=S O699U9YLAEK2WIFI:M],8:0F39 B,("/(LQJ,(B+
M]?W>RZ;?_LD5Z56CK#240U\>+_M+:-?81<-8L6S7%(,84E:(XZL>VILFEIJ4
M49D5D/89*2%CC99Z=6[&%F +-"/T83*YXX<HF:VA5U$^XW8"A+2[493LS2<O
MD==T_M?5]!Z[1L=J4O'VUBL*=,E>Q^ 44:YA,1HF5#,6QZ5SYWF3F<I;6=M,
M-3*31'D )X;X1,131UA9_N 1/L"J-SIK2N77';,V<-Q6.QZD8+_J=&FJY\TC
M:XM)K;"VV<4G=X1:3 Z0V4%.C"X,YF,.Y62BR2A&'8"$G:UG3W2"US[EV/;/
M:^!Z\T-KA*9/!Y%35(W3,;:?K:J^%OT(B][U2.U(T[H*1D*]-/;&A\?+&0R/
M3TQ#5$-[X>$C)0BL@/&2<.,5F;O!V$=R:_1*\9?4R#4.<WS'ZNH>L]A[;L"+
M6K!88&%P2T+C64<QE(HM*D7K\I>13CU(H)"90# BUF3#!$E$&&<&/Q\HK6EV
MD2?N\?8CK!8MW234 B'VC2^TE@ZK7)2-C;<Z_P!;H(;+Z^@:2Q53@RVY+U+=
M'+'-?&1R2IF]K8$2YQ4N9V"0EY*\J@1>W7*D3:FB.=*]UTBG78<BKYL8IC.X
M3MG0>BEAZXT@YN,8A:.CX'.ZDM2[=H+BG\G S+CG$->1I C$L3X$M5. R"4R
M ( >87(3\=,:^L536Z]>ZJJ]_KV<J49JF>JOS)JND=YT'(W2S*XG:FUJDBD_
M#7KRZ2V(PEQ6OU(3@M:K1KRHX^X$L-:E85.#/+C&!5G+#C%68O?MZ9* WXA6
ME$JI!(Y-D]>F^),-G,6PU-.LQQ*GBKG>R6DUXUR;7-?;4:@9Q[0-H-?W0I$2
M%:((BB3RAE",+'QUQY5?CUM=NBC?VP45?R75::ZX*IKK''-NJ<=I!9<+L=OL
MNEGJPW*K5;P8"*I$"J'NB"8MV2RT*T E"A-GTP@DX\H1C/#C'6MZ(M2+M>L/
M7R]=H*YBE37=N).I)V"RW7"L*OD-FT]6L?@>(1J/$;^=D4"D!D.1>J0'#*4M
M.$6\G+'+"O!@@F&"'@!I8PK%9M%&$CW^XM2N]1R^T'71>T8XK-JO6J[Z+B"V
MX:W6K[PJ[9.^\ZX,+X!T;T1[?7CFTV.$0<('/TABE%C!PQ)O-@/(=J]*NNSO
MO*6P+6"67@]ZD CUGU'LE;6L-\T;8FV6OU9!KJ?U#%BIHZ@C-E2U>E:;A-D\
M?7(_T1'&V]6L<%BH)00!!D!PZ1\=9I6U-'3(!W!22_K/B<*U5T;NG8*(YJ77
M>Q;DL!IG]7PD%*/VTM6K[6JB$N\<F#JA427"1B3D!D;JE5%)63UD L!4Y\H!
MDX1$5F8AL/1KM'LSMOI UVEM!%7Q++C[)MA$S64\R2"N@+4:2;/F99QS5&X2
MG1 A396RPH44+2JDY(E6&?UHGS$' 'DGR1&.5(7'\,' <!P' <!P' <!P' <
M!P' <!P' <!P.-WML/16L%>.EL[$6Y7]+UNSB 4NF%C2AJBS-E6: 8TS8B/=
M%) G1Z7>C$%,A2A.6*1X\I18Q>&.!5^5W:U=.P!<=8M'^S3;R'* A-:[.IC3
M^0QBKGU.+Q\JI@F6P,BI1.])C X\P#$I1H!AS@6,YQG&<A_L/>)KO!321[9:
MT[^:)L1QQ"7-@[3:FS-LJ4A4I-P224OM>HUMN0-E)$8+&!'N"U&G*QGS&# '
M^+@6SUK9];W-"(_9=13Z&V?7<K1!<8S.8!)6>7Q)_0B%D'K31(&%8O:UY03
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ML8;0+%>30$&8R6,\:37;U2OC/2Q(HUL1HO-RMF6)30O7^T5JAI"%$:]Q%DV
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ME:B193!6*TJ02U46B1X4J"B,JUIH##"DB;!HP9/5&%DC$$L'B/. YSC'AC/
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MAME2=*GL%FCB^7]=K.8@Q*S#"07ZT,BTA[!Z40SU(090B38SY<B/CB8K]/\
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M*>DPY%#)#*''_;R5[=B^W);&K6IJMR]A8'8[C*)6X/KQ:M-W.\2^!0]_6)G
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M. X#@. X#@. X#@. X#@. X#@.!\RW^JO_N:?^C%RN_\?Z?="#K1_P#]$_\
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,^7Q=T_93UIQ]JO_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g718407pc2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g718407pc2.jpg
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M P,# P,# P,#_\  $0@ ?P$L P$1  (1 0,1 ?_$ -0  0 " P$  P$
M       &!P4("00! @,* 0$  @,! 0$!            !08#! <( @$)$
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M&FG&FG&FG&FN;B;TV*_3UM;]:XLF;&-UPTFJI)V<1H8_A:T,ZJW;AMX;TW
MB"08YA=+B5H\!-P(KRR,D73N",%FY2\SMR6H+79B#P6>\ "WB>S##L=S[-H0
MWX2?DVUZXF^+OE$W+L#R_P"J,<+> Y$N7BC#S]$LJXO%XL1.2^XC[>*CEW79
MNY+(-^D*!&89Z65;PR8)9BDM*>K5:6O=3:\"D4H(V%.-!J5+ZJE\7<!B)0!,
MPLEBNJ4Q+@'&< ++6'9)P$6"\AS6.<W;,31-!$%:6T_@6\#:696'M_%$QZ?X
M(W^7>8Y!\:?+N0X%\#/A<9' ^5Y+>ZE>P6#\FJY*K80;OMTUER4C0'VLT4?<
MW!;>0"]-*OA5%<E09LJ;Y:KFI^(TZ[N^4,?]XL[3$++M.RTKNVEA1!2F.*QP
MM12E,":$16"$I60XP/(\YPOS.V]V"]V8P\$\DH&[;$R111$'Q]@$0(^^3\FH
MO_>^Y3]NL!SL8C'>=X_GK64BBZY^B66UC\=CVBD/7U!$3&QR*5(8O(X)*A0,
M1$O2[KF(SI;.TMH3Q6N7,VH;*8B4((V%*$G4$^OSXL:$12 )O<EXJ_)PXXZ]
M"_,F=CP= >'+/SBY8@[#01!=[1]K?]J[O5\OXO=/3_!&_P N^_G?C-Y9G>-Q
M\:FPV,CKQS\GE#J\_5OR@7A9&Q?;:KYY^Q_K=M.YU;MO]UWI?5TOU[MK7DRT
M)V%AMRM]>ZV=) %!'/?#2WZ\G!-8W%O)\AA"8MD>0]%H3 9+!C/S6 <_#S>X
M<I!E!!$)8);,@&[;$V1LP/C[%_%_Y=]?-?XR^65_5/!^JB8;&?6>"RV<OQP=
M<_:E?.@B:-SU]82#?Z(J03^/U:]\8],RO(O:4OM1-9<W4.<PFNN<V6-AR&/X
M0IE>N,&>H+'T)!@$6#Q)9$B>QGK<YSXP&@#@K(0]<<^9N:W)J*46AC[:1V$!
MW;V6'5V/X5*[#_EUJYCXPN59CA='A4V'QJ4Z&.SU1) \_6RYZY%<G<@OMU0/
M"$B'L*DEP3MK#OOI:5N_:YVAK@HM&>$Q^T8OK=%G*0EH(YEY:TNMD:B4:CZE
M 2)#Y(P^2IXD4:NP8$00#.'@KPXP'&,B\YNIEH<N(8N]"]E@-VV)LL[-O_!Z
MST_@\=2&-^-+EN-]6,-ZM187&-E,-<S]B. O/VI&S]BS8G5SU]8%=K3+#TD$
MA5Z]SOK-LWIH5\RV;8MG$V7.#G&QK-K.SW!L,0Q["%O<:RJNR:I;VQ&8%#A0
M-"YMEE'JCQ#%DP)Z4K ,X!D>!8FYI;:E%2,,71%#)&#NV^TDD4A/M]H,0 ^\
MQ^]J.R'Q@<IR'#\3PZ3#XU:F)PV0QR2!Y^MX\ADL?DGD8=?2'CDQZ1H .DI(
MY8%@NV#EOI9UO+M<[(UQ66C/$\?LGZO7O"1$H(X)Y;OJ\5M75:L7DB1(<(1_
M$*"N4ZI9W Y\!ZDS!7A!@.,9H>=78<O#F%@B[T!GV7=MCWY9)6W]OS3(0/O
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M29D5,0LL.8I,5)N)*MQVL2=&Q"$ZRN5V$\V&IASAW$><%QM(M>1IBS2^BK)
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M,2S'??Z6&(?,+@V$X>G+ G >J@S+&F@,ZHS:Y9O&?"B8/_*EES2%7(79$_\
M5%_RZ9F.5B*393> 0B\=3/$+V\T_MA:!O$0Q_P >2%6\6]T0H4'3X_+[3O\
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M^\+ZH7[)8/SHV3_)Y+_88_\ /3:_HOZG_P E]1OZK>GG\YW==,=._M)ZU?\
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M80(\+0O5A&Y][!&2BL9R3WQ?)S8;7J!B)Y+CK%8 L-4*[A/#R\HD;?W_  W
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MC>I?J_Z>>IU;F/(8;_U9E.3X'&218Z2&=XJ-O%W@KXJO)#!VA#/6C6W4E"I
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M2!Q54-XRSP^89)(ZO?D1D$^N_8F-T><R-ZV'6'8;^],<NE^8S63&VOKXU0.
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M$/&,"$+&,YSC]/*XD<DCB.-2TA^0#<_Z-<"JT;MZVM"E#+->=NE8T1GD8CY
MB@L3X'P W\-!.S4$!Y@G-O"6F2IURDP2U-@"=$K[OE5AXLF>$I*I[ ^V8+H
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MPY),?3$UE@N7NS5UMP08QXX9$E\Q6DKRQ2V#6@(MU$:5))U74W#MA7F;7-K
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MK VQ/*5C:H(FS^B/28)<EC:J:32#,NA2(L.1\DI.+W4G6)9:[QDRAI%8E(S
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=.].@,CM?2:62$R-WD3OCSD^OYB:<::<::<::_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g718407pc3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g718407pc3.jpg
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M P,# P,# P,#_\  $0@ (P J P$1  (1 0,1 ?_$ (@   (!!0$
M      D*" 0%!@<+  $!                     !    0% 0,&!0P3
M     @0%!@$#!P@) !$3%!(5%A<8&30W6#E9(5%AD2(DU;9W.!K:8B,S0S55
M928V9M8GERB8*9FI:A$!                     /_:  P# 0 "$0,1 #\
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MZOAJ\"I0<=&0/I@"O1NCYZL 5:-:['>7T]-4!ERJ-SUSAX2]HF^&!'=<C[Y
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(M P-H/:#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g718407pc4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g718407pc4.jpg
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M P,# P,# P,#_\  $0@ +@ N P$1  (1 0,1 ?_$ (L  0$!  ,!
M      <("0($!08!  $$ P$!              <$!08(  (# 0H0   ' 0
M!@(# 0        (#! 4&!P@! !$2$Q0)%18B%Q@D$0 ! P,#! $# P,#!0
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M0]NYC2]1=Z=$D.9'R0,*%$4UH5"(LUT](1% -$+^?:;=9*;BZAM:'(/VC;4
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KE2-=3!%Z%OQMF"\IN#_%F+[BVI$QMGS^C[_H$R760X+C[P;;4C^0V-G_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g718407pc5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g718407pc5.jpg
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M P,# P,# P,#_\  $0@ +0 : P$1  (1 0,1 ?_$ (8   $$ P$
M      L !@@) 0(*!P$!                     !    0$ @((#A,
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'N_'.MP'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g718407pc6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g718407pc6.jpg
M_]C_X0 817AI9@  24DJ  @              /_L !%$=6-K>0 !  0   !D
M  #_X001:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B \
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M
M,30Z-38Z,C<@(" @(" @("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(B!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM<$U-.D1O
M8W5M96YT240](GAM<"YD:60Z0D5%040U-S0V,31%,3%%.3@S,3=!,#8R,#5"
M03A"0D(B('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z0D5%040U-S,V,31%
M,3%%.3@S,3=!,#8R,#5"03A"0D(B('AM<#I#<F5A=&]R5&]O;#TB4%-C<FEP
M=#4N9&QL(%9E<G-I;VX@-2XR+C(B/B \>&UP34TZ1&5R:79E9$9R;VT@<W12
M968Z:6YS=&%N8V5)1#TB=75I9#HU.#,X.3 V,"TX93 X+30S-C$M8C)B9BTX
M,S4Q9C%E-# W.38B('-T4F5F.F1O8W5M96YT240](G5U:60Z-F9D8F%A,#(M
M-S1E,"TT,#AD+6$U-#<M-&4Q83!E,F4W,3(Y(B\^(#QD8SIC<F5A=&]R/B \
M<F1F.E-E<3X@/')D9CIL:3Y3;&%Y=&]N5#PO<F1F.FQI/B \+W)D9CI397$^
M(#PO9&,Z8W)E871O<CX@/&1C.G1I=&QE/B \<F1F.D%L=#X@/')D9CIL:2!X
M;6PZ;&%N9STB>"UD969A=6QT(CXP,S%&2$-?0V%L>7AT7T-O;6UO;E\T+3 X
M+3$Y7U\\+W)D9CIL:3X@/"]R9&8Z06QT/B \+V1C.G1I=&QE/B \+W)D9CI$
M97-C<FEP=&EO;CX@/"]R9&8Z4D1&/B \+W@Z>&UP;65T83X@/#]X<&%C:V5T
M(&5N9#TB<B(_/O_M $A0:&]T;W-H;W @,RXP #A"24T$!       #QP!6@ #
M&R5'' (   (  @ X0DE-!"4      !#\X1^)R+?)>"\T8C0'6'?K_^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ *@ J P$1  (1 0,1 ?_$ 'P   (" P$!
M      @)!0H !@L#!P$!                     !    8" 0 ## 8* P
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GGZO,= M\?E@/;CD^49[(5/<W\RSPQO?!_;O\7Y_QG0+I'0,Z!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g718407pc7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g718407pc7.jpg
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M P,# P,# P,#_\  $0@ )@,T P$1  (1 0,1 ?_$ +L  0 !! ,! 0$
M       (!08'"0,$"@$""P$!  $$ P$               $" P4&! <("1
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M*$G%73![IW'Q3XP"#W!KL^E"3BKI@]T[CXI\8!![@UV?2A)Q5TP>Z=Q\4^,
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MV#8(Y@13.O&."9&Q6..$+'(5<@C4N@SJK XKH5/8<YF,\ICHW$"9'1R2$J0
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MSC0#^ZZWTYI[.=6ZAL=*Z=@==9_F5W#:VT+:8I)YWMCC8"=@J]PJ30-%7$@
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MW\CK#]Q44H@CS.6?9(].A*5*A]FE($L4FF_B*F\:8,=?Q$*N@W#^JEW[G<<
M68)'>R%6\9><!"W.R-L\D%&3G-UMY9J#1"YSNX(+2@EJQTN-)V28RY[C#JSN
M8FYE7,!="Z)G!&$T1HJ&G43A. .:[_ZJ TG#MI1JCZ]0&:V?LGU!=I9S#[,6
MTDD5@V(H)/;K'%6Y*+$Q^1%WA8J_^P2W1:O6EI:HE^\< TRIB=4<>52@ AH
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M0YI8_P X6R^0RBY%UX+.VV]$I519Z3"<+_WBE*O[3'F\I9L,K%(^@5(FXE4
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MQC2''J,NXY+&XND?)&G?V"8G'*U"N<-,X^Z#E::7N)J\_P"J6?4BHI+/&48
M1->SHH*4]%'V/Q8Z]2MR-\J;!*)8P3[#YCLP8GLG=!_;)?/4A\REBV:2.9L9
MR,]AF*J=JG0U_3R)B$A*"D-(&424501?95 ,P(U!2BG['EV*NT*Y81RU\.[=
M*<95D2ML[MZO$%GN&QV(4FSV9*S(\ENL<ZJ9^H?:*'814P<I"J>U1HSW )PB
M1F_YGLZ!#2B@0R/-:^JIK'RP<+8Y;&QEG6BV;ZFM]C?>Q5D/:!H%<>='J8Y=
MI:O YJ9"L=CGL;D_I!K"Z"H@6F'(PTILH7L_#2@3['U)]2*+47S$^3 [Y19D
MM+Y87':VUKX1<N21.Z&0F62^\DA"L^ZU>W(=PHU%\=2U'V@N9R!,G*5#<TY!
MB9:<KVB&D'52,4%M3L5UDV%E''^@I_JO1M<ZV4)N_;.<V=GC6H=K=W%A[O 9
M6SDN2UK5N$4>V\;4X("W9L.3."$\Y .H.W(& T%?Z@UI752XX)!J-ZZ=G+2P
M.P=JX#9:UK2H8;<VQC2.(PMF5NC@]J6Q@05-$E2'N[N>J<W$P%3Q;33S!F"V
M_C73<A)<:G>L06<PJQHL18J:8T6_ML1_8?<1UG3Q-X%+7I[FS=)%5R2"$TS)
M<%,E7+UXD#L2F!2A #0@3U#O%;@ME:  !15.>YSL1WA1WLIR@\!,>6J[[9:>
MT3]'3[X05^MA-Y&?<N=NDQ26XE% @D,*A4K6O)CQ"&9Y)"$I2-O,*6'E!H P
M\0:4IJ T!297NI4[ED6/\M?#:)J,5%D3M<MBKCA9]Y!CR[QZ;2]J=HL1)'<Q
M]D220N"5V"IGJ%]=5*@U62\56 .^K4!K3=.'2J@4?8[;[[U'_#K$6Z,0YA_,
M9S5O% &2#AO:^PRW%@D[>]Q]Z7/%J8LA1$/LX=RV%:N$R.\S5Q1G-.(5]DKK
M4(J#!39H!M)53G@QM8/3>MF%S;9P"\UOI?:FZD3:)S;J?,BJ.R^)OI(SFQZ:
M%=0"&0=V1A*E.>0>4 XA0286H3*"P&E# 8 (J2K8)!J-Z@[C_P I; +&>-7>
MB=LK$)%#3?:(K[?70'/9-))\YO\  ',5#5L)3.3^X'*62.GJ0%GB BJ0H&H(
M)-&:(P@H0(#0%6Z61Q!)W*S;+<E_EY8_RH^;6SM-+V^4J(=<.WYKN\7?N/(#
M!0^Z,5=H1+F6B9Q?1H0E&Q=\4I4IM"J'I*#H8 ?:AH/0- 4F:1PH2I,-^#&+
MC?B45@W6V8'/&,A@5QM/;]\D,A>%29 JD:F7@4II8L<1R@AY;9.JJM1K0*J*
M$IP0;@J!#0.IH*4]%3C=BQ_[EC/$GE?X8X/35WN+CE;N21::O\-.@3V_/]QY
MI,S7.-J'=M?#4YZ*0.JIK*5B<&=-7MR2"C*%E4!38&HJ5@ #<I=(]XHX[%L"
MU*MIHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)
MHB:(FB)HB:(FB)HB:(FB)HB:(FB)HBI#^P,4L8'V*2EH02",2AE=8W)&%T("
MI;'R/OJ!0U/+0X)Q?TG(G)M5FDFA_F ==%.[:M7$"E5]>7.TI[,W-MK=O)C#
MF) JWV-R$L['UETKSV:MZ0*M&2TN1-IFH0IO+FN (JA0M$RCQ#D-2UDDEN"4
ML\NI@HW?T5P@2;10/]1Q]PJW.^9KR[[A0:8V^DM[I@U-4XBK]$'TG^P;(IID
M"!ND36I:'$)9+A9T_P"@="$ZL>Y0TD= &4IO!%3\*\FRO'V%Y%?0T,T,C7MJ
M#2K2'"M*&E1MH1_5;%H_46::)U;E>L\H9$_-LHS"WO(6R@NB=+;2MFC$C6N:
MYS"]@#@US26U <#M45;FWXY45U[ VGQND635XD-N[/U;AL V.U-[$3Z\F-+6
MN:6XR3JE%@5C>O$E(<3A@[!*FI0T>VE-GX:V3+M:9CEF=7.?6\=N;ZYKBQ->
M6MJ03@ >"-PWN=L"]$Z!_+KR=XZ\RZC\ZY)E^0S:WU.)1<"X@G?;P":6.:06
MK&W3)(P]T3&G'+*2QM-^U4"W5T>41;^*77@ZW)2]UR(K>.+MT4E33<BWU_WL
M")&TN57AM<HV>AL6U*&=\1.="SBE&\9N#)!L#LWJ"NW^N\WOKFVNVLMH+BUD
M+V&)CA4N&$AP<]P+2*@C96N_=3,ZX_-KS%K/46G-6VECIS(M1:7S"6\M)LLL
MG0&1\T7TRQ739)Y6SP218F/CHW$U[JNW$7=CID3RI\<)(]S=IR5NY<V=/$?3
M0TB87<MAD%*W>/P9$-.8EA\?H595 E0,X*I":"I4 Q5 2$ -PO> +CY]K',<
M^@9:2,@M[-K\99"TL:Z0UJ]U227;3PVFIJ:%:UYP_*[R5YSR*TTGF-CD>0:0
MM;UUZZRR:V-G#<W[PX/O;FLLCY)CC>1U-&)[GNQOHX9;<\Z^6*Z7XB&0YU]Y
M61-H5 7VW32VI+'7T)BYS,_K5"]4N7H/[$1.!KRG.5#H2<6J+ $-:;0"K2E=
M8N/.[J/)I<D&$VLLS92XXL8<T 4!Q8<)H*@M)X$+K:P\OZRR_P /9GX2B;;O
MTIFN<V^9S2O^UUVV>WC;&R..3[A&('-:"]CHG.)K1[02%FO]V?E_>>CMZ&9$
M\)M8G$%U1]4G#_"A/D'?;E19#SJEQW?)V]-N98XQD$(FJ^U5N<A(R7<:$EB#
MNQF9IE%DW(E>C[ -"1"#0%3" @ 90RA9>YMN1ZTS'(K,V,45M/;!^.,3,+C$
M_P#FPAS2#7:.!)(I4U]7>%OR\\F^$](_^#9;EVGL\TW!?F_L8\WLS='++XC_
M .U9.;+$8WXJO .+#(7.86%\F*J7<R$Y2=U8/:>%(;\W(M0=8M+]OM+,K56L
MR)CTSAS4:E(2.#8F>%5G7$:Q,[ 3A,4C-I50-3O&T,H(PS?MY7K'-,LO+F[>
M(KEMV:S1S-Q1O-202T%M,-: ;J4%-@IP/&WY8^6?'>K=1ZJNV97J.+5TGV9Q
M99O;BYL;V4/<^.5T+'QACX2XMB#3];8J1EA:QF#F6Y$\I)1C*#$]%?2X;-;(
M;JUOSJO;[27\,F,@?&^0I)0J=GQY<;(+DBQ4].J(OZG8E &A( EDT*" &[#-
M89JS4'_DKOJ=F :6M!:[ UI:6@- <" T$TZC4DEU:E6;7\K?+4/GP_D;=C+;
MK7HMY;>*.2%XLK:WDMGVC(;>"*:-[&00O=]597'&7/D,CG.KF*]V>_*]R#MD
M]6FN1>.0+(J\4;SBS&JS&1+:\,CHSF!.9GMB<*6A.HB<VPT/]%1%F%# (99@
M!EC$&N*RC.;S),P9F5BX"X;7>*M<#^YKALJ#[$$&A!! *ZQ\3^5=<^%=?6OD
MC0LT<6HK7[&D2L$L$\4P+9X+B.K<<4H/4 YKFN#7L>U[6N&,<<,J^5WC8X3&
M2LN3=V[DW!GI38AD]R+L6QR'E$O6,C($(6B/IU9=FD1*5J1]F"M:;@C3:E%T
M$/<*+ #(Y]JF\S]D4$L=O;V4-2R*%A8P.=O<0222=OL*G94DG?O.?Y):Y\[6
M65Y#FF79'D6B\F=+):Y9E%MVEDR><DS7+F%[W/F?5PK4-:'/+6XI'N=*L/-I
MP  ((PWU=Z"#6@@UI8S(G;00:[:5I_\ $W\:5IK6ZM.Q>=70.<"UPJTCV4!F
MNY?)_:KRTNZ#(6[JML3W 479:[,K;;9"G6;9[G*1T/,F2*+4LJ%15<4JI0PH
ML:@18-@2Z[Q 0DTW237F</RG_JPVW:\P_2Z<,(G=%_ NK2A]33:>K]W4O9.8
M?F_YJS'Q=_\ S5]OD<=^_)6Y/+G;+3#G<V5,&$63[O[2WZRSH>YL8<ZI>,,K
MG2&I7QO#RC;^70572E61EWV%9)$\=27-B<,MOD,QPZ[B6)FIS8^5/&VME5*A
M:-"%(4#M"3B15"4$0=PVG:ZMY1KC-<ERX9=;LMWM9B^I\C"Y\..N+ZS4 5J=
MA!WD&HV+@>)/S-\O^&_'\?C[3MKD5Y;6+[E^57E]:??>Y,^\:X7!R^7[6M8)
M,;W87L> 7.!Q1GZUGV^^=W+'R$M"^V2F5^)<S0M^#'BSO"-E+]MCDA3Q=U;G
M9I3-AJZRKHB3IRCFLHNH!$#IV-*AILKLK3#9-GEWD>:,S>TP/NV8OW@D'&TM
M<30M-=I.\;5TWX?\N:P\*^3+/RQI=EK=:JLS<EO>-?+%(Z[AEAF?*(Y8GN<6
MRO<")!UT)KM!PSDMD#RJLJ'&W+E<'*&]#&9:UF/:(H1!K77P92"!*3D)QSPH
MJNL&[J/O0Z-J<';%&$TH H--W;2E=973^LLPTY'/'8Q6S^Y=B>9&O<?7I&%[
M1AVG80=YVKM+P/\ EGY'_'BQSRPT7EFGKMFH;ILUVZ_MIIW.#&R-;"WZ[F%O
MT#[9'?6]K^I[MM#19(QOS3Y9V,,4?XA"\G;L2M!(I%22JUMQ[6Y 2-U3+*-B
M1K^E0*TUDFH!#?V*,(^SJ 0NU$*N]LKLIC\^U!<ZAN675W'!$]C, $37-!%2
M:D.<[;MX@4]%HOG3SEJKS_J.RU-JG+LDRV\L;'M61Y9;.M87L^U\N.1CI92Z
M3$\MQ!P&$ 4V5.:I3S0.6_-HS(8;*[P+7R,2ME<H](6=98O(NJ5S9G=(:B<$
M1VY:@!@ G)SA4H(%0C +8(-:"I2M,3;74MI<,NK9Q9<1O#FN&\.::@_W756G
MLZSW2F?66J-.3R6FH,NNHKFVG81CBGA>)(WMK4'"YH-""UPJUP()"AO82\O*
M5Q_GR2XS/DK>:?OL<95\9MPGN?;C(23--K(TY_4 6LT)0%63;RT19R96:309
MG:;A1IE A",P8Q;5G6N,TSNR-A+';P0O<'2F)A:Z9PI1TA+C7: =F\@5-  O
M4'F/\RO+'F?1LNA\SL=/Y-E%]=1W69NRJS-K-FUU%A,<]](99"\M<QDF%N'$
M]C"XEK&M&>+A9T\L.Y5P++7(?+ZRE$^V*DCY*(BD9K&7R2-#DO?VU*V+")*E
M/L@K/7HB24@!E!)-3#"9MK45:5V:PUCGEW865W8183#>,:UY=B+@&DD%A#@
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MR15)(H].P2PDE@2)B*"@#U.]6W.%,+?VCFIRZE4)HB:(FB)HB:(FB)HBYO\
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I^^Z?>=W<^IQ,[/[9]OV[_P#]7NQ[3ZS\/\;?V?RV?CIUI2WXFGZK_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g718407pc8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g718407pc8.jpg
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M P,# P,# P,#_\  $0@ 20,@ P$1  (1 0,1 ?_$ .<  0 " @(# 0$
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MQV51F0-8ME)P2N#2$A>TJA"*T86:2:$._ /T\9+%%B-ORX3VDGFLHRB&EO&
MF'B$A7_%,=)(E_"GA2O'J%TTE=+.B&Z-GY@8[V6QW4C%MMRFQ%4D0WL-E7XT
MAASB2QIC!,R6T0M)"0*J:AX8AW,^-M3R"%(KL7()@GLA=;?&"NE+VQVC9\;2
M&1"57U7T(D#5J.Q^7ML9+&Y1>2+4HU(4850?.\P)FC  &&HV1F9[,I<:"MK#
M2/)<1":;)=8,.."NH@4N!BBVO;A94MPJ_=SSJYOC%[B<Z=QG8![2:P6X9XLO
M8['2"25&PLZ6PYSWXKDA4;D,-.(VKJMKITJ"@1"MB%.TO7E"PT$!K%K=6B+E
MN:]X C>99+9HMTO<]E;6&;>IJ^2%[$4/9(?"5M1LHOI] (>N^L/R.2F963YW
M.(2?LB70 !+)_D@(CX?8K5+?W4+=74W<"[GWB\P_F59!I3:C18@:&[Z4Y,1E
MAFZ76Y<O47])5LE2IE!4*KB'\M2:PO92,L1JLUH<BTI0.GC,4C1G!(+!UWK7
MB&;O6M>G7IWGHRHHZ*E[G4E_R7JOQ9-!DXQR%06$?;4E7L04-+JOY$O5+[%Q
MGOA[:ZFA<EAZ[;)7\&@%-(!3QN!/(DIB[%8U,V2-_ET2U*&<3^G):5QC,H*,
M5D'C-BJ@7C\.P^;DMW-XIHY$EAQ.:\ZX\O+70:&3;S>D#TKIXHAHJ(J6=3_!
M]",EUAZ9XZ;G-PX>>U\XY3)3<J?F3BPI(R'H&5@(S%D^;.\DE= 98$+1@@Y)
MI--T+1L*\U+>;OQAJZBHA'"V"8D2^7NDO6NSLNB<'BZJ!R*42N*:B:QB2R-T
M204VS-L2N)MVBS=BC*$*168 0#<LS60Q36<?RL@]<96P0$1$(R1P1 ]:$HHI
M\KF(Z7_J%J%%X5BK'[YZ;0.LF9ZE9Z6LK % BMQ0::"3,DC-8CQI/G(/$PV4
MQ,?YXUDG]0VR#Q/L"2$%<O?+%-)Q)>/MD;I^8.\K01J,NP(JKC9<@8HY)5<G
MBK])6;[2LTI8)'2D_8"D.MDR,!BQJ<4A1R)22H#H))WGBG8T5F7"\X;&.KA)
MJ0M)$* 8B6E0(7FROQ;X&*JA(J7NE#TRR6W=N8C=.T4ST!C".S)#:R1D*P\_
M'&/)9CN^;NQGV,O"?4[' 46I+#I-R&G&E57&X84USRA:=('];73D[/1%RMW,
M5F;8M)%B[Q204 MI),*D?S7@#*0RNSNA$R,I" D2IK+4KQ& 4"\(AAN8S<$Y
M=D7A%I8RPU4A1/%YC2@Z-KW1%UFI+8K#94K(+.[>C$Y7<7&RS+&/+;[FU77)
M,< _W?SW&%%R;"-*Z3K31^=RS>-&Y"MLB)-)=!7YHGP_M-Q43-QD:1&@>HPT
MNKHRRUTCBIWLM]DBFY.0<]=6FMIP"7HDL/8YC]I$1+D6<WK@JFER"2'17HV7
MVD;B@ C0LJJM&2(0(2(V(\F.VBN!H53(-)**H0V,;\?#[9SKULJ(WCXN)-QW
M'S'VFWHS;XM8]F..*P<)MV?#6*92GHOF[IQR!]E6Y,=7%U\4/-W1C<9S9''6
M7R*FYL<QPVLF6)*BIYQX<YXN9YDSR:)K%QZ(!LC:3H&I-2D>(E]\I:2/10MZ
MUOR.@Z0'FXL*8PS(;YKKY&FB0C:*!"2)?Q5U\>T/%7_SJ.0LE$VWM'=F"Q.X
M,<.2R&9=E"L+.-P@=B.QY( )JC#J3!0EL</4R2:D153F7&7;RJILN*:62Q2^
M"M4]5L#QQ;<H4UN[8C<M(8.;98ASQR;P+-:"4!4E(>R738-Z$<A)"6/0@^ .
M[?BYYXZ*P['=)H3&4AJBJESY7B(MOR@H^P2JJ>&H)TWWM,V#M[$9+ Y)_&,2
MF-QMRW&G#;US$Q]H3;BCVJ)+$*.BI87C4QLNI4BM^I>]DBI(4V$GK(2AG'(+
M<6@S5%B6=1%&=UMMI<8DI4R0J4*-.[,[1Q(,U"G"@2^KI1:!U_@]:'7LY+%$
MBJXJ))5J/J-2OJ5&50[#IX$)+XRZENO'PU-<9U"Z:/LF<PA;W$YC<)YS,<DJ
MZ,EUO&.A*$8ZQQY3K3Y(+QJ\YS'$4OZ:J.2T='K(K)FY&K(A5$A2OJF,>N1I
M7(XP7%97)[5,<YSLIHE*I#)'.(6T>V*G)&>?.T2-O,<T)X */61I@Z)\,H]"
MG.PQDR 5I'+$@EJ 6K-\1110VKHBHC"J6DDX6OQM'4?*[1WCD-I1\]G(AXT)
MNB0+$A9,:/C4;AW=C";#<K&(X+;H!AG77QCO 1-<H755R G3C%>9C0@AKQ!F
M-V!1D/ER".OA:%;/G)_C\DFE?3;0Z2G4D=8BOBESL32<\)6UP6MQY6G!M3%B
M!HG>CMW9O.8OF+);=(5E.@I#= 02$' ]^ 4)"9)4!2$21=)$O;PK)\+K'TV&
M>[N"!DI+!;EGQ3?94PA-LOQXDZ);+PV&Y02<2\ZD5R0PR^!<B0\8DKB*VF3-
MU0SAW:KJ@#%5!B"97/9<]9I++WFL'FK=CJU]N65S)[42.^FUSDKC+29- B2D
M"'21L*4I3UY'T->4/8/$\C%;=C3'9"+&C,-J("ZCOOHLB Z6%04#2=R*Y*BH
M*\>/&SR]^;;@3MO;HR6<1W ;>P\)V/%:R+61_P#D6<5&B,BQA7&X[<98\U2>
M>YL@FW 8=\;QQU3%:<3MRP:GJ($XA<Q62-KK:;QJVTD33,[\H.?V]YKMM7NQ
M$=>3DC=.XS*#(RM<0,QH2S7UC,-1ZT6<I"'+;!D8^)/D^:NMHR3P$RIW'Q5%
MQ434EU AU".M+H!HA<42H#LK.;%VMOC.EMS(8]O$O9>'(QA22=9%&#:G. T3
M[2$Y#D1TD-,+*%2&',$)"J;;2K7SR"O7MWXDP6*O58NJ!,SV.L7_ &0CM8FR
MQB+BR623 Z,N\IXZR>6KWI5!W<A4B/,AZ1WVLCIBE.-*(HMMT47RU,:;S[K[
M3XJ1,(FLG-!:](:D"0(HB&EE3FJ%G+*A74[KZXO=6.@=<\EF\=F6'7I&($/.
MG\@D9Y9),14D-1L['C R,QHA= <H[%1J<+;HO(92U,\*INFMNMK.0;GHA&6.
M4Q6$M/JK_3;C/&YO:$/'R ,"YBU?#S,GDYM:4[\SKDAK6M3K#Q*=""-6<(_S
MMU62R2!!3YMEJJ 9K<7D;5560X2%R$ ;KI450A5$M9=*(EJD/4#J D+9+*]/
MMS.*$*;,=U,95N$X;IYR:\#WS,U$:1QTF7671D,FT"-Z2%AL6N6DU1^N5=0<
M>N, (Y6;L@'7+[74NLN&05E*427:Q97SS&9<Y;8&\X!TA=R)&_E*7 !.SE)H
M"C30!-$#0=VQV:.0R\Y7GQ5'@<!LS7Q;(XA@FI?<HHBJ#>R75$X7K'F5W8QO
MSJKO(LMF&'1RT:=%Q\N8ZHQ] SFI$5OGFBHPT3#)-L*: V*D $H(2JD9<?N,
M<Z/LALM2:-Z"#*HV^,,D;SE\8.46JZH'*&N8CX.9.D\O-:VN&IE$JV6[->FU
M7L;@D-"$_6MA,!79?-Q$AE!C*KHF!"MB]Z14-/'T:+J=AN!:D\54X>"ICU2Z
MQ[:;VD]LK;SKN28F1GHYH$A!QK9MRF[3$AE%1QR40QM4:3SVK,.@I-JJ$!<K
M8?'1A;;*M*>)*03O,4D%B5>Z6$WQB/(5#U9< .87E=.6XML3C+4RI 79>V9Y
M>6OIL3L!N,!Y2D>]$F></,NG!8BG*49 ,NHVI$NEMS4* M^P5Y6L +^CJ3B*
M<4HMJ=6,G+VAA=LO[C*/FXN)R+<$Y#YBSCYJ/-!#-7"11C&N/\ZB1)'9&5\2
MULBBN!ZY15MV2CCS#ZCKV,*(H!^LJ<RYB13![<(T16%91B0R29TM'7I>QII&
MZ-CDV2+4:-2M!99H"$*,QO.$4 D6M<L3\8QF',C+<1Q08 "4!0N:Z0B#Q(A:
M45%'F(I^$E0TNJUVPV].G>&ZJS]][JF#.*-AX<5XXK(2%R.0D,1XF6?9!XF&
MW&W&/G 7)1$*F\Z$IL3)Q%K$WV%3F7ESY]4T+8Q/(";%NDB3SQ.L*8 ,E4OE
M>L^U=4D34MZ3)C%9>PJ8TGCWF!T0_;]M]"@A"X;J&I,2.K+0RV5Q+5AT*FK4
MZ+A6=T:;V['5<\+?O7'W%7S&;BVW@3Q>-9W/B2Z78Y6V"A$*OJ]DF9SNG)+$
M5DB05][GG.TKKA?_ !US55BI[Y#6426$$FMW%6Q@4E[-LU# ZR1L.T2QHMUX
M00(+%8K=7ICJD'51"\3<ZHFUTV%$%I7 4N(]I=.GK)O#,Y\5L<]GYSU-*;BE
M=%917-3:N67FVN!$/C:AT@FKEZ4\\5O'.1W""7O;$KU%YV/.;D#>UB[BVCF\
MZ"Y.1LDR1!S(SLB/=U9+*LQ!YWF7)"('F@^29[#(8B]QF5OZ578$TN5V=6]S
M+T7()S(*XF5*N3.CU[03JO9#BD!I_)#X"R/.<BC-!"9KH&XMY;"HZ$AHVP)&
M091%3W+8N \BKPM=%][7PV%4[*GN/ZG=(6LG%SN.F08KP8N)BFFC;6[$-B?%
MRS;I^]D/-;)?,B6Y'H8,550XEF#13EK%2-I=+@K>8SBL8K'*SJ>9PLDD$J%/
M(#2YULQV*2/[,%.!HI26\3.1-LJ<&_8#%"I$$D0R3A)])]TSN2QZL$WCGFFI
MKANN@?N=#CR-$8ZK>+8!)H2[$*Z(J7O5@G[_ -D'B7X6PLOC\;O&;+R&3B2U
M58WF4W+#C'Y+'G"@GFRM1&)&-8?NC;;RN(+C:.\U/V*U9+&&;DOIM%V-]M6]
MXJF0TY*=-Q9ZBM:6B]DS61/56O$R]N#"E< 4VHU'SF+SE>U2A:0F_A- VH*2
M)\=Z,K22F?-E%T7AOP<>)L!%U T\4YWOB'9+(*EPO9>,WO7!Y/;I8UO<N)_9
MUV/DF,K&UJ@Y#+2($1AK(M1.2BD"Y45FC,TM<MMIQ[Q%)&CY^"\;Y\\ND";[
M]J**RU8BN=GN7<@\\R9H6-/:D)GZ^TXT>O?VUK4-VFNVF-$Z'-Z<LY"0)U1Z
M(,-T3O97C+S,1L'CQ,@VQ6,K.GW"ERC;1HK"JWNTJBA*NI=!7M?C:]R]7-L8
M^%DY73#.S8+#FWG<3R-*1#>+&RX08V0(,.."YS,8\['!\R%XTC2%< %<\>9N
M"T&/@D>D:!\K\^'S%0F9Q25R54L?7*]X7$KW\9^G2<CD3Z1:BPL]6(S2X $O
M31FS/!_#] 6W=,I)3H$T]S(R*6E$>YB(EA[ TCRDX=G'_P"E8^[RFY&MRY6)
M*QN4&?@ -WS=L<LD\&@4&$3EPT897&BHBB<E5<NHH&KWNY;\9$ZUBIBE,4IB
ME,4IBE,4IBE,4IBE=2ZB/V/_ (B#];+'^N^0.9]RWZPVC\&WY$>ON/U+^OO=
M4]!@?$X2K:^V]\HJION/MGWBL3,?[O\ K^]Z2SY+=:-=[;[]F<^T>,^(@UUQ
M.P9\PJ-?=39_U8@S,?5;ZH?ZUOVTKZT_B=_=6E_36.^,.H\X%_-_K3XD[._P
M3S*S=?JZ=]%#^:I5WFON&Y?[(X__ ).K.8_^U#\1/]V<R^JK3R$'^B[1^';_
M -E6G64^IG=1^F(GQF-K76\?DV=KKXD7CWON7+OC/6+FO0P\AFLK=-_O_=9O
MLBS\EQ-72=^+Y=-@?>!57O@BS''2SZX,_!N>37SV_#/^]?B_HO)?)3JD#@#\
MHGND?XL?^I469,WAZP,-_7]JOHUWH/OV]&/]?\:=?O9!_0SN0?"DX?54]STZ
MG_IN&].'RAI^(U]8.DGVV;^,AUBU@_)"X3_&K*?YS<>=L?ZR<C]&-^VQ5YVK
M_$9ZB?\ 3R-[6*JWJ?\ ]X1H7X4G;W8N+(!$]4LOTU/+9K1';'\++<_VW;^4
M8JM'?Q*7[4>+'Z@V3[PQC)3T5_19WP@>TM;'_A#_ %-WK])P/B)%0ASX^4%V
MO/XZ0?4[MEPVAZP<S_5]JLC=V'[^/6;\UCXUNO%]_N]<.^*U5[QRK.H^ME[T
M+_,IC?XI^0^Q(_$1JLF3_/7XO?!*W>X%E9#B]6,[Z17XUJM1GOX:^\_^HKGR
M['UF'8Z_2[N.?%6X_6<YREZE_H^)]#_F;JP_B/?J+I-]B@^+AU0QRV^<G-/C
M$KWWJAV97P'JW'T O(6OIIT,^X!C_L%.^32JRGOO_,8L;]0JI]S$&>72OZGM
M_GN>6567\-#[I^)^D\E\K.KI+Q^<QVO_ (:WCW3NG,;8SU=9STS^W'KYZ]./
MX?O67[7M?*<36E]%?V9>_P"?>#,_>.V<D&6_7&UO@D\AFM@^I7KA[K_T7%^3
MXRK?^"'R>JX^&BSOWLZS'^Y_6$[Z8U_LZT.[RWW]LM]L,=_R===C\/Y_;_3?
M<I9/^?C.9?ZL?5$/AF_:6OJY^*+]UXOM# \F144=MGYM]1_?9;/NW8N7'>?J
M]?\ @&_+"IQWNON+9W[.XWY1!JR6-_I%^(V_W-)OY]=>0M_^XVA^</D,5J+E
MOU5W3/2(_D8BH<O/Y4G:-^_]3[X3W*_&_7O.^C!Y#=3[IO\ ?;ZZ?9<?DL*K
M?>_E\O22?>I5_P!;*\Q_TJ^MS?P)_P!FM#_PQ/O41/H7(_%A5*G![Y,G<R_6
M>-_S2#9DK=7K'P_YA^T5?0WO'_Q ^C_H<CRIE>796_8UW1?A34^ZMN9Z=2_U
MK@_3T\MJGXAOK!Z,?;8?E.,KA+ ^3+V[/C&F?O7;V(GK%ROT<UY#-7':W\0+
MJM]@8GR;%U;=)O[PM7GPJK?=J<YCYCU3O>F)Y85HOA_X5^5^VH?*(=:#?B3?
MVU\9_NMF7O8DR7]%_P! F?##Y*5L]^$7ZO-X?347Y,51OSZ^6%VCO]26?4C'
ME1M/Z[9W\X?[52WNP_?'ZZ?"!\:]7<V3_P"CD?Q)7[P.:Z%[I?RU^?AW^]+\
MY?;J ^3E'G7_ %.OA33)=PF;,\BA]B5C.=( .NH99U<25MF,(?SVPPPD+DVE
M/+2 E<G\8!*$!YQ81 $+0M77"9-,3/228<R,0&VX%[:VW!4#&_@6RW1? 2)?
MA63NCG4=OI=OAK<4Z)\X[=D1)4'(0]:M^=X^?'<BRV$<1%Y;BM.J;)V5 >!L
MU14146$H+7/,JPK<K><\DI%4$!A-.?:)T:H%Q[D]C.Y5LSA]8%463R"P5\N9
MHQ[-A<<:G-6H;V  ' 0W$X!RE2/U8K6[G*F;<B0'HV&"0[)D:44Y MIR@$D+
M2V@*5S)41"-;>+P$4NM9&W)NSN_[5V+E]M](XF>RFXL_R&W9N<CP&EQD-EX9
M),00BNR.9+?<;;!^:JL(C DVTR/.-4WOR+5K/5:3GQ>Y+QK@6V\9*DG5>L=J
M'.[\@DDN5/TRC[** RFRY/,),UQN1L<;7RADD#U&7@#5I:6C :BVH/.3F!.+
M(,R:IG,+(W66;GM/%!TBHAI BUBV "I"I(*HA(I6U66PHJ*BJE;?0^LW2#,=
MYI[K%OG&Y63LH6&3CQ19BOO>>QL?'BQW'V'I 1WF&9#2R>43JB[H;;=$FS<"
MLE@U.\O$7'N4TZ4HXW<;W6)-$(3\>%W'=384BCC&=$W@#VM8IZUSF.,2@R+R
M0+8G;E^T8CEJE&O7&B'I1Y8Q>$K(;=7+-Y"TV8V9'YPDA&Q)4(=*$VH$7C#=
M2&]A11%$2UZM.Y-_=!Y'5.%OXQW=NZ%.?F%G0SHP6'WDDM*R#T)R&^\*2&.8
M;[*.H+3;K,8$%6M0IQK7Q!E%_3&S[$YM,%='[G-?UC53'5=/32PSF)CC=73]
MWM1#)G6QMHJYEKA*W&P7,M4F D3(R&Q*B*+\9YAIP\[GN)C$QF(>V3>3E/..
MDZ\#>HB<;1I11N[@(*-HJ+=54E55LB(B55S.O.&Z7X##;4[NLK+"F-RF0R3V
M2RD2"CSTC(PFL:<=N!KGQ@C-P6R;<5UQTY#CIEI: &QKCZK[>[92\GY>OU32
MU[K-PO"-LD7J"7H)W8T]DU:IDU>,+6X.SRAL1\>6QX=D]B-.W%*88:J4:;_"
ME">04+9(>^0W<>3CX]F>V+PQ3(GA5MML7%5PE1!5L45$Y9:52R)J\91)>-56
M]N]/,ZA8;8>,WQ!CYB+MR6](RD4X<"%'R!%.?<!IHX++3C310748<$1;#GW>
M)ITT1Q?O;.,]\7I+S9-S#5U.@01_C]:O'Z-QZE765/)<D,O!)'6JTK-?7.6Q
MZ.&1\UQ98FD3M3&22N B\]0,Y8<+R]:ZGF\7BH_(VZCZD<MJ01/(*:>0I*TV
M*"1:K$:J1JHWLB(*<:I9G6'IGTVP(X?H(&<=DRMTXW-R'\LW&:6.F')]S'8]
MEN,^^CZ-NR77),PS95[0T(1VTUJOE2G'/DB78?'QVY OE1'Q?B1!)5#JT<:R
M4RH^16P_R2*M=>DSV=M4A96UM@>F^!H3PF-#>J=BSG5>:;I2 @@DL7&3S.&6
M',;Q(R$?R#HFXCFG2T(FKF@%%54[FJ>.2#811+*JJM<=1.K/20]J;J@]+8V=
M'-;ZR<:5D&\@,86,:S'DN3EA0G&'7')NN:8*,I]N,01F0!62<<<--B./%,R&
MJ5-_N\N<V=X?KHY#V#;(5K.8M,]6BCHBC\4@#(O.6I$9VG)B@T30)SP%Z&06
M<$>BAC#]+=HS&29GI$;CB0M1H;;5EMQ-%(G"2RKP(S)4OQ5.U*Q3U6Z@XK>[
M.UX&"9?CXS;VU(.,T.H":I+9OR9KP(!&G+>F27C!2L9 HZQ%>":?USP^Y"LB
M3CU1$N?*A%QQXN6RV6?"IPP*I0.Y+ 0PD^2*JPB,BBBN/I(E$%32H?2O;KJE
M=7 ;L6D\)1"?UH[8)#,W'B73F96.,CYYGQU:,"0>2VIZ4<(20E,[Z?$%1'3?
MBJV2L];LZ]]*\B_NKJ9@HV>3JUO3!N8Z7#?&.F*A'+&..1E,21?*3*%T62\S
MC.1F$C$[<W'>2WJRC7%[D#,[?CAMK+:,75Q"[L27"=;L79E#7R"N!HA,A=97
M2%66 VH8@S1EH9JQ?%#=M2X$N:\3J4Q)/"F3&'J3->'SYB(V//S!)2378JL\
MHEO'94Q0'G6U4U)5<'585$=',+QB1$2K*O6;I=M_8<L-D-[D:W;D=NEBDQ<A
MT7,)BW9;#<;+Y*$X<IV0Z[D&1?1M@H["1BF/W>=!ID5XUPXBWFI?GVF27VL=
M\3)/R@3<H'1V/6235N)B]V2W7B\4NDBQ;)]E#F1VN-OVIT^"=@'$LJ@Q-ZD(
M\(#L] W%C!;#)*#WS^$%8J)8>5_=JPCREJU:D96VC3931%U6X561>N_3=G&Q
MNH#D;,_OQA[,+;K;2!'^;"7S!S#M98I*O><H\UBCY?F:1E$Y8 ]YP+:DW5G>
M0>M-Z8I3%*8I3%*8I3%*8I3%*8I3%*8I5:Z;C?RJD=XUZ1:,_KB4\>::Y$SW
MD; Y*)PEZV\7HZ1,M@-D&JQ_;5K:7$VF-5N.R%1):Y.N4&*VYN1$A3D;\W>I
MHN:P3.,>6"R\WEY,-N.8V!&4TDVINBJ+J4G.6BV5$L1$JJM;=O=7.B>)Z<95
MS9F+RT+JKN#:<+ S8^B*&'91AZ$Y,R3+@.+)=D3T@-F3)L@+;[\AQ77$T)6S
MMW4](;,L#B_+&5Q9T2"D+L<++DJ=S,6@5N;,KI^T:\+1,84J-22:YA=IPF.V
M$\9!7JY1N]#V/00"LF+R+,&'.CNH2G*BHV-K614>:<N5U3A8%3A=;VX>%,.=
M.=^XK9^U]YX/(-2').X]NACXY-H"BVZ.4QTY3>U&*HWRH;@HH(9:R!-.E2(8
M/KCALY5=SJLCDQ%Y(VE51955R- KK89B[2Z.7+,YC GJ=2J/IM(Q-9$?G**
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MEC_7?(',^Y;]8;1^#;\B/7W'ZE_7WNJ>@P/B<)5M?;>^454WW'VS[Q6)F/\
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M^S6A_P"&)]ZB)]"Y'XL*I4X/?)D[F7ZSQO\ FD&S)6ZO6/A_S#]HJ^AO>/\
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M8B*B\%6H=MG>_5;;^)CXS;92PQ4CF.,H,47$>2,^W,>(")HE<1AV.)NJ*J@
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MV"595;19;#G)4B<+L=K/BT2#7AA3Y%D0S7&5/B)C96O;>2H$D&,"8XM*6(X
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MS'4&M0-IF?/&<@FK4B^-%\T$;)Q)UU%MI6_(5UQXNFL&&8[:G$E_F,AXY,$
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ME9!$ 704E5"&]A0K_P#TJ8]Z+KAT9W#W-<UM7 [KV[-W*[@L>V$5C(179!N
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-%*8I3%*8I3%*8I7_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
